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Abstract
Humans are ubiquitously exposed to peroxisome proliferators including hypolipidemic agents,
industrial solvents and natural products. Because of this and the fact that peroxisome prolifera-
tors cause non-genotoxic hepatocarcinogenesis in rodents, it is of importance to elucidate the
mechanism of action of the peroxisome proliferators in order to provide an assessment of the
hazard, if any, of these compounds to humans. It is also known that the peroxisome proliferators
begin their actions by inducing hepatic DNA synthesis. Thus, the aim of this thesis was to find
genes that could be responsible for triggering the induction of hepatic DNA synthesis caused by
peroxisome proliferators, specifically ciprofibrate.
First, it was important to indicate when the induction of hepatic DNA synthesis actually hap-
pens. This was done with BrdU immunohistochemical procedures. The induction of hepatic
DNA synthesis with ciprofibrate in mice was observable only after 4 days making it difficult to
specify when the induction actually happened. In rats the induction of hepatic DNA synthesis
was found to peak at 24 hours and this system gave the better opportunity to find the genes re-
sponsible. The difference in the timing of induced hepatic DNA synthesis between mice and rats
implied that there could be a species difference in the mechanism of each species’ response to
PPAR. With immunohistochemistry it was noticed that there was a difference in the lobular lo-
calization of hepatic DNA synthesis in the liver tissues of rats and mice dosed with different
inducers, with the rat livers exhibiting periportal distribution while hepatic DNA synthesis in
the mice seemed to be distributed throughout the liver tissue.
The effects of ciprofibrate or cyproterone acetate on liver gene expression in rats were studied,
using cDNA microarrays, transcriptome sequencing and quantitative real- time PCR. A 1- 5
hour treatment period was chosen to detect the immediate early gene response, while a 24 hour
time point was chosen to elucidate the confounding effects from the hepatic DNA synthesis seen
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during the 24 hour stimulation. The results showed that ciprofibrate altered the expression of
numerous genes including previously known PPARα agonist-responsive genes involved in pro-
cesses such as PPAR signalling pathways, fatty acid metabolic pathway, cell cycle, palmitoyl-
CoA hydrolase activity, lipid metabolism, inflammatory responses, and stress responses, in ad-
dition to a large number of novel candidate genes.
Three novel induced genes G0s2, Ccnd1 and Scd1, (and two marker genes CYP4A1 and
CYP3A1) were confirmed with quantitative real- time PCR. The G0s2, Ccnd1 and Scd1 were
found to be up-regulated at the hours 1 and 3 after dosing and not 24 hours, and the G0s2 and
Scd1 were specific for the ciprofibrate suggesting they were involved in a distinct PPARα path-
way responsible for the hepatic DNA synthesis. The complete database of the transcriptional
response provided here opens doors of opportunity for further research to identify genes respon-
sible for the liver growth induced by peroxisome proliferators.
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CYP4A1 Cytorochrome P450, family 4 subfamily A, polypeptide 1
DAB 3,3’ diamino-benzidine tetrahydrochloride
DECP Diethyl pyro carbonate
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DEHP Di-(2-ethyl-hexyl) phthalate
DMSO Dimethyl sufoxide
DPX Distyrene, plasterine and xylene
EdU 5-ethynyl-2ƍ-deoxyuridine
F Forward primer
F-344/NHsd Fisher-344/NHsd rats
FDA Food and drug administration 
FDR False discovery rate
G0 Gap zero
G0s2 G0/G1 switch 2
GAL GenePix Array List
GPR GenePix results
GstYb4 Glutathione S-transferase mu 3
H Hepatocytes
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HGF Hepatocyte growth factor
HNF4α Hepatic nuclear factor-4α 
IGFBP1 Insulin-like-growth-factor-binding protein-1
IP Intra-peritoneal
IQR Inter quartile range
KEGG Kyoto encyclopedia of genes and genomes
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LI Labelling index
MAPK/ERK Mitogen-activated protein kinase/extracellular signal-regulated kinase
MCP Methylcyclopentane
MEEBO Mouse exonic evidence based oligonucleotide
MIAME Minimum information about a microarray experiment
NCTR National centre for toxicological research of the U.S. A 
NF-kB Nuclear factor kappa beta
NP Non-parenchymal cells
NTC No template control
OD Optical density
P Probe
PBS Phosphate buffer saline
PCN Pregnenolone-16α-carbonitrile
PCR Polymerase chain reaction
PPAR Peroxisome proliferator activated receptor
PPRE Peroxisome proliferator hormone response element
PS Portal space/ periportal
PXR Pregane X receptor
R Reverse primer
RGD Rat genome database
RNAseq Transcriptome sequencing analysis
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RPKM Reads per kilobase of exon model per million mapped reads
RT Reverse transcriptase
RXR Retinoid X receptor
S phase Synthesis phase
Scd1 Sterol-coenzyme A desaturase 1
SD Standard deviation
SDS Sodium lauryl (dodecyl) sulfate
SSC Saline-sodium citrate buffer
STAT 3 Signal transducer and activator of transcription 3
T3 Thyroid hormone
TBE Tris boric acid EDTA
TBS Tris buffer saline
TCPOBOP 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene
TGFα Transforming growth factor alpha 
TGFβ Transforming growth factor beta
TIFF Tagged image file format
TNFα tumour necrosis factor alpha
Tween-20 Polyoxyethylene sorbitane monolaureate
WY-14,643 Pirinixic Acid/ 4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidi-
nyl]thio]-acetic acid
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Chapter 1 Introduction
Section 1.1 The Liver
Section 1.1.1 Histology and physiology of the liver
The liver is the largest organ in the body. Found on the right side of the abdomen under the lungs
covered partially by the lower ribs, it consists of two main lobes, the right lobe and the left lobe
with the right being the largest (Mader, 2004). The liver has a central role in metabolic homeo-
stasis of the body, as it is responsible for the metabolism, synthesis, storage and redistribution
of nutrients, carbohydrates, fats and vitamins. One of the main functions of the liver is detoxi-
fication, which removes waste and xenobiotics by metabolic conversion and biliary excretion
(Kurt, 1991). 
The hepatic parenchyma is organized into units called liver lobules (Michalopoulos and De-
Frances, 1997), as illustrated for the pig liver in Figure 1.1. The classic liver lobules are divided
with connective tissue and appear in a hexagonal shape with a central vein in the middle and
portal spaces (triads) at the corners. 
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A different structure of the liver is the portal lobule where the structure appears as a triangle
with a central vein at each of the corners and a portal space in the middle. A third structure is
called the liver acinus which appears as a diamond shape connecting a central vein to a portal
space then a central vein and a portal space then back to the same central vein. It was reported
that the liver acinus is the functional unit of the liver and is divided into three zones: Z1 peri-
portal, Z2 intermediate and Z3 perivenous (Ross, 2003) indicated as 1, 2 and 3 in Figure 1.2.
Figure 1.1 Histological view of the classic liver lobules. Histological view of a pig liver tissue, with a light mi-
croscope. Staining was with azan stain. The central vein is in the middle of the slide and the portal space (triad) are shown
at the sides. The liver lobules are clearly identified with connective tissue defining each lobule (blue in colour). Magnifica-
tion X40. Figure from (Kühnel, 2003).
central vein
connective tissue
portal triad
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Liver cells closest to the terminal portal vein (periportal) receive blood richer in oxygen and nu-
trients than those located near the central vein (perivenous). The cells in these different zones
perform different biochemical functions and respond differently to injuries, with regard to the
cell organelle number and size, ploidy, pattern of enzymes activity, autonomous innervations,
number of non parenchymatous cells, concentration of hormones, substrates and their metabo-
lites, and the partial O2 pressure (Taub, 2004). Figure 1.3 depicts the structure of a liver lobule,
with hepatocytes branching from the central vein to the portal vein (traid) in rows 1-2 cells thick
called plates. The portal space includes the hepatic portal vein, the hepatic artery and the bile
duct.
Figure 1.2 Diagram of the liver structure. Shown is the classic liver lobule were a central vein is in the middle
and six portal triads are at the periphery. The portal lobule appears as a triangle with a central vein at each of the corners
and a portal triad in the middle. The liver acinus appears as a diamond shape connected between a portal triad, central
vein, portal triad and central vein this is the functional unit of the liver and is divided into three zones (the area around
the central vein is zone 1 (Z1), the area near the terminal portal vein is zone 3 (Z3) and the area in between is zone 2 (Z2)).
Figure from (Henrikson et al., 1997). 
portal lobule
central vein
classic lobule
central vein
portal spaces (triads)     liver acinus
Abeer Amer   Section 1.1.1
Page 21
The main cell type found in the liver is parenchymal cells also known as the hepatocytes, which
makes up most of the hepatic cells. Other cell types are the endothelial cells, Kupffer cells, lym-
phocytes, stellate cells and lipocytes (Dudek, 2000)(Taub, 2004) (Figure 1.4). 
Endothelial cells line the sinusoids of the liver, and provide a large surface area for nutrient ab-
sorption, and Kupffer cells are situated in the sinusoids and have a phagocyte function. Also, it
is thought that Kupffer cells produce cytokines (Taub, 2004). 
Lymphocytes are considered part of the innate immune system that resides within the liver to
help resist infection. Hepatic cells have various functions, including the storage of vitamin A
and the production of the extracellular matrix and most of the factors that lead to hepatic fibro-
sis. All of these cell types are activated by hepatic injury (Taub, 2004).
central vein
hepatic portal vein
hepatic artery 
bile duct
hepatic cells
Figure 1.3 Diagrammatic structure of a liver lobule. the hepatocytes form rows of one or two cells thick and
are called plates, the plates start at the central vein, also known as the inter lobular vein, and branch out in a star shaped
way to the portal space. Between the cell plates are the sinusoids which contain the Kupffer cells and the epithelium cells
(not shown), between each two hepatocytes starts the Bile canals which get larger and larger to make the bile ducts. A bile
duct along with a portal vein and a hepatic artery get arranged in a group making the portal space. Figure from (Mader,
2004).
from intestinal capillaries
bile canals
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Section 1.1.2 Liver regeneration (growth)
Normally, mature hepatocytes live long and do not divide; they only proliferate in response to
toxic injury and infection. Loss of liver function results in proliferation and restoration of func-
tional liver tissue (Mangnall et al., 2003). 
The fascinating two thirds partial hepatectomy (PH) model in rodents was first pioneered by
(Higgins, 1933) as a model for regrowth. In this model, two thirds of the liver was surgically
removed, and the remaining liver enlarged until the original liver mass was restored, approxi-
mately 1 week after surgery, after which the regenerative process stopped. In this experimental
system, liver regeneration does not require the recruitment of liver stem cells or progenitor cells,
but involves replication of the mature functioning liver cells. The regenerative process is com-
pensatory because the size of the resulted liver is determined by the demands of the organism,
and, once the original mass of the liver has been re-established, proliferation stops (Michalo-
Figure 1.4  Histological section of liver cells.  Histological section of liver tissue showing the hepato-
cytes in rows making the plates. Between the plates are the sinusoids, the endothelium cells are covering the sinu-
soids and some blood cells are shown in between the cells. The Kupffer cells are shown as dark stained cells. The
stain is Giroud-Leblond; nuclear staining with carmine red; magnification: X300, from (Kühnel, 2003).
Kupffer cells
central vein
hepatocytes
epithelium cell
blood cell
sinusoids
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poulos and DeFrances, 1997).
Section 1.1.3 Basic characteristics of liver regeneration
Because hepatocytes are mostly found in the G0 phase of the cell cycle, hepatic cell division is
rarely found in the normal adult liver (Michalopoulos and DeFrances, 1997). It was reported
that after partial hepatectomy the liver cells start dividing, and by day three the liver mass begins
to increase, while the whole mass restoration is complete in just 5-7 days (Grisham, 1962).
Thus, after partial hepatectomy in rats nearly 95% of hepatocytes rapidly re-enter the cell cycle,
and hepatic DNA synthesis (cells in the S phase) increases after 12 hours and peaks around 24
hours (Mangnall et al., 2003). However, the induction of non-parenchymal DNA synthesis oc-
curs later (36-48 hours for kupffer cells). 
Subsequent to the partial hepatectomy, the levels of hepatic DNA synthesis are lower, as the liv-
er mass requires an average of 1.6 cycles of replication in all cells to be completely restored,
taking around 7 days. The expression of the gene encoding β-actin (a growth related gene) after
2 hours is high until about 36 hours, while the insulin-like-growth-factor-binding protein-1
(IGFBP1) (encoded by a cell-cycle-regulated gene) peaks after 2-3 hours. Genes encoding the
α isoform of CCAAT enhancer binding protein (C/EBPα), are down- regulated within the pe-
riod of maximal growth and are expressed again after the growth phase has occurred. This is
clarified in Figure 1.5 (Taub, 2004).
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By comparison, in mice after partial hepatectomy the DNA synthesis peak occurs later (36- 40
hours after partial hepatectomy) and varies between strains (Sigal et al., 1999). 
Early studies in vitro with isolated hepatocytes, identified a number of potential hepatocyte
growth factors such as HGF, TGFα and TGFβ. It was difficult to confirm that any of these fac-
Figure 1.5 Diagrammatic illustration showing patterns of DNA synthesis and induction of gene 
expression during rat liver regeneration.  a) 24 hours after partial hepatectomy, (H; green) DNA synthesis in he-
patocytes peaks, but in the non-parenchymal cells DNA synthesis (NP; yellow) reaches its highest at 36-48 hours. Re ac-
cumulation of liver mass in red is finished in around a week. b) The pattern of induction of the genes expression for growth
regulated genes, (β-actin). c) While the induction pattern of insulin like growth factor binding protein-1 (IGFBP1) rep-
resenting the gene expression for cell-cycle-regulated genes. d) The genes encoding the α isoform of CCAAT enhancer
binding protein (C/EBPα), are down- regulated within the period of maximal growth and are expressed again after the
growth phase has occurred.(Taub, 2004).
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tors had an vital role in liver regeneration, but it was noted that growth-factor-and cytokine-reg-
ulated pathways are activated during liver regeneration (Taub, 2004).
Transcription factors have been acknowledged to play a major role in making hepatocytes pro-
liferate (Fausto, 2000), apparently through the induction of the hepatic expression of numerous
immediate early genes linked to the cell cycle (Scearce et al., 1996). Knockout mouse studies
were used to identify specific genes induced during the induction of DNA synthesis during he-
patic regeneration. These studies established that cytokines might be responsible for regenera-
tive response (Taub et al., 1999), and IL-6 could collaborate with additional factors to trigger
the other up- regulated genes (Cressman et al., 1996). Other genes that are regulated during he-
patic regeneration are the genes that encode the cyclin D1 (Schwabe et al., 2003)(Talarmin et
al., 1999)(Diehl, et al., 1994), IGFBP1 91, STAT 3 and AP1 (Leu, et al., 2001)
One transcription factor, termed NF-kB, has been suggested to have a role in liver regeneration
(Tewari et al., 1992). A potent inducer of NF-kB is tumour necrosis factor α (TNF-α) (Grilli et
al., 1993)(Menegazzi et al., 1997). 
The beginning of DNA synthesis is well synchronized in rat hepatocytes, starting in cells that
surround the portal vein of the liver lobule and proceeding towards the central vein (Taub,
2004). Hepatic proliferation is also noted in the liver regeneration caused by apoptosis or necro-
sis that is induced by toxic chemicals e.g. CCL4 (Taub, 2004) and peroxisome proliferators
(Moody et al., 1991). 
Section 1.2 Peroxisome proliferation
Section 1.2.1 Peroxisomes
Peroxisomes are single membrane-limited cytoplasmic organelles present in both animal and
plant cells. They were first detected in 1954 and are known as “microbodies”. They were re-
Abeer Amer   Section 1.2.2
Page 26
ferred to as peroxisomes after it was found that they contain catalase and oxidase, which are in-
volved in the degradation and production of hydrogen peroxide (Deduve, 1965). Other
functions of the peroxisomes include β-oxidation of fatty acids and cholesterol metabolism
(Holden and Tugwood, 1999). 
Peroxisomes are mostly found in liver and kidney cells (Bernhard and Rouiller, 1956) (Rhodin,
1954). Leighton and his group found that peroxisomes account for nearly 2.5% of protein in rat
liver (Leighton et al., 1968). The following year Weibel and his group found that the peroxi-
somes occupy about 1.5% of the parenchymal cell volume (Weibel et al., 1969). 
Hepatocyte peroxisomes are affected in number and size by chemicals not related in structure,
called the peroxisome proliferators (Reddy, 2004).
Section 1.2.2 Peroxisome proliferators (PPs)
Peroxisome proliferators are a group of structurally unrelated chemicals with different applica-
tions, such as hypolipidemic drugs, and industrial and agricultural chemicals (Moody et al.,
1991).
It is reported that peroxisome proliferators induce peroxisome proliferation in livers of some ro-
dents. Peroxisome proliferation involves changes in the ultra structure and metabolic capacity
of the liver cell, such as the increase of peroxisome volume density, hepatomegaly, and an in-
crease in β-oxidation of fatty acids and peroxisomal enzymes activities (Moody et al., 1991). 
Interestingly, it has been reported that DNA synthesis is not affected by peroxisome prolifera-
tors in pure hepatocytes, rather they stimulate Kupffer cells to make mitogens which stimulate
proliferation of parenchymal cells (Parzefall et al., 2001).
However, peroxisome proliferation involves several other changes that are not strictly 'peroxi-
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somal', and these changes involve metabolic functions in the cell, as well as shifts the rate of
entry of hepatocytes into cell proliferation (mitosis) and cell death (apoptosis) (Cattley, 2003).
Although many chemicals have been evaluated for peroxisome proliferation, several have been
commonly used in mechanistic studies. Among the hypolipidemic drugs studied, clofibrate (es-
ter), clofibric acid, and ciprofibrate are in clinical use (Cattley, 2003). Other hypolipidemic
drugs include WY-14,643, BR-931, methylclofenapate, and nafenopin, compounds that were
discovered in the search for more potent drug candidates, but were not entered into clinical use. 
Among the non drug compounds used in research is the phthalate ester plasticizer di-(2- ethyl-
hexyl) phthalate (DEHP), which is often used because it is cheap, available with high purity,
and easy to dose (Cattley, 2003). 
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Section 1.2.3 Ciprofibrate, cyproterone acetate and pregnenolone-16α-carbonitrile
Ciprofibrate is a strong peroxisome proliferator activated receptor-alpha (PPARα) ligand
(Mukherjee et al., 2002) from the fibrate hypolipidemic drug family, and a potent hepatocar-
cinogen (Meyer et al., 2003) (Yadetie et al., 2003). 
The anti androgen cyproterone acetate (CPA) and pregnenolone-16α-carbonitrile (PCN) are
pregane X receptors (PXRs). Cyproterone acetate is reported to cause liver tumours and has a
mutagenic effect in rats (Topinka et al., 2004a). It is also known to induce cell proliferation
(Schulte-Hermann et al., 1980) and apoptosis (Kasper and Mueller, 1999) in rat liver in vitro
and in vivo. Cyproterone acetate is used as a hormonal therapy to treat prostate cancer as it sup-
presses the action of testosterone and dihydrotestosterone on cells (Green et al., 2002). It is also
reported to be used in some countries other that America and Japan as a hormone treatment for
acne, with some contraceptive benefits (van Vloten et al., 2002). 
Table 1.1 illustrates the chemical structure of ciprofibrate, CPA and PCN used in this study.
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Table 1.1 Chemical formula and structure of ciprofibrate, cyproterone acetate and pregnenolone-16α-
carbonitrile. This table shows the systematic IUPAC (International Union Of Pure And Applied Chemistry) name, the 
chemical formula and 2 and 3 dimensional structure of the chemicals used to perform the induction of the hepatic DNA 
synthesis in this project. Chemical structures were drawn using CDS/ISIS DRAW Program.
Systematic IUPAC 
Name
 Chemical 
Formula
Structure
3D Structure
red=carbon 
blue=oxygen 
green=chlorene 
yellow=nitrogen 
pink=hydrogen
ciprofibrate
2-[4-(2,2-dichlorocyclopro-
pyl) phenoxy] 2-methylpro-
panic acid 
C13H14Cl2O3 
cyproterone acetate 
(CPA)
chloro-6-hydroxy-17 alpha 
methylene-1 alpha, 2 alpha 
pregnadiene-4,6 dione-3, 20 
acetate
C24H29ClO4
pregnenolone-16α-car-
bonitrile (PCN)
3S,8S,9S,10R,13S,14S,16R,1
7S)-17-acetyl-3-hydroxy-
10,13-dimethyl-
2,3,4,7,8,9,11,12,14,15,16,17
-dodecahydro-1H-cyclo-
penta[a]phenanthrene-16-car-
bonitrile 
C22H31NO2
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Section 1.2.4 Peroxisome proliferator activated receptor-alpha (PPAR-α)
A number of years ago PPARα was the first of three structurally related peroxisome proliferator
receptors (PPARs) to be identified of the soluble nuclear hormone receptor superfamily. Perox-
isome proliferators are believed to act through this family of proteins (PPARα) (Issemann and
Green, 1990). The other two receptors were later indicated and are now known as PPARβ and
PPARγ (Dreyer et al., 1992)(Kliewer et al., 1994), but they do not mediate peroxisome prolif-
eration (Peraza et al., 2006). 
PPAR along with constitutive active androstane receptor (CAR) and aryl hydrocarbon receptor
(Ahr) are known to operate as sensors of xenobiotic entrance into the cell. Mice carrying knock-
outs in genes for the receptors cooperating with xenobiotic were revealed to be deficient for the
promoting effects of these compounds (Yamamoto et al., 2004) (Peters et al., 1997a). 
Also, PPARs are thought to be transcription factors that are activated by ligands and by inter-
action with elements situated 570 bp upstream of the peroxisomal enzyme acyl CoA oxidase
receptive genes (Tugwood et al., 1992). Studies have demonstrated that PPARα is an obligatory
factor in peroxisome proliferation in rodent hepatocytes in vivo and in vitro (Klaunig et al.,
2003).
It has been suggested that Human PPARα have many similar functional characteristics to the
rodent receptors, suggesting that the former also may be activated by peroxisome proliferators
and regulate specific gene expression (Ashby et al., 1994). However, PPARα is less abundant
in human liver than in rodent liver, which has led to the suggestion that species differences result
from quantitative differences in gene expression.
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Section 1.2.5 Toxicological changes induced by peroxisome proliferators
Although there are no acknowledged toxicities linked with endogenous ligands of PPARα,
there is a number of findings related to toxicity and the synthetic PPARα ligands in animal mod-
els (Peraza et al., 2006). 
For example it has been reported that administration of clofibrate (a fibrate peroxisome prolif-
erator) can cause some signs of maternal toxicity if used prior to or during pregnancy in high
doses (Cibelli et al., 1988)(Stefanini et al., 1989)(Wilson et al., 1991). 
Other PPARα agonists, like phthalates and trichloroethylene in rodents have been reported to
cause altered ovulation (Davis et al., 1994), reduced fertility rates (Peters and Cook,
1973)(Singh et al., 1974), teratogenesis including cardiac, skeletal, and neural tube defects (Gao
et al., 2003)(Ritter et al., 1985) impaired spermatogenesis and altered development of the male
reproductive tract (Corton and Lapinskas, 2005). 
It is also noted that exposure to perfluorooctanoic acid causes reduced fetal weights and cardiac
and skeletal malformations (Lau et al., 2004). However, the toxic effects were not proven to be
linked with PPARα pathways as clarified by Peters et al. (1997b) who administered Di(2-eth-
ylhexyl) phthalate (DEHP) during organogenesis, in wild-type and PPARα-null mice and this
caused neural tube defects in both, indicating that PPARα was not required to mediate the ef-
fect. 
On the other hand, fibrate therapy is linked with cholelithiasis (gallstones), as it has been record-
ed in humans treated with fenofibrate, clofibrate or bezafibrate which were associated with an
increased incidence of cholelithiasis (Caroli-Bosc et al., 2001)(Raedsch et al., 1995) and also
myopathy and rarely rhabdomyolysis (Bridgman et al., 1972) (Alsheikh-Ali et al., 2004).
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But it is well-known that PPARα ligands cause hepatocellular carcinomas in rodents, and they
have also been connected to other malignancies, as they cause pancreatic acinar cell tumours
and Leydig cell tumours (Reddy et al., 1980). Furthermore, pancreatic acinar cell tumours and
Leydig cell tumours have been reported to occur only in rats, but not in mice (Klaunig et al.,
2003). It was also reported that clofibrate and Wy-14,643 treatments increase the growth of hu-
man breast cancer cell lines (Suchanek et al., 2002). 
Section 1.3 Mechanism of action of carcinogenesis
Among the first stages of cancinogenesis provoked by chemicals are initiation and promotion,
when both initiation and promotion occur this is known as “complete carcinogenesis” and the
peroxisome proliferators would cause both initiation and promotion activities (Kobliakov,
2010). The initiation stage is provoked by genetic changes in the genome caused by genotoxic
metabolites of carcinogens, whilst the promotion stage is initiated by a non genotoxic mecha-
nism and does not effect the DNA structure (Gujaeva et al., 1998). 
Promotion requires particular scenarios, including increased cell proliferation, decreased inter-
cellular interactions, and inhibition of apoptosis (Kobliakov, 2010). This promotion stage,
caused by non genotoxic compounds is not well studied and it is unknown if the pathways are
similar to the initiation stage or not (Kobliakov, 2010). 
Additionally, it is stated by Wu that the promoter induces the production of reactive oxygen spe-
cies in the cells and this affects intercellular interactions, stimulates the cell migration, and in-
hibits apoptosis (Wu et al., 2006). However, the pathways responsible for these changes have
yet to be resolved. 
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Section 1.3.1 Peroxisome proliferators induce liver cancer in rodents
Peroxisome proliferators are known for their ability to cause hepatocellular carcinoma in labo-
ratory rodents (Reddy et al., 1980). The effect of this is recorded by (Cattley et al., 1991) who
showed that in rodents, after just one year of treatment with Wy-14,643 (a potent peroxisome
proliferator) there was 100% incidence of multifocal liver cancer. Gonzalez and his group es-
tablished that the PPARα mediated pathways that control lipid metabolism and the cell prolif-
eration pathways are independent of each other. This was achieved with PPARα humanized
transgenic mice, and this suggests that these mice would not be susceptible to peroxisome pro-
liferator induced hepatocarcinogenesis (Cheung et al., 2004). 
Other studies showed that just one week of exposure to Wy-14,643 causes hepatomegaly and
hepatocytes entering S-phase. Also, this exposure resulted in hepatocellular neoplasms, includ-
ing some carcinomas after 11 months exposure in wild type mice and not in PPARα null mice.
This makes it clear that PPARα is essential for the increase in hepatic replicative DNA synthesis
in response to peroxisome proliferators.
Although it is known that PPARα cause cancer in long term exposures in rodents, there are sig-
nificant differences in species response, and PPARα is not recorded to induce peroxisome pro-
liferation and hepatocarcinogenesis in humans (Yadetie et al., 2003).
Section 1.3.2 Peroxisome proliferators are non-genotoxic carcinogens
Chemical carcinogens are commonly classified on the basis of their mechanism of action; geno-
toxic (mutagenic) and non genotoxic (non mutagenic) (Weisburger and Williams, 2000). An
important aspect of peroxisome proliferators is that they are non-genotoxic carcinogens (Ashby
et al., 1994)(Peters et al., 1997a). 
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It has been proposed that during carcinogenesis peroxisome proliferators promote liver tumours
by increasing the production of H2O2 leading to the production of peroxisomal fatty acyl CoA
oxidase (Yeldandi et al., 2000). Moreover, through carcinogenesis and tumour growth intercel-
lular interactions are affected and this is important for the normal regulation of organs. The mor-
phology of the cells are also changed, and the epithelial mesenchymal transition is detected
(Radisky et al., 2005). 
It is understood that peroxisome proliferators reduce the expression of glutathione peroxidase
and increase the oxidative stress in hepatocytes caused by the large increase in the H2O2 levels
and the gathering of lipofuscin in the liver cells (Yeldandi et al., 2000)(Kobliakov, 2010). It is
also reported that peroxisome proliferators begin hepatocarcinogenesis in rodents by increasing
cell proliferation (Reddy et al., 1980) (Becuwe and Dauca, 2005). However, the mechanism that
PPARα ligands cause cancer is still vague (Ashby et al., 1994)(Klaunig, 2003)(Peters et al.,
2005). 
Luci (Luci et al., 2007) argued that the hepatocarcinogenesis is a result of oxidative stress and
an impaired balance between apoptosis and cell proliferation in the liver, while Shah and Mo-
rimura (Shah et al., 2007a) and (Morimura et al., 2006) found that PPARα humanized mice ap-
pear to be resistant to the induction of peroxisome proliferators and less sensitive to the
development of liver tumours.
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Section 1.4 Induction of hepatic DNA synthesis by peroxisome prolifera-
tors
It is clear that DNA synthesis plays a significant role in carcinogenesis and that peroxisome pro-
liferators provoke hepatic DNA synthesis that is associated with carcinogenesis (Marsman et
al., 1988). It is therefore desirable to understand the mechanism of the induction of DNA syn-
thesis by PPARα ligands, particularly since these ligands increase the normal liver size, in con-
trast to the regenerative growth pathways induced by partial hepatectomy (Mangnall et al.,
2003).
Section 1.4.1 Acute and chronic effects of peroxisome proliferators on hepatic DNA 
synthesis
Menegazzi’s group showed that rats treated with a peroxisome proliferator known as nafenopin
or with CPA (a PXR) would cause hepatic DNA synthesis that starts 18 to 24 hours after treat-
ment. They also reported that the levels of hepatic TNF- mRNA, NF-B and AP-1 were not
changed indicating a difference from the results obtained after partial hepatectomy, although the
hepatic cells entered the S phase of the cell cycle at similar times (Menegazzi et al., 1997).
In a recent study, Al-kholaifi showed that the effect of ciprofibrate on hepatic DNA synthesis
in male F-344/NHsd rats peaked between 24 and 48 hours after treatment, while 129S4/SvJae
and 129S4/SvJae PPARα-null mice treated with ciprofibrate showed hepatic cells entering the
S phase only after 3-4 days (Al Kholaifi, 2008)(Al Kholaifi et al., 2008). 
It is known from former studies that the replicating hepatic nuclei are not distributed randomly
within the rat liver, but are found predominantly in the periportal region (Barrass et al., 1993).
Barrass‘s results were achieved in male Sprague-Dawley rats treated with methylcyclopentane
(MCP) and clofibric acid for 1-26 weeks. This was confirmed by Al kholaifi with Fisher rats,
while most mouse species’ livers didn’t show any preference in the zonation of hepatic DNA
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synthesis (Al Kholaifi et al., 2008). Other zonation studies on mouse liver using a different ap-
proach/ method on young non treated B6C3F1 and C57BL mice showed that the distribution is
mostly in the mid-zone Z2 (Amacher et al., 1998).
The difference in the kinetics of induction of hepatic DNA synthesis between mouse and rat af-
ter exposure to PPARα ligands suggests that there might be a difference in the mechanism of
hepatic DNA synthesis of the two species, and how each of the species’ livers respond to PPA-
Rα.
Frick and Blaauboer showed in separate studies that humans do not display the same range of
hepatocarcinogen peroxisome proliferator-induced responses seen in rats and mice (Frick et al.,
1987)(Blaauboer et al., 1990). Also it has been demonstrated that non-human primates and
guinea pigs are unaffected by peroxisome proliferators (Bell et al., 1998). So, establishing an
explanation for, and understanding the risks to man of exposure to these chemicals has been a
major focus for research (Lake et al., 2000).
Section 1.5 Gene expression in response to peroxisome proliferators
PPARα forms a heterodimer with the retinoid x receptor α (RXR) -after being provoked by the
peroxisome proliferators- which then binds to precise regions on the DNA (called peroxisome
proliferator hormone response elements; PPREs) of the targeted genes (Tugwood et al., 1992)
as shown in Figure 1.6. 
The PPARα-RXRα heterodimers attach to DNA sequences with repeats of the sequence AG-
GTCA (AGGTCA X AGGTCA) separated by one nucleotide (Jpenberg et al., 1997). This het-
erodimer would be able to stimulate transcription of a large number of genes, including those
involved in lipid metabolism such as cytochrome P450 4A and acyl CoA oxidase. 
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Several studies showed that peroxisome proliferators are involved in the regulation of several
genes that are involved in hepatic proliferation, metabolism, immune modulation, mitochondri-
al and peroxisomal fatty acid β−oxidation (Desvergne and Wahli, 1999) (Latruffe and Vamecq,
1997). Other studies reported that ciprofibrate is involved in modulating the expression of genes
implicated in cell proliferation such as cyclins (Rininger et al., 1996)(Peters et al., 1998).
Yadetie examined the effects of 50 mg kg -1 body weight of ciprofibrate per day for 60 days on
gene expression in the liver of rats by using a cDNA microarray analysis. From this it was found
Figure 1.6 Schematic diagram of the PPAR mechanism of action. The blue triangles are peroxisome
proliferator that bind to the PPAR, leading to heterodimer with retinoid x receptor (RXR) which has been activated
by its ligands (orange squares). The PPAR/RXR heterodimer binds within the DNA binding C domain to peroxi-
some proliferator hormone response elements (PPRE) through a DNA sequence with repeats of the sequence AG-
GTCA (AGGTCA X AGGTCA) separated by one nucleotide (this would be located at the promoter of the target
gene). The diagram is a modified version from (Keller et al., 2000). 
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that a number of up- regulated genes were involved in lipid and sugar metabolism while other
genes were implicated in growth and stress responses (Yadetie et al., 2003).
Peroxisome proliferators are reported to induce the transcription of the CYP4A1 gene (Hard-
wick et al., 1987), and the induction of CYP4A1 is linked with the transcription of genes encord-
ing the 3 oxoacyl CoA thiolase and the bifunctional enzyme acyl-CoA (ACO) (Furuta et al.,
1982)(Reddy et al., 1986). 
Bell also characterized the induction of CYP4A1 and acyl-CoA in vitro and found them highly
induced after dosing rat hepatocytes with clofibric acid for 4 days, or with methylclofenapate,
nafenopin, clofibric acid or mono (ethylhexyl) phthalate for 1 h and 8 h. This suggested that the
different time course of induction of CYP4A1 and acyl-CoA oxidase is not related to the type of
peroxisome proliferator but to the process of peroxisome proliferation (Bell and Elcombe,
1991a).
In vivo studies in rats dosed intraperitoneally with methylclofenapate also showed significant
induction of CYP4A1 after 6 h, 8 h, 24 h and 30 h, while the acyl-CoA showed no increase at 8
h but increased significantly after 24 h (Bell et al., 1991). As the induction of the CYP4A1 gene
is the first sign of the peroxisomal reaction, it is possibly the most significant enzymic indicator/
marker of peroxisome proliferation (Orton and Parker, 1982)(Hardwick et al., 1987). 
In other reports the effects of peroxisome proliferators on immediate early gene expression have
been related to the extracellular signal-regulated kinases and phosphorylation of the upstream
regulator MAPK/ERK kinase signal transduction pathway (Rokos and Ledwith, 1997).
As PPARs can induce the regulation of a number of genes, PPARs can also down- regulate gene
expression as they are necessary for the suppression of apolipoprotein CIII mRNA expression,
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but the mechanism is not clearly understood (Peters et al., 1997a). CYP2C11 expression is
clearly down- regulated by peroxisome proliferators as reported in (Corton et al., 1998).
Gonzalez and his group demonstrated that hepatic microRNA expression was largely activated
by PPARα. They studied a microRNA involved in cell growth, let-7C, and found it was sup-
pressed following 4-h treatment, 2-week or 11-month constant treatment with the potent PPA-
Rα agonist Wy-14,643 in wild-type mice. let-7C was shown to target c-myc. The induction of
c-myc through let-7C consequently amplified expression of the oncogenic mir-17-92 cluster;
this did not arise in PPARα null mice (Shah et al., 2007a).
(Suzuki et al., 2010) examined the effect of Wy-14,643 on DNA damage in rat livers treated
orally for 14 days and found that a number of DNA repair genes were induced such as Gadd45,
Apex 1, Xrcc5 and M1h1. These results implied that hepatic DNA was damaged by Wy-14,643
but might be repaired via the activation of these DNA-repair genes.
The development of microarray tools has significantly changed gene expression analysis re-
search. However, the reliability and reproducibility of RNA microarray data can be challenged.
Therefore, confirmation of results with quantitative real- time PCR or a similar technique is es-
sential (Baker et al., 2004). Baker found using cDNA microarray analysis and confirmation with
real- time PCR that in clofibrate treated rats, hepatic expression of acyl CoA, topoisomerase II-
α and CYP4A1 were highly induced. Another tool used recently to study global gene expression
is the RNAseq analysis technique. Also known as illumina sequencing, this technology is still
very expensive and needs experience in bioinformatics, but it is fast and the illumina sequencing
data is highly reproducible, with reasonably low technical variation in enabling identification of
differentially expressed genes (Marioni et al., 2008).
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Section 1.6 The aim of the Thesis
The overall aim of this thesis is to shed some light on the mechanism of action of hepatic growth
induced by peroxisome proliferators activating receptor ligand (PPARα), specifically ciprofi-
brate. This work is based on the assumption that increased DNA synthesis is causally related to
the development of liver cancer. 
To investigate how peroxisome proliferators induce hepatocyte proliferation and which genes
they induce to cause cancer, the specific aims were; 
1- To indicate when the induction of hepatic DNA synthesis provoked by ciprofibrate happens
in mice and rats, by immunohistochemical technique.
2- To investigate where in the liver tissue the induction of hepatic DNA synthesis occurs in mice
and rats dosed with ciprofibrate.
3- To characterize the genes responsible for triggering the induction of hepatic DNA synthesis
caused by ciprofibrate in comparision with cyproterone acetate (CPA) by studying the immedi-
ate early induced genes. This was done with cDNA microarray, Transcriptome sequencing anal-
ysis and Quantitative Real Time PCR. 
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Chapter 2 Materials and Methods
Section 2.1Materials
Section 2.1.1  Animals 
Male F-344/NHsd (Fisher) rats (14-15 weeks, 260±20g) were bought from Harlan Laboratories,
Inc. UK. DBA/2JCrl (22±2g) and C57BL/6Crl (20±2g) mice were used at age 9-10 weeks, and
were purchased from Charles River Laboratories, Inc. UK. 
Animals were matched for sex, strain, supplier and age, and were randomized on arrival on the
basis of body weight in to the appropriate number of groups. 
Animals were maintained under specific pathogen-free conditions, in plastic cages and were
kept at 24±4oC. The humidity was 70±5%, with a 12 h day/night light cycle, with food and wa-
ter available ad labium throughout the experimental period. 
The animals were humanely killed with a single overdose of Dolethal (pentobarbital 200 mg ml-
1, purchased from Vetoquinol Company). The animals’ experiments were performed in accor-
dance with the Home Office guidance (Scientific Procedures) Act 1986. 
Section 2.1.2 Chemicals 
The peroxisome proliferator used was ciprofibrate as a powder and was a generous gift from Dr.
T. J. B Gray, Sanofi- Aventis (Alnwick, UK). 
The pregnane X receptor agonists used were cyproterone acetate CPA and pregnenolone-16α-
carbonitrile PCN, and were bought from Sigma-Aldrich® as powders. 
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Section 2.1.3 Immunohistochemistry materials
All chemicals used were of the highest quality available. 5-bromo-2'-deoxyuridine (BrdU), 3,3’
diaminobenzidine tetrahydrochloride (DAB), bovine serum albumin (BSA), polyoxyethylene
sorbitane monolaureate (Tween-20) and 10% (w/v) formalin were purchased from Sigma-Al-
drich®. 
A primary anti-BrdU mouse monoclonal antibody was purchased from GE healthcare (UK),
and a secondary antibody (blotting grade affinity-purified goat anti-mouse IgG (H+L) horserad-
ish peroxidase conjugate) was purchased from Bio-Rad. 
Ultrapure tris base was obtained from Melford Laboratories Ltd. DPX (Distyrene, plasticiser
and xylene), hydrochloric acid and 30% (w/v) hydrogen peroxide were obtained from Fisher
Scientific, ammonium hydroxide from Aldrich, and cobalt chloride from AnalaR. Amersham
cell proliferation kits were purchased from GE healthcare (UK). 
Poly-L-lysine-coated slides (PolysineTM) were obtained from Fisher, pure paraffin wax (melt-
ing point 56oC) from RA lamb, Peel-A-Way® disposable histology molds from Polysciences
Inc, and TAAB embedding stubs (25mm) from TAAB laboratory and microscopy. 
Glacial acetic acid, xylene, ethanol, methanol, sodium phosphate and haematoxylin stain were
purchased from Sigma-Aldrich®. Pure water was produced in this laboratory at a quality of <
0.2 µS.
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Section 2.1.4 Microarray materials
Section 2.1.4.1  RNA isolation materials
TRI reagent® solution (a mixture of guanidine thiocyanate and phenol in a mono-phase solu-
tion) and 1-bromo-3-chloro-propane, Isopropanol and ethanol were bought from Sigma-Al-
drich®. SDS Sodium lauryl (dodecyl) sulfate (C12H25SO4Na) and ethidium bromide were
bought from Fisher Scientific.
Section 2.1.4.2  Synthesis and labelling of cDNA
cDNA synthesis and labelling was with an amino allyl cDNA labelling kit from Ambion the
RNA Company. Reagents used and included in the kit for cDNA labelling reactions are, 10X
RT buffer, Oligo(dT) Primers [Oligo(dT)18, 50 mM] random decamers (50 mM), RNase inhib-
itor (10 units/ml), dNTP Mix (no dTTP) (10 mM each: dATP, dCTP, dGTP, dTTP)+ AA dUTP
Mix, 3 mM dTTP, 3 mM 5-(3 aminoallyl)-2'-dUTP. 
Also M-MLV reverse transcriptase (200 units/ml), 3 M sodium acetate (pH 5.5), glycogen (5
mg ml-1), 1 M sodium hydroxide, DMSO (100% dimethyl sulfoxide), coupling buffer, 1 M
HEPES (pH 7), 4 M hydroxylamine, water for 75% ethanol, 100% ethanol and nuclease-free
Water.
The fluorescent dyes used for the labelling were Alexa Fluor® 555 and Alexa Fluor® 647 re-
active dyes from Invitrogen.
Section 2.1.4.3  Microarray slides and hybridization materials
Whole genome mouse Mouse Exonic Evidence Based Oligonucleotide (MEEBO) array slides
were used. The arrays were printed over 2 slides (A+B), and were accompanied with a specific
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GenePix Array List (GAL) file. 
The array slides were Gentix Aldehyde Plus arraying slides and were a kind gift from Dr T.
Gant’s lab, Systems Toxicology Group, Leicester University. 
For the microarray hybridization of the cDNA, the tRNA used was from Invitrogen and 2X-en-
hanced cDNA hybridization buffer from Genisphere.
Section 2.1.4.4 Microarray scanner
An Axon 4200 scanner and GenePixPro(6) program was used to scan and analyse the slides.
Both were situated at Dr T. Gant’s laboratory, Systems Toxicology Group, Leicester University. 
Section 2.1.5 Transcriptome sequencing materials
RNA sequencing was done with the AB SOLiD 3 platform, using short reads, at Dr Aziz
Aboobaker‘s lab, Next Generation Sequencing Facility, Queens Medical Centre (QMC), Uni-
versity of Nottingham. Associated equipment for the transcriptome analysis was a COVARIS
S2 sonicator, a DIGILAB hydroshear nanodrop 2000 and 3000 and a Qubit nucleic acid quan-
tification agilent bioanalyser. 
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Section 2.1.6 Quantitative real- time PCR materials
Section 2.1.6.1  Synthesis of cDNA
Total hepatic RNA was reverse transcribed to first strand cDNA using a High Capacity RNA-
to cDNA kit, and TaqMan® Gene Expression Master Mix which were from Applied Biosys-
tems. 
Section 2.1.6.2  Primers and probes
Real- time RT-PCR primers and probes for rat genes were designed using PRIMER 3
(Skaletsky, 2000) at http://frodo.wi.mit.edu/primer3/. 
The primers and probes were checked for hairpins and dimers with AutoDimer v1 software and
the primers were checked for specificity by Blast searching against the rat genome using the
standard rodent database, at http://www.ebi.ac.uk/Tools/blastall/nucleotide.html. 
The probes and primers were synthesized by Eurofins, MWG Operon. The sequence of the
primers and probes and the dyes and quenchers that they are attached to are listed in Table 2.1.
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Table 2.1 RT-PCR oligonucleotides primers and probes for rat genes. Primers and probes are designated by 
letters indicating the forward primer F, the reverse primer R or the probe P. Sequences are given from 5’-->3’. The reporter 
dye is at the 5’ end of the oligonucleotide. At0647N was used as an alternative to Cy5 where indicated.
Rat gene Oligonucleotide sequence
Genebank 
accession no.
Reporter dye
AhR
F
R
P
GCA GCT TAT TCT GGG CTA CA
CAT GCC ACT TTC TCC AGT CTT A
TAT CAG TTT ATC CAC GCC GCT GAC
ATG
Af082124 HEX- BHQ1
β-actin
F
R
P
CTG ACA GGA TGC AGA AGG AG
GAT AGA GCC ACC AAT CCA CA
CAA GAT CAT TGC TCC TCC TGA GCG
V01217 Cy5-BHQ2
Ccnd1
F
R
P
GCG TAC CCT GAC ACC AAT CT
GGC TCC AGA GAC AAG AAA CG
CTG GAT GCT AGA GGT CTG CGA
NM_171992 HEX-BHQ1
CYP3A1
F
R
P
AGT GGG GAT TAT GGG GAA AG
CAG GTT TGC CTT TCT CTT GC
TAG AGC CTT GCT GTC ACC CA
NM_013105 FAM-BHQ1
CYP4A1
F
R
P
TCA TGA AGT GTG CCT TCA GC
TGT GTG ATC ATG GGC AAG TT
ATC CAG GCC ATT GGG AAC TT
NM_175837 FAM-BHQ1
G0s2
F
R
P
GGT GTG GTG CTC GGT CTA GT
ACA AAG TCG CCT CCT GTG TC
CAG GCC CTG ATA GCA GAA GG
NM_0010096
32
At0647N-
BHQ2
Scd1
F
R
P
TCC TGC TCA TGT GCT TCA TC
GGA TGT TCT CCC GAG ATT GA
TAC TGC TGG GGC GAA ACT TT
NM_139192 HEX-BHQ1
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Section 2.1.7 Software used in data analysis
The NORT.T normalizing program was obtained from the Systems Toxicology Group, Leices-
ter University (Dr Shu-Dong Zhang and Dr Timothy W. Gant) and was used for the initial nor-
malizing of the scanning results and the microarray comparison experiments. The program can
be downloaded from http://143.210.176.81/SystemsToxicology/Microarray_Softwares/
Softwares_NorTT.aspx
The microarray experimental information [(in accordance with Minimum Information About a
Microarray Experiment (MIAME)] was stored in ArrayTrack, a software system for managing
and interpreting microarray gene expression data developed by the Center for Toxicoinformat-
ics at the National Centre for Toxicological Research (NCTR) of the U.S. Food and Drug Ad-
ministration (FDA). The database generated from this thesis is accessible under the Univerity
of Nottingham, file ABEER, from http://edkb.fda.gov/webstart/extdb_arraytrack/3.4/. R soft-
ware version 2.9.0 (R foundation for statistical computing) was used to analyse the final results
for the microarrays.
The data from the RNA sequencing facilities (University of Nottingham Next Generation Se-
quencing Facility) were analysed with CLC Genomics Workbench 3.7 software. The original
data can be found at http://spldeepseq.nottingham.ac.uk/~aziz/wtp_rat/. 
The rat genome used was from Ensembl at http://www.ensembl.org/Rattus_norvegicus/Info/In-
dex, and the translation to gene names was done with rat genome database RGD tools at http://
rgd.mcw.edu/rgdweb/search/genes.html?100. Microarray heatmaps were established with
High-Throughput GoMiner (Zeeberg, 2005). This software uses just + or - so it dose not show
the differences in between but it gives the main pathways.
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Section 2.2  Methods
Section 2.2.1  Dosing of animals
The chemicals were administrated to the animals in different dosing schedules depending on the
study, ensuring that the least suffering and stress was applied to the animals at all times.
The dosing schedules were:
1- Acute dosing schedule.
2- Chronic dosing schedule.
3- Gavage dosing schedule.
Section 2.2.1.1 Acute dosing schedule
In the acute study 100 mg kg-1 5-bromo-2'-deoxyuridine (BrdU) was given to the animals by
intra peritoneal (IP) injection, in a volume of 5 ml kg-1, two hours prior to killing the animals.
The BrdU was dissolved in phosphate buffer saline (PBS; 15mM NaH2PO4, 150mM NaCl, pH
adjusted to 7.4 with NaOH) then sterilized with a micro-filter (pore size of 0.2 µm).
All the animals were humanely killed with a single intraperitoneally overdose of Dolethal and
death was confirmed by cervical dislocation of the neck. Figure 2.1 represents a cartoon of the
experimental schedule of the acute dosing protocol.
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Section 2.2.1.2  Chronic dosing schedule
The dosing of the BrdU to the animals in the chronic experiments was carried out by acclima-
tizing them to 10% (v/v) Sainsbury’s orange juice as their sole source of fluid for 7 days then
on orange juice supplemented with 0.08% (w/v) BrdU. All drinking bottles containing BrdU
were covered with aluminum foil to protect them from light, and were changed on a daily basis.
All the animals were humanely killed with a single intraperitoneally overdose of Dolethal and
death was confirmed by cervical dislocation of the neck. In Figure 2.2 and Figure 2.3 a cartoon
is illustrated showing the experimental schedule of the chronic dosing protocol for the testing
of the effects of BrdU (Figure 2.2) and for the experimental design of the chronic dosing sched-
uale.
Figure 2.1 Schematic representation of acute and gavage dosing protocols. Cartoon describes the acute dos-
ing schedule for studying the time course of induction of hepatic DNA synthesis. The blue arrows represent the number of
hours when the acute IP dosing of the BrdU (100mg kg-1 body weight) accrued. The black arrows show the time of scarifying
the animals 2 hours after the BrdU. The red arrows indicate the time of gavage dosing of the drug or vehicle at 0 or 24 hours.
Each sequence of the time course line specifies a 2 hour time limit, the red is the time before the BrdU started. 
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Figure 2.2 Schematic representation of chronic dosing protocol alone. Cartoon describes the chronic dosing
schedule for studying the BrdU effects in mice. The green sequences show the number of days the animals were given 10%
orange juice as sole source of drinking fluid. The orange sequences represent the number of days the animals had BrdU with
the orange juice as their sole source of drinking fluid. Each sequence of the time course line specifies a 1 day time limit. 
Figure 2.3 Schematic representation of chronic and gavage dosing protocols. Cartoon describes the
chronic dosing schedule for studying the time course of induction of hepatic DNA synthesis. The green sequences show
the number of days the animals were given 10% orange juice as their sole source of drinking fluid. The orange sequence
represent the number of days the animals had BrdU with the orange juice as their sole source of drinking fluid. The red
sequences show the number of days the animals had started the ciprofibrate with the BrdU in the orange juice as their
sole source of drinking fluids. The red arrows indicate the time of gavage dosing of the drug or vehicle and the black
arrows show the time of scarifying the animals. Each sequence of the time course line specifies a 1 day time limit. 
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Section 2.2.1.3  Gavage dosing schedule
The ciprofibrate, cyproterone acetate (CPA), pregnenolone-16α-carbonitrile (PCN) in the time
course was 50mg kg-1 ciprofibrate for 1, 3, 5, 16, 20, 24, 30, and 48 hours in the rat study and
100mg kg-1 for 2, 4 and 6 days in the mouse study. For the CPA and PCN the dose was 100mg
kg-1 for 24 hours. The doses for the dose response was 50, 100, 200, and 300mg kg-1 after 24
hours. 
These were administrated to the animals in corn oil as a vehicle by a gavage injection that en-
ables the drug to be administrated straight to the stomach.
Section 2.2.2 Animal observations and tissue collection
The animals were observed 2-3 times daily for signs of distress or discomfort. Daily measure-
ments of body weight were recorded at the same time (10-11am) each day, to monitor the well-
being and health of the animals. 
Immediately after killing the animals, blood samples were collected in plain tubes by cardiac
puncture. After the blood had clotted (2-4 hours) it was centrifuged at 14000 Xg and the serum
frozen for the clinical chemistry procedures.
The liver weights of the animals were recorded and the percentage of the body weight to liver
weight calculated. Aliquots of fresh liver and a part of the intestine (as positive control) were
fixed for immunohistochemical analysis (formalin fixation), or snap frozen in liquid nitrogen
for storage at -80οC prior to biochemical analysis. 
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Section 2.2.3  Immunohistochemistry technique for BrdU paraffin sections
This method was used to determine the percentage of BrdU-labelled cells during induction of
DNA synthesis in the animals’ liver as a result of the ciprofibrate’s or cyproterone acetate’s ac-
tion. The two-step indirect method was originally optimized by (Al Kholaifi, 2008).
In this method the thymidine analog BrdU was dosed to the animals orally or injected.
Section 2.2.3.1  Tissue processing
Tissues were freshly collected from the animals. The livers and a section of the intestine were
stored in a fixative 10% (v/v) formalin until used. The tissues were left in the fixative not more
than 3 days. Fixed tissues were dehydrated and infiltrated with paraffin wax by processing in a
Shandon Citadel 2000 Automated Tissue Processor (protocol shown in Table 2.2).
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After the tissue processing, the tissues were manually embedded in paraffin wax, and left on ice
for at least 48 hours before sectioning with a microtome set to 4.5µm. 
The sections were floated on a preheated water bath to 37oC before mounting on PolylysineTM
adhesive coated glass slides. The slides were then left overnight on a hot plate at 37oC to dry.
Table 2.2 Protocol for tissue processing. 
Solution Time
70% ethanol 6.5 hours
80% ethanol 1 hour
90% ethanol 1 hour
95% ethanol 1 hour
100% ethanol 
 
1 hour 
100% ethanol 1 hour
100% ethanol 1 hour
xylene 1 hour 
xylene 1 hour
xylene 1 hour
paraffin wax 1 hour
paraffin wax 1 hour
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Section 2.2.3.2  BrdU immunohistochemical staining
Immunohistochemical staining was performed by heating the sections for 2-3 minutes or until
the wax was melted, then placing them in xylene for 5 min. The sections were rehydrated in a
decreasing series of ethanol concentrations (100%, 70%, 50%) and then washed in water. The
slides were then treated with fresh 3% (v/v) hydrogen peroxide in methanol to quench the en-
dogenous peroxidase, and then washed twice with PBS. 
To retrieve the BrdU antigen a heat induced epitope retrieval technique was used, where the
slides were plunged in boiling 10mM citric acid followed by 10 min. at 60oC, using a 700 Watt-
microwave (heating induces epitope retrieval by breaking the DNA, and unmasking the BrdU).
Slides were then washed with PBS.
The slides were incubated horizontally, and in a warm, moist chamber with a 0.5% (w/v) bovine
serum albumin (BSA) blocking solution to block non-specific binding of cytosolic BrdU. Then
the slides were incubated for 45 min with Amersham mouse monoclonal anti-BrdU antibody
[1:1000 dilution in tris buffer saline (TBS)], then washed with distilled water. 
The secondary antibody, blotting grade goat anti-rabbit IgG horseradish peroxidase conjugate,
was added for 30 min. The slides were then rinsed in PBS.
The slides were returned to a vertical orientation for incubation in the staining solution DAB
reagent, before being washed with water.
The slides were then subjected to a standard histological staining procedure as shown in Table
2.3, where the slides were dipped in haematoxylin solution, washed, dipped in acid alcohol, then
rinsed in running tap water, then in ammonia in water, and washed again in tap water. Then for
the final dehydration of the slides, they were placed in an increasing series of ethanol (50%,
 
Abeer Amer   Section 2.2.3
Page 55
70%, 95%, 100%). 
Finally the slides were treated with 100% xylene, and then mounted with DPX and covered with
a cover slip each to protect the tissue from shrinking. 
The slides were ready to be examined, preferably after 12-24 hours so the slides were complete-
ly dried.
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Table 2.3 Protocol for BrdU immunohistochemical staining. 
Application Preparation of Application Time 
Heat heat the slides until the wax melts 2-3 minutes
Xylene Xylene 5 minutes 
Ethanol 100%-70%- 50% 8- 4- 3 minutes 
respectively
H2O H2O 2 minutes
H2O2 3% H2O2 (180ml methanol+20ml hydrogen 
peroxide)
15 minutes
Phosphate 
buffer saline 
PBS
0.1M is 11.5g Na2HPO4di-sodium hydrogen 
orthophosphate 2.96g NaH2PO4.2H2O sodium 
phosphate and 5.84g sodium chloride NaCl in 
1litre distilled water
5 minutes twice (X2)
Citric acid 10mM 2.1g citric acid in 1L dH2O, adjust pH at 
6.0 using 1N sodium hydroxide NaOH.
Boiled citric acid 10 
minutes at 40oC
PBS Phosphate buffer saline (as before) 5 minutes
Bovine serum 
albumin
BSA 5% (blocking solution) is 5g Bovine serum 
albumin, 0.5ml Tween-20 in 100ml PBS.
15 minutes
Primary 
antibodies
(anti-BrdU mouse monoclonal antibody from 
Amersham). Freshly prepared 1:1000 dilution 
buffer is 3g BSA+100µl Tween-20 in 100ml TBS 
(Tris buffer saline) pH 7.8.
45 minutes
H2O  H2O 5 minutes
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Secondary 
antibodies 
(peroxidase anti-mouse IgG from Bio-rad) freshly 
prepare 1:100/slide. Dilution buffer is 0.087g 
monosodium phosphate monohydrate 
NaH2PO4.H2O, 0.194g disodium phosphate 
(anhydrous) Na2HPO4, 1.75g sodium chloride 
NaCl and 2g BSA in 200ml distilled H2O
30 minutes
PBS Phosphate buffer saline (as before) 9 minutes
Staining solu-
tion DAB
(development reagent is 200µl hydrogen perox-
ide+ A + 4ml of B) A development reagent is 
176ml TBS 10mM Ph 7.6 (1.21g tris base+5.64g 
NaCl, adjust PH to 7.8 using HCl in 1 liter distal 
water) with 20ml intensifier 0.25% cobaltous chlo-
ride. B is the DAB 25mg/ml stock solution, and is 
0.5g DAB powder in 20ml phosphate buffer.
8 minutes
H2O Distal H2O 3 minutes
Haematoxy-
lin solution.
(Harris) Haematoxylin 100ml+glacial acetic acid 
4ml, filter before use.
30 seconds
H2O Running tap water 3 minutes
Acid alcohol (for differentiation) 700 ml commercial grade eth-
anol with 300ml distilled water and 10ml concen-
trated hydrochloric acid.
5 seconds
H2O Rinse in running tap water 1 minute
Ammonia 0.2% Ammonia in water 1 second
H2O Tap water 3 minutes
Ethanol Ethanol 50%-70%- 95%-100% 1 minute each
Xylene Xylene (X2) 1 minute each
DPX Mount with DPX (Distyrene, plasterine, and 
xylene) and cover with cover slide.
~1 minute each slide
Table 2.3 Protocol for BrdU immunohistochemical staining. 
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Section 2.2.4 Examination of the slides
The immunohistochemically stained slides were examined in one of two ways, depending on
the study: 1- Labelling index studies
2- Zonal distribution studies
Section 2.2.4.1  Labelling index studies
To determine the hepatic DNA labelling index, one slide (with a slice of liver and gut) from each
animal was used and 2000 nuclei were examined from random fields of view of each slide (the
mean was calculated as the number of animals). Nuclei labelled with BrdU give a dark black/
brown colour (Figure 2.4) indicating that the cell has undergone DNA division. These cells were
also counted as well as non-labelled nuclei. The percentage of the labelled nuclei was then cal-
culated. A CX21 Olympus microscope was used with a graticule eye piece. The magnification
used was X400.
Figure 2.4 BrdU labelled hepatocytes. On the left a section of the liver with non-labelled and labelled hepato-
cytes. On the right a section of the intestine used as a control and shows the labelled epithelium cells in a dark colour and
the non-labelled cells are pale at the top. The magnification of the liver is X400, and of the intestine is X100
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Section 2.2.4.2  Zonal distribution studies
To determine the zonal distribution of the BrdU-labelled hepatocytes; the number of labelled
and non-labelled nuclei per field was counted. 
A field is defined from (Barrass et al., 1993) as a radius of five to seven cells around either the
portal space, which is the periportal region, or the central vein which is the perivenous region
(Figure 2.5). 
Ten random areas of both periportal and perivenous regions were counted (five each). Small
central veins or portal spaces of similar sizes were selected for the analysis of the perivenous or
periportal. One slide per animal was used. The total number of labelled nuclei in five fields was
recorded for each of the periportal and perivenous zones. 
An Olympus CX21 reflected light upright microscope was used at X400, with a graticule eye
piece.
Figure 2.5 The periportal and perivenous zones. On the left is a portal space containing the portal vein, the he-
patic artery and the bile duct and the surrounding hepatocytes which are the periportal zone. On the right is the central vein
with the surrounding hepatocytes which count as the perivenous zone. The magnification is X100.
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Section 2.2.5 Microarray analysis
Section 2.2.5.1  RNA isolations
Total RNA was isolated using TRI reagent® solution from frozen liver cells with the following
procedure: 
TRI reagent® solution (1 ml) was added to 80-90 mg of frozen liver tissue pieces in a 1.5 ml
Ependorff tube, and homogenized with a mini homogenizer for 2-3 min. The mixture was left
to sit at room temperature for 5 min, before 200 µl 1-bromo-3-chloro-propane (Sigma) was add-
ed and the mixture shaken vigorously for 15 seconds. 
Then the samples were vortexed on full speed for 5-10 seconds, and incubated for 2-3 min at
room temperature. The samples were centrifuged at 14000 Xg for 14 min, at 4oC. 
The upper layer was carefully transferred to a new RNAse-free 1.5ml Ependorff tube and 600µl
isopropanol was added. After mixing, the tube was incubated at room temperature for 10 min.
The samples were centrifuged at 14000 Xg for 10 min to pellet the RNA. All subsequent pro-
cedures were performed at 4oC (on ice). The supernatant was removed carefully, then the pellet
was washed twice with 0.5 ml ice cold 75% ethanol, centrifuging between each wash step. 
The pellet was resuspended in ~50-100µl diethyl pyro carbonate (DECP) water and stored at -
80oC until use. 
Note; DECP water was made by mixing 1ml DECP (diethyl pyro carbonate) and 9 ml pure eth-
anol (absolute) in 1 litre distilled water, and then autoclaved.
Filter pipette tips and clean gloves were used for all the procedures. The gloves were changed
on a regular basis.
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Section 2.2.5.2  Synthesis and labelling of cDNA from RNA
This was done with a modified technique, using an Amino allyl cDNA labelling Kit Ambion®
the RNA company. 
To reverse transcribe the RNA, 1µl RT primer was added to around 20µg total RNA and dena-
tured at 75oC for 9 min. Added to this was 2µl 10X RT buffer, 1µl RNase inhibitor, 1µl dNTP
mix (dATP, dCTP, dGTP), 1µl dTTP+AA dUTP mix and 2µl M-MLV reverse transcriptase.
The mixture was incubated at 42oC for 1 h and 45 min, then 4µl 1M NaOH was added before
incubation at 65oC for 15 min to remove the template RNA by alkaline hydrolysis. The reaction
was then neutralized with 10µl 1M HEPES buffer.
The cDNA was recovered by ethanol precipitation, by incubating with 3.4µl 3M sodium acetate
and 100µl 100% ethanol at -80oC for 1-2 h. 
The cDNA was pelleted by centrifugation at 14000 Xg at 4oC for 15 min, the supernatant was
carefully aspirated and discarded, and then the cDNA pellet was washed by adding ~0.5 ml of
75% (v/v) ice cold ethanol and vortexed briefly, before centrifuged for ~5 min at 14000 Xg at
4oC, and carefully removed and the supernatant discarded. 
To remove the last traces of ethanol the tube was re-centrifuged for ~5 min at 14000 Xg at 4oC,
and a small sized pipet was used to remove the residual fluid.
The cDNA was then resuspended in 4.5µl coupling buffer and 2.5µl nuclease-free water, mixed
thoroughly and gently vortexed, and then the tube was centrifuged briefly.
To couple dye to the amino modified cDNA, 3µl fluorescent dyes Alexa Fluor® 555 or Alexa
Fluor® 647 were dissolved in 3µl 100% DMSO, then the dyes were added to the cDNA and
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incubated in the dark at room temperature for 1 hour. 
6µl of 4M hydroxylamine was added to the mixture, before incubation for 15 min at room tem-
perature in the dark to terminate the coupling reaction. 
The labelled cDNA was purified using rehydrated NucAway spin columns after hydrating the
columns with 650µl nuclease free water for 1-2 h just before use. The cDNA was transferred on
to the matrix of the NucAway spin columns and centrifuged at 750 Xg for 2 min (according to
the manufacturer’s instructions). 
The dyed -labelled cDNA was run through the column to a 1.5 ml Ependorff tube positioned
beneath the column and the free dye was retained in the spin column matrix. 
The dye-labelled cDNA was prepared for concentration by ethanol precipitation by adding 9µl
2M sodium acetate and 250µl 100% ethanol and storage at -80oC overnight.
The next day the labelled cDNA was centrifuged for 15 min at 14000 Xg at 4oC then the super-
natant was carefully removed, and the dye-labelled cDNA pellet was washed by adding ~0.5 ml
of 75% (v/v) ice cold ethanol and vortexed briefly. 
The tube was then centrifuged for ~5 min at 14000 Xg at 4oC, and carefully removed and the
supernatant discarded. To remove the last traces of ethanol the tube was re-centrifuged for ~5
min at 14000 Xg at 4oC, and then with a small sized pipet the residual fluid was removed.
The cDNA was a small pellet, 1-2 mm in diameter, which was visibly red for the Alexa Fluor®
555 or blue for the Alexa Fluor® 647.
The dye-labelled cDNA was suspended in 25-40µl RNA-free water and the success of the la-
belling was assessed with a nanodrop machine to measure the optical density (OD) of the cDNA
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and the labelled dyes. 
Note that all the labelled fluorescent steps were done in the dark.
Section 2.2.5.3  Hybridization of the cDNA
The dye-labelled cDNA was mixed with 2µl tRNA (4ml ml-1) and 40-80µl hybridization buffer
and centrifuged briefly to collect the mix, then denatured for 5 min at 100oC and incubated for
1 h at 42oC.
The MEEBO array slides and the cover slips were prepared for use by washing the oligo arrays
twice in 0.2% (w/v) sodium dodecyl sulfate (SDS) for 2 min, then twice in ddH2O for 2 min
each, and then dried by centrifugation at 250 Xg for 4 min. 
The cover slips were washed in 1% (w/v) SDS for 30 min and then underwent 5 X 5 min washes
with dH2O, before being spun dry/wiped dry and stored in a dust free environment.
The cDNA was spread on the MEEBO array slides by placing the slide over a template slide (to
indicate where the array is located on the slide) and placing the coverslip over the array before
carefully and slowly pipetting the labelled-cDNA between the slide and the coverslip at either
end. The sample draws itself underneath the coverslip by capillary movement covering the en-
tire array area. This was done in the dark. 
The slides were then kept in the dark and placed on a slow moving shaker for a couple of min-
utes to assist an even spread of the cDNA on the array slide.
Nucleic acid hybridization was then performed by incubating the slides overnight at 42oC in a
Gentix hybridization chamber. To ensure that the slides were kept humid, 5ml water was added
in the chamber.
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The slides were washed after hybridization, for 5 min with 1X SSC buffer and 0.03% (w/v) SDS
after removing the coverslips, and then were washed in 0.2X SSC for 3 min, and in 0.05X SSC
for 3 min. 
The slides were then dried by centrifuging them at 250 Xg for 4 min.
Section 2.2.5.4  Scanning of the array slides
The slides were scanned with a GenePix 4200A Axon scanner and a Genepix professional (6)
and a Genepix professional (6) software program, with hardware settings of 635 (standard red)
and 532 (standard green) for the wavelengths and laser power of 70% and filters of Cy5 and Cy3
for the high and low wavelengths respectively. 
The slides were scanned at two wavelengths (532 nm for the Alexa Fluor® 555 dye and 635 nm
for the Alexa Fluor® 647 dye). 
The ratio was always on 635/532 with the GenePix array list (GAL) file. The images were saved
as 3 multi-images, Tagged Image File Format TIFF (compressed).
Section 2.2.5.5  Fitting features of the scanned array slides
The images were opened for analysis with the GenePix Pro (6) program at a ratio formulation
of 635/532. The blocks from the GenePix Array List (GAL) files were subsequently aligned on
the images from the scanner. The relevant GAL file (A or B) was superimposed on the slide and
each of the blocks and features aligned automatically. The features were then checked manually
for empty or irrelevant features. 
After fitting all the blocks and the features for each of the A and B slides, and the results from
the analysis were saved as a GenePix results (GPR) file which could be opened in Excel.
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Section 2.2.5.6  Normalization of the GPR files
 The files were normalised with NORTT, which is a normalise program and Student’s t- test
gene expression data program 1.1.0, from the MRC Toxicology Unit.
The normalization was an intensity-dependent normalization with settings to treat the back-
ground fluorescence as zero and to pre-condense data by gene identity. The labelling method
was chosen as Cy3 for the control (555) and Cy5 for the treated (674). Data that is flagged by
GenePix as having failed to record a florescence in both channels was ignored. A normalised
data file *.NOR was generated and saved. Data which had a single channel only, failed the
threshold test, or failed to pass the circularity test in GenePix 5.0 was written to a *.NEG file.
Section 2.2.5.7 Analysis of the microarray data 
For the comparision and the quality control of the microarray data, microarray stastical analysis
was done with Microsoft Excel 2007, where the power of the normalised log2 ratio of median
was used. 
To compare between the microarray data with linear regression, a VLOOKUP (VLOOKUP
searches for a value in the first column of a table array and returns a value in the same row from
another column in the table array) was used to identify the value of one array data corresponding
to the value in the second array of data. The linear regression line was fitted with Graphpad
prism 5. The microarray experimental data was stored and normalised in the Array Track and
then the R software was used to analyse and identify the genes of interest.
High-Throughput GoMiner program (Zeeberg, 2005) was used to interpret the the microarray
data.
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Section 2.2.6 Transcriptome sequencing 
Section 2.2.6.1 Sequencing
RNA sequencing was performed on RNA liver samples from F344 rats treated with ciprofi-
brate/corn oil for 3 hours. The University of Nottingham Next Generation AB SOLID 3 plat-
form Sequencer was used, where it was broken up to ~20 Kbp with a sonicator, then each
sequence was ligated with a labeled sequence of nucleotides, this generate a monoclonal se-
quencing unit (which is the sequence attached to beans on a 1:1 basis).
The monoclonal sequence units were then placed on slides, and then the sequencer read the in-
formation from the slides as short reads (which are readings of short parts of the whole DNA).
These short reads were assembled with Ensembl software.
Section 2.2.6.2 Expression analysis
After generating the data it was analysed with CLC Genomics Workbench 3.7 software. To
analyse differential expression, it was of importance to tell the workbench program how the
samples were related. This was done by setting up an experiment to define the relationship be-
tween the samples, which was defined as a two group experiment (control and treated) n=4. The
samples were specified as unpaired multi-group comparison with the number of groups as 2
groups.
Normalization with CLC Genomics Workbench program was essential in order to ensure that
the samples were comparable and assumptions on the data for analysis were met, and to remove
the bias effects of the sample preparation and array processing. This was done with a quantile
normalization method before the statistical analysis was carried out.
Quality control was performed on the normalised data with CLC Genomics Workbench pro-
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gram to enable visual inspection of the distribution and variability of the data, and to allow in-
decation of any unwanted systematic differences between the samples. 
The tools used were box plots/analyzing distributions, Hierarchical Clustering of samples and
Principal Component Analysis. After the above steps the samples were ready for statistical anal-
ysis. Following statistical analysis the retrieval of the genomic information was processed using
rat genome data RGD base tools, by entering the Ensembl number of the genes manually to re-
cover the gene name and description.
Section 2.2.7 Quantitative real-time reverse transcriptase polymerase chain 
reaction (qRT-PCR)
Section 2.2.7.1 High Capacity RNA-to-cDNA
cDNAs were made from each of the 4 biological replicates obtained for each of the 3 treatments
at the 4 timepoints. This was done using the high capacity RNA-to-cDNA kit (Applied Biosys-
tems) according to manufacturers’ instructions. As negative controls, the reaction was set up
without a RT enzyme mix (-RT) to ensure no contamination from the buffer, and the whole mix
without the RNA (-RNA) was used to control for genomic DNA contamination. The samples
were prepared by using up to 2 µg of total RNA per 20 µl reaction as in Table 2.4.
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The tubes were mixed well and briefly centrifuged to spin down the contents and to eliminate
air bubbles. Everything was on ice until used.
The samples were run with the program shown in Table 2.5 to initiate the reverse transcription
reaction. 
The cDNA was stored at -20oC until used.
Table 2.4 Preparation of the RT reaction mix. 
Component Volume/reaction (µl) Volume/reaction (µl)
+RT -RT
2X RT buffer 10.0 10.0
20X RT enzyme mix 1.0 -
nuclease-free water quantity sufficient to 20 µl quantity sufficient to 20 µl
RNA sample up to 2 µl up to 2 µl
total per reaction 20 20
Table 2.5 Optimal conditions for use with high capacity RNA-to-cDNA kit. 
Temperature oC Time (min)
Step 1 37 60
Step 2 95 5 
Step 3 4 infinity
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Section 2.2.7.2 Standard curves for qRT-PCR products
Standard curves for each of the genes used (CYP4A1, CYP3A1 G0s2, Ccnd1, AhR, β-actin and
Scd1) were created by using 5-fold serial dilutions of a control cDNA to demonstrate the qRT-
PCR efficiency. This was done in triplicate.
The standard curves for each of the genes were generated with MX4000 software using a least
mean squares curve fitting logarithm. The regression value r2 was generated for each gene as
(Y= mlogX + b) where m is the slope of the line.
The average amplification efficiency was determined as it is directly related to the slope of the
curve throughout the cycling reaction. The amplification efficiency is 10 (-1/slope). This corre-
sponds to the number of template molecules that are duplicated every cycle. 
Section 2.2.7.3 Quantitative real-time PCR using TaqMan® gene expression
This was done with TaqMan® gene expression master mix real-time PCR, which supplies a flu-
orescence reading of messenger RNA mRNA expression throughout each cycle of the PCR pro-
cedure, which in turn uses a quantitative study of mRNA expression based on PCR cycling
threshold (Ct) values using MX4000 software. The primers and probes were amplified, with one
or more endogenous control gene in the same reaction. The endogenous control was chosen on
the fact that the gene induction was not changed in the control and samples treated with cipro-
fibrate or CPA. 
The qRT-PCR was used to study the changes in gene expression of CYP4A1, CYP3A1 G0s2,
Ccnd1, and Scd1 by using AhR and β-actin as normalization genes. CYP4A1 and CYP3A1 were
used as positive controls for the ciprofibrate and CPA respectively. No template control (NTC),
-RT and -RNA were run in parallel as negative controls, and each sample was done in two rep-
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licates.
The best annealing temperature, the amounts of Forward, Reverse, primers and cDNA were all
optimized with stepwise procedures (data not shown). The real-time PCR reaction was deter-
mined as in (Table 2.6) and amplified as in (Table 2.7) with a TaqMan thermal cycler MX400.
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Table 2.6 Real-time PCR reaction. The amount of master mix is 18µl and then DECP water 
was added to the final amount of 45µl. This was ready to be spread in two 20µl well on a 96 well plate. 
The concentrations of the primers were 10 pmol/µl for the primers and 5 pmol/µl for the probes.
Gene
Forward 
primer (µl)
Reverse 
primer (µl) Probe (µl)
AhR 1.5 1.5 1.5
β-actin 1.5 1.5 1.5
Ccnd1 1.5 2.25 2.25
CYP3A1 2.25 2.25 2.25
CYP4A1 2.25 2.25 2.25
G0s2 2.25 2.25 2.25
 Scd1 2.25 2.25 2.25
Table 2.7 Real-time PCR cycle program. The conditions of the real-time PCR reaction, the 
whole reaction was 90 min.
Number Of Cycles Temperature (oC) Time 
1 95 10 min
40 95 20 sec
40 60 1 min
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Section 2.2.7.4 Statistical analysis of qRT-PCR 
Biogazelle qBasePluse software was used to normalise and analyse the gene expression with the
relative quantity method. The magnitudes of RNA number of the genes targeted were deter-
mined from the experiments Ct values. The copy number of the samples was normalised to that
of the endogenous controls AhR and β-actin.
Section 2.2.8 Quantity and quality measurement of RNA and cDNA
To quantitate the RNA, absorbance at 260nm was determined with a CECIL CE9500 Spectro-
photometer, while a Nanodrop machine was used to measure the quantity of the cDNA and the
amount of fluorescent labelling of the 555 and 647 dyes.
The concentrations of nucleic acid in the samples were determined according to 1 OD (optimal
density) at 260nm = 20-33 ng/µl of single stranded DNA (for cDNA), and 1 OD at 260nm = 40
ng/µl of RNA. 
Agarose gels [2% (1.0g/50ml)] were used to check the quality of the RNA. They were prepared
by adding 1g agarose powder to 50 ml 1X tris boric acid EDTA (TBE) (10X TBE was prepared
by adding 108g Tris base, 55g Boric acid, 9.3g Na2EDTA to 1 litre diluted water) with 0.5ml
10 X SDS. Gels were post-stained with ethidium bromide.
Section 2.2.9 Measurement of serum Alanine Aminotransferase ALT
Measurement of serum Alanine Aminotransferase (ALT) activity was carried out using Vitros
ALT slides (Ortho-Clinical Diagnostics). The serum ALT test was performed as a service, in
the Clinical Chemistry Section, Pathology Department in the Queens Medical Centre (QMC),
Nottingham. 
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Section 2.2.10 Statistical analysis 
All data is represented as mean ± standard deviation. Statistical significance was tested by Un-
paired Student’s t- test to compare between two data sets with two tailed distributions and a two
sample equal variance. Dunnett's Multiple Comparison Test with a one way analysis of variance
(ANOVA) was used for multiple comparisons. This was done with GraphPad prism 5.0 soft-
ware (Inc, SanDiego, CA).
Statistical analysis for the RNA sequencing data was done with Student’s t- test. Also the false
discovery rate FDR was controlled (the false discovery rate is the proportion of false positives
among the declared positive). The method used in CLC Genomics Workbench for controlling
the FDR is that of Benjamini (Benjamini and Hochberg, 1995). 
The inspection of the result of the statistical analysis was done with CLC Genomics Workbench
software.
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Chapter 3 Results
Section 3.1Induction of hepatic DNA synthesis
Mouse liver was initially chosen, as it might provide a better model than rat liver, because of
the availability of knockout mice. However, previous studies on strains of mice dosed with per-
oxisome proliferators (Styles et al., 1990) showed that the induction of hepatic DNA synthesis
in mice starts at 24 hours, while others (Al Kholaifi, 2008) and (Al Kholaifi et al., 2008) found
that it did not start until after 3-4 days after dosing. It was therefore necessary to investigate
when exactly the hepatic induction happens in different strains of mice. 
Section 3.1.1 Studies in mice
Section 3.1.1.1 Optimization of immunohistochemical technique
The aim was to optimize the protocol for immunohistochemistry, specifically the secondary an-
tibody concentrations and the dewaxing time for the histological process. 
A set of liver sections were stained by immunohistochemical protocol as described in Section
2.2.3.2 using the Amersham mouse anti-BrdU labelling system to detect BrdU incorporation
into DNA. Two antibodies were used, the primary antibody was anti-BrdU mouse monoclonal
antibody (1:1000) and different concentrations of secondary antibody (blotting grade goat anti-
rabbit LgG horseradish peroxidase conjugate) from Bio-rad company. The concentrations were
1:50, 1:100 and 1:500. Preliminary experiments revealed that the Bio-rad antibody gave a stron-
ger signal than Sigma and Amersham antibodies (data not shown). 
As shown in Figure 3.1 the immunoreactivity observed in slide A (1:50) is very strong but the
noise is also very high. The other hand slide C (1:500) has very low noise but BrdU is not de-
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tected in the hepatocytes. Slide B (1:100) shows a good signal-to-noise ratio, and this concen-
tration of secondary was used for immunohistochemical staining for the rest of the experiments. 
The next part was to optimize the dewaxing time. The existing protocol required leaving the
slides in xylene pots for 2 X15 minutes. 
After preparing the slides (Section 2.2.3.1) they were left at 40oC for 2 minutes (or until the wax
started to melt) then in xylene for 5 minutes. Liver and gut sections stained with this protocol
had a high signal-to-noise ratio when compared with the 30 minute dewaxing time (Figure 3.2).
Gut sections were used for all the experiments as a positive control (Figure 3.2 E and F). The
intestinal epithelium consistently undergoes cell renewal, so it will show if the BrdU is taken
up by the animal or not, and the labelled nuclei have a high signal to noise ratio especially in the
intestinal crypts where the proliferation and differentiation occurs (Wille et al., 2004). 
Figure 3.1 Optimization of secondary antibody concentration for immunohistochemistry. The fig-
ure shows slides stained with different concentrations of secondary antibody on 4.5µm thick liver sections from male
129S4/SvJae mice 9-10 weeks old. The animals were treated with 0.05 mg/kg BrdU with orange juice as their sole source
of fluid, then gavaged with 100 mg/kg ciprofibrate for 4 days. The livers were then processed as in Section 2.2.3.1. The
slides were stained according to immunohistochemical protocol using Amersham cell proliferation kit with different con-
centrations of secondary antibody from Bio-Rad. In slide A the concentration of the secondary antibody: buffer is 1:50,
in slide B its 1:100 and in slide C 1:500. The slides are Harris haematoxylin counterstained. The photos were taken with
a gray scale camera. The sections were examined under a light microscope at 400x. The scale bar=10µm.
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Similar optimization was undertaken to reduce the time needed for dehydration, hydration, and
the time for primary antibody immunodetection of the incorporated BrdU (data not shown). 
The overall time required for the immunohistochemical staining protocol was reduced from ~6
hours to ~3.5 hours. Thus, these data show that reducing the time for the immunohistochemical
staining protocol does not necessarily decrease the quality of the slides. This revised procedure
was used for the immunohistochemical staining for the rest of the experiments.
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Figure 3.2 Optimizing of the dewaxing procedure. Liver and gut sections from male 129S4/SvJae mice. The
animals were treated with BrdU for 5 days and gavaged with ciprofibrate for 4 days as shown in Figure 3.1. The slides were
then stained with immunohistochemical protocol (Section 2.2.3.2). A,C (liver sections) and E (gut section) were dewaxed
by putting the slides at 40oC for 2 minutes, then (while still hot) left in xylene for 5 minutes. B,D (liver sections) and F (gut
section) were dewaxed by leaving in xylene for 2x15 minutes. Slides were counterstained with Harris haematoxylin. Sec-
tions were examined under a light microscope at 400X. Photos were taken with a gray scale camera. For A and B the scale
bar=10µm for C,D,E and F the scale bar=50µm.
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Section 3.1.1.2 Effect of ciprofibrate on hepatic DNA synthesis in mice
Previous work (Al Kholaifi, 2008) in 129S4/SvJae mice showed that induction of hepatic DNA
synthesis starts 3-4 days after dosing with peroxisome proliferators (methylclofenapate MCP),
and this differs from work done by (Styles et al., 1990) on C57BL/6J mice who found that DNA
synthesis starts as early as 24 hours after dosing with MCP. 
This experiment was designed to study the time course of hepatic response to ciprofibrate in dif-
ferent strains of mice, to see whether the time course is distinct in different strains. Two inbred
strains of mice were chosen C57BL/6JCrl which are resistant to liver carcinogenesis and DBA/
2JCrl which are relatively susceptible to liver carcinogenesis (Diwan et al., 1986).
Section 3.1.1.2.1 Effect of BrdU in DBA/2JCrl mice
Before studying the effects of ciprofibrate on liver growth in DBA/2JCrl it was of importance
to exclude any toxic effect from the BrdU -which is used as a DNA label- by studying the effect
of BrdU on body weight (the effect on body weight acts as an indication for toxicity). 
Male DBA/2JCrl mice were acclimatised for 7 days with 10% orange juice as their sole source
of fluid, then dosed with 0.05% or 0.08% 5-Bromo-2'-deoxyuridine (BrdU) in 10% orange juice
for 6 more days. The animals body weight was measured daily. The results established that,
there was no significant difference between the weight of animals when beginning the experi-
ment and at time of death (Student’s un-paired t- test) (Figure 3.3). 
From this result we can draw a conclusion that there was no gross toxic effect from the BrdU.
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Figure 3.3 Effects of BrdU on body weight in DBA/2JCrl mice. Groups of (matching weight) male
DBA/2JCrl mice aged 9-10 weeks old were acclimatised to 10% orange juice as their sole source of fluid, then were
dosed with 0.08% (indicated by red squares) or 0.05% (indicated by gray triangles) BrdU in the orange juice for six
more days (the beginning of the BrdU dosing is indicated by the horizontal black line). Mice body weights were mea-
sured on a daily basis for each individual mouse and relative body weight was calculated relative to the body weight
for each individual mouse on day 0. BrdU administration started on day 8, see Section 2.2.1.2. Data are the mean±SD
of 6 animals. With un-paired Student’s t- test there was no significant difference between the weight of animals when
starting BrdU and at the time of death. P<0.05.
Abeer Amer   Section 3.1.1
Page 80
Section 3.1.1.2.2 Effect of ciprofibrate in DBA/2JCrl mice
The aim of this experiment was to test the effect of ciprofibrate on the induction of hepatic DNA
synthesis in DBA/2JCrl mice.
Male DBA/2JCrl mice were acclimatized to 10% orange juice for 7 days then on day 8 they
were given 0.08% BrdU with orange juice as their sole source of fluid. After one day of expo-
sure to BrdU, 100mg kg-1 day-1 ciprofibrate or corn oil (which is used as a vehicle) was admin-
istrated to the animals by gavage daily (see Section 2.2.1). Figure 3.4 shows the body weight
relative to the body weight of each individual mouse on day 0. 
By day 3 it became apparent that one of the mice -in a control group- was preventing the rest of
the group from eating by aggressive behavior, so the average body weight of the group came
down on that day. The mouse was isolated, and the body weight of the group rose.
The results showed that the animals’ body weight was significantly larger at the end of the ex-
periment compared with the beginning of the experiment, (un-paired Student’s t- test, P<0.05). 
This shows that the BrdU and the ciprofibrate have no toxic effect on the body weight of the
DBA/2JCrl mice, and the growth of the animals was normal in comparison with the controls.
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The effect of ciprofibrate on liver growth of DBA/2JCrl mice is presented as relative liver
weight and hepatic DNA synthesis (Figure 3.5). 
Relative liver weight was significantly increased from 5.4±0.6% in the pooled control to
7.8±0.3% and 9.2±0.4% in the 4 and 6 days treated groups respectively, but there was no sig-
nificant difference between the pooled control and the treated group for 2 days (6.2±0.4%) with
Dunnett's multiple comparison test (P<0.05) (Figure 3.5A). 
The induction of hepatic DNA synthesis (the percentage of the BrdU-labelled hepatocytes to the
total number of hepatocytes) was assessed as described in Section 2.2.4.1. The mice treated with
Figure 3.4 Effect of ciprofibrate on body weight in DBA/2JCrl mice. Groups of (matching weight)
male DBA/JCrl mice aged 9-10 weeks old were acclimatised to 10% orange juice then given 0.08% BrdU with or-
ange juice as their sole source of fluid. After one day of exposure to BrdU the animals were gavaged with corn oil
(vehicle) or 100mg kg-1 day-1 ciprofibrate (Section 2.2.1), and then killed after 2, 4 and 6 days of exposure to the
ciprofibrate/corn oil. Mice body weights were measured on a daily basis and body weight was calculated relative
to the body weight for each individual mouse on day 0. The BrdU administration started on day 8 and the red arrow
indicates the beginning of administration of ciprofibrate/corn oil. Data are the mean±SD of 6 animals. Significant
difference between the weight of animals when starting the experiment and at the time of death was done with un-
paired t- test (P<0.05).
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ciprofibrate for 2 days had no significant difference from the pooled control with Dunnett's mul-
tiple comparison test. On the other hand, animals dosed for 4 and 6 days with ciprofibrate had
a significantly larger hepatic labelling index indicating more hepatic DNA synthesis occurs than
the pooled control, as shown in Figure 3.5B. 
These data show that ciprofibrate increases liver weight and hepatic DNA labelling index after
4 days of dosing with ciprofibrate, but does not significantly affect the liver weight or hepatic
DNA synthesis after two days’ dosing. This result is substantively the same as previous findings
in 129S4/SvJae mice (Al Kholaifi et al., 2008). In conclusion the ciprofibrate has no effect on
body weight in DBA/2JCrl mice treated with ciprofibrate up to 6 days. In liver growth studies,
ciprofibrate did not show any significant increase on liver weight or on the induction of hepatic
DNA synthesis after 2 days exposure to ciprofibrate but the statistically significant effect started
after 4 days exposure.
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Figure 3.5 Effects of ciprofibrate on liver growth in DBA/2JCrl mice. Groups of six DBA/2JCrl male
mice aged 9-10 weeks were dosed with 100mg kg-1 day-1 ciprofibrate or corn oil vehicle as described in Figure 3.4, and
killed on days 2, 4 and 6. The left panel A shows liver to body weight ratio, the right panel B shows hepatic labelling index
(the percentage of the labelled hepatocytes to the total number of hepatocytes). Comparision with Dunnett’s multiple com-
parison test is against the pooled control group and statistically significant difference is indicated by an asterisk (p < 0.05).
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Section 3.1.1.3 Effect of ciprofibrate in C57BL/6JCrl mice
Styles (Styles et al., 1990) has previously shown that methylclofenapate induced DNA synthesis
at 24 hours after administration in the C57BL/J mouse strain. This experiment was designed to
test the effect of ciprofibrate on the induction of hepatic DNA synthesis in C57BL/6JCrl mice
by using immunohistochemical detection of BrdU. 
Male C57BL/6JCrl mice were acclimatised to 10% orange juice for 7 days as their sole source
of fluid, and then on day 8 they were given 0.08% BrdU with orange juice. After one day of
exposure to BrdU the mice were gavaged daily with ciprofibrate or corn oil/vehicle (as a con-
trol) (Section 2.2.1). Figure 3.6 shows the time course effects of 0.08% BrdU and 100mg kg-1
day-1 ciprofibrate in male C57BL/6JCrl mice on body weight relative to body weight of each
individual mouse on day 0. There was no significant difference between the animals body
weight when starting the experiment and at time of death for all treated and control groups. Sta-
tistics was done with un-paired Student’s t- test (P<0.05). 
From these results it can be indicated that there was no toxic effect from BrdU or the ciprofibrate
on C57BL/6JCrl male mice as measured by body weight loss. 
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There was significant increases in the relative liver weights, from 4.8±0.7% in the pooled con-
trol to 6.1±1.2% and 8.3±0.4% for the groups treated for 2 and 4 days respectively (Figure
3.7A). There was no significant difference in the hepatic labelling index between the pooled
control and the group treated for 2 days with ciprofibrate, while the labelling index was signif-
icantly higher after 4 days of dosing with ciprofibrate, as shown in Figure 3.7B (statistics were
done with Dunnett's multiple comparison test, P<0.05). 
From this we can establish that ciprofibrate has no toxic effect on body weight of C57BL/6JCrl
male mice, while it increases liver weight significantly over control after 2 days’ treatment. The
hepatic labelling index did not show any difference after 2 days’ exposure to ciprofibrate but
was significantly different after 4 days’ exposure. 
Figure 3.6 Effects of ciprofibrate on body weight in C57BL/6JCrl mice. Male C57BL/6JCrl mice aged
9-10 weeks were dosed with BrdU in the drinking orange juice and gavaged with corn oil (vehicle) or 100mg/kg/day
ciprofibrate, then killed after 2 and 4 days (Section 2.2.1). Mice body weights were measured on a daily basis and relative
body weight was calculated relative to the body weight for each individual mouse on day 0. The BrdU administration
started on day 7 and the red arrow indicates the beginning of ciprofibrate/corn oil administration. Data are the mean±SD
from 6 animals. There was no significant difference between the weight of the animals at the beginning of the experiment
and at the time of death with students t- test (P<0.05). 
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Figure 3.7 Effects of ciprofibrate on liver growth in C57BL/6Jcrl mice. Male C57BL/6JCrl mice aged
9-10 weeks were dosed as described earlier in Figure 3.6 with 100mg/kg/day ciprofibrate or corn oil, then killed on
days 2 and 4. In A Liver to body weight ratio was determined as described in Section 2.2.2. B shows hepatic labelling
index (the percentage of the labelled hepatocytes to the total number of hepatocytes). Data shown are mean±SD (n=6).
Statistically significant difference from the control group is indicated by an asterisk, with Dunnett's multiple compar-
ison test. (P<0.05).
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Section 3.1.2 Studies in F-344/NHsd rats
The demonstration that the induction of hepatic DNA synthesis with ciprofibrate in mice starts
after 3-4 days makes it quite hard to determine when the induction is triggered (there is a win-
dow of ~2-3 days where the signal could have happened). Therefore, rat liver was used to de-
termine if species difference would affect the timing of hepatic DNA synthesis. 
Section 3.1.2.1 Effect of ciprofibrate on hepatic DNA synthesis in F-344/NHsd rats
Section 3.1.2.1.1 Time course of ciprofibrate effect in F-344/NHsd rats
To identify the genes responsible for the hepatic DNA synthesis, it was necessary to identify
when the induction of hepatic DNA synthesis peaks in F-344/NHsd rats dosed with ciprofibrate. 
Groups of male F-344/NHsd rats were dosed with 50mg kg-1 day-1 ciprofibrate or corn oil (ve-
hicle) as a control, then killed after 16, 20, 24, 30, 36 and 48 hours. Two hours before killing
they were dosed intraperitoneally (IP) with 100 mg kg-1 BrdU. This experiment was done on
two different occasions. On the first the time points were 24, 30, 36 and 48 hours, and on the
second the time points were 16, 20, 24 and 30 hours. both with controls at the latest and earliest
time points. The animals were from the same source, and were the same strain and age (Section
2.2.1). 
Liver weight to body weight ratio is shown in Figure 3.8. Analysis with Dunnett's multiple com-
parison test showed a significant difference between the liver weight to body weight ratio for
the pooled control 3.6±0.4% and treated groups at the time points 24 hours (4.0±0.2%), 30 hours
(4.2±0.3%), 36 hours (4.1±0.3%), and 48 hours (4.8±0.2%) while for the groups killed at the
time points 16 and 20 hours there was no significant difference (P< 0.05). 
As a further test of whether the statistical significance found at the time points 24, 30, 36 and
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48 hours is spurious the treated and control groups were compared against each other at each
time point. It was found that the groups killed at the time points 24 and 30 hours had no signif-
icant difference when compared with the control groups at the same time point (24 hours treated
against 24 hours control, 30 hours treated against 30 hours control). The group treated for 36
hours (there was no control at that time point) was compared against the control groups killed
after 30 and 48 hours and there was no significant difference. 
This indicates that the difference at the time points 24, 30 and 36 hours are not biologically sig-
nificant and the significance that appeared when comparing the treated with the pooled control
was spurious. On the other hand, the group killed after 48 hours had a significant difference
from the control at the same time point (Student’s t- test, P<0.05). 
From this result it is established that the liver weight to body weight ratio of F-344NH/sd rats
treated with 50 mg kg-1 ciprofibrate is biologically and significantly high at 48 hours, while
there is no biological difference for the other time points.
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Figure 3.9 shows the time course of the hepatic labelling index in male F-344/NHsd rats. The
results showed a significant difference in the hepatic DNA synthesis between the pooled control
groups (0.3±0.4%) and the group dosed with ciprofibrate at time 0 hour and killed after 24 hours
(3.8±1.8%), 30 hours (2.1±1.1%) and 48 hours (4.3±1.4%), while the groups dosed for 16 hours
(0.2±0.1%), 20 hours (0.3±0.2%) and the 30 hours (2.1±1.1%) had no significant difference
from the pooled control group and fell to background levels. This gave two peaks; the first at 24
hours and the second at 48 hours. 
From these results it can be established that for F-344NHsd rats treated with 50 mg kg-1day-1
ciprofibrate the labelling index starts low then goes up at 24 hours and comes back down to
background level, then up again at 48 hours. This could be as a response to the second dose that
Figure 3.8 Time course of effects of ciprofibrate on liver weight in F-344/NHsd rats. Groups of
male F-344/NHsd rats aged 14-15 weeks were dosed with 50mg/kg/day ciprofibrate or corn oil (vehicle), then
killed at the time points indicated, BrdU labelling was intraperitoneally (IP) two hours before killing (Section 2.2).
Each point represents the mean±SD of 6 animals, and is representative of results obtained from two experiments.
Statistically significant difference from the pooled control groups is indicated by a black asterisk with Dunett’s
multiple comparison test (P < 0.05). Statistically significant difference from individual controls is indicated by a
red asterisk with Student’s t- test (P < 0.05).
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is given after the first 24 hours and this would suggest the pattern that a peak develops after 24
hours from dosing. However, this needs to be investigated further.
 
Figure 3.9 Time course of effects of ciprofibrate on hepatic DNA synthesis in F-344/NHsd 
rats.  Groups of male rats were dosed with 50mg kg-1day-1 ciprofibrate or corn oil (vehicle) as described in Figure
3.8. Immunohistochemical protocol and counting as in Section 2.2.3.2 and Section 2.2.4.1. All data are expressed
as mean±SD of 6 animals, and are representative of results obtained from two independent experiments (in one
experiment the time points were at 24, 30, 36 and 48 hour and in the other experiment the time points were 16, 20,
24 and 30 hours). Statistically significant difference from the pooled control group is indicated by an asterisk (P
< 0.05) (Statistic done with Dunett's multiple comparison test).
Abeer Amer   Section 3.1.2
Page 91
Section 3.1.2.1.2 Dose response for ciprofibrate in rats
The objective of this experiment was to determine the optimal dose of ciprofibrate in F-344/
NHsd rats that give the highest hepatic replicative DNA synthesis. 
Al Kholaifi (Al Kholaifi, 2008) demonstrated that the induction of DNA synthesis in hepato-
cytes in F-344NHsd rats starts after 1 day of dosing with ciprofibrate, using a chronic BrdU la-
belling system where the hepatic DNA synthesis was acclimated in the liver. Also, Section
3.1.2.1.1 showed that the hepatic replicative DNA synthesis in F-344/NHsd rats is at the highest
after 24 hours. Therefore the hepatic labelling index was determined after 24 hours.
Groups of six animals were gavaged with different concentrations of ciprofibrate dissolved in
corn oil [0, 50, 100, 200, 300 mg kg-1 body weight] and killed after 24 hours. Two hours before
killing, the animals were given 100 mg kg-1 BrdU intraperitoneally (IP) (Section 2.2). The liver
weight ratios increased significantly at the doses 100 and 200 mg kg-1 ciprofibrate to 4.1±0.3%
and 4.6±0.5% in comparison with the control group 3.5±0.2%. The liver weight was not in-
creased at the dose 300 mg kg-1 to (3.9±0.08%) as illustrated in Figure 3.10A. 
A similar pattern was found in the labelling index data. At 24 hours after dosing the labelling
index for rats dosed with 50, 100 and 200 mg/kg body weight ciprofibrate were 6.3±2.6%,
6.0±3.0% and 5.9±1.0% respectively, in comparison to the control (vehicle) that was 0.2±0.2%
and all three doses were significantly higher than the control with Dunnett’s multiple compari-
son test. As for the group dosed with 300 mg kg-1 ciprofibrate the induction went down to
0.76±0.64% (Figure 3.10B). This reduced response of the 300 mg kg-1 implies that it is a result
of a toxic reaction and is suppressing the liver growth. 
These results establish that the doses 50, 100 and 200 mg kg-1 body weight give a similar label-
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ling index. The concentration 50mg kg-1 was selected for the assay as a optimal dose of cipro-
fibrate for F-344NHsd rats, because it was the smallest amount of compound and it gave a
reasonably good labelling index. 
Figure 3.10 Dose response of ciprofibrate on liver growth in F-344/NHsd rats. Groups of (matching
weight) male F344/NHsd rats aged 14-15 weeks were dosed at time 0 hour, with the indicated dose of vehicle or cipro-
fibrate, then at 22 hours they were dosed intraperitoneally with BrdU and killed at 24 hours (Section 2.2.1). A shows
liver-to-body weight ratios. B shows labelling index (determined by immunocytochemical localization of BrdU see Sec-
tion 2.2.4.1). All data are expressed as mean±SD of 6 animals, Statistically significant difference from the control group
is indicated by an asterisk with Dunett’s multiple comparison test (P<0.05).
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Serum from the F-344HN/sd rats was assayed for alanine aminotransferase (ALT), as a test for
hepatic damage (see Section 2.2.5.1). ALT level in the F-344HN/sd rat groups treated with cip-
rofibrate appeared higher at 100 and 200 mg kg-1 than in the control group, but this was not a
significant difference with Dunnett’s multiple comparison test (P<0.05) (Figure 3.11). 
In conclusion the doses 50, 100, 200 and 300 mg kg-1 ciprofibrate have no significant toxic ef-
fect on the liver tissue. 
Figure 3.11 Effect of ciprofibrate on serum aminotransferase (ALT). Groups of (matching weight)
male F-344NHsd rats aged 14-15 weeks were dosed with the indicated dose of vehicle or ciprofibrate, and killed after
24 hours as described earlier in Figure 3.10. Serum aminotransferase (ALT) activity was determined using Vitros
ALT slides (Ortho-Clinical Diagnostics). The procedure was performed in the clinical chemistry department, Queens
Medical Center (QMC) at Nottingham (see Section 2.2.5.1). Data are the mean±SD of 6 animals. Statistics done with
Dunnett’s multiple comparison test (P<0.05).
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Section 3.1.2.2 Effect of pregnane X receptor (PXR) ligands on hepatic DNA synthesis 
in F-344NHsd rats
It is known from the literature that the pregnane X receptor (PXR) ligands strongly enhance he-
patic DNA synthesis of male and female Wistar rats (Schulte-Hermann et al., 1980). This ex-
periment was designed to test the effects of the pregnane X receptor (PXR) ligands on liver
growth and hepatic DNA synthesis of F-344/NHsd rats. The PXR ligands are used as a positive
control, with a different mechanism for induction of hepatic DNA synthesis.
Section 3.1.2.2.1 PXR ligands in male and female rats: Pilot study
The aim of this experiment was to choose between cyproterone acetate CPA, and pregnenolone-
16α-carbonitrile PCN, based on their effects on hepatic DNA synthesis in male or female rats. 
Two male and female F-344/NHsd rats were dosed with 100mg kg-1 (the doses were chosen
from the literature (Topinka et al., 2004b) and (Guzelian et al., 2006)) CPA or PCN or corn oil
(vehicle), then killed after 24 hours. Two hours before killing they were dosed intraperitoneally
with 100 mg kg-1 BrdU. Liver weight to body weight ratio is shown in Figure 3.12A. 
There was an increase in liver to body weight ratio for the male group treated with CPA 4.8%
and 4.5% in comparison with the control at 3.9% and 3.7%, the liver weight ratio in male rats
treated with PCN is 3.9% and 4.0% and for the females treated with CPA it was 3.9% and 3.6%.
The labelling index for the male group treated with CPA was 6.7% and 7.6% and for the group
treated with PCN was 6.6% and 6.3% in comparison with the control group 0.5% and 0.3% but
the female group was extremely high at 49.2% and 53.3% (Figure 3.12B). 
From these results it was decided to use CPA on males as the CPA gave the highest liver to body
weight ratio and a high labelling index for the males (in comparison with male F-344/NHsd rats
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treated with ciprofibrate the value was 3.8±1.8% as shown in Figure 3.9), and the CPA was eas-
ier to dissolve in the corn oil than the PCN, which could only be used as a suspension. Although
the female group gave a very high labelling index it was not a properly controlled experiment
since there was no female control group, and so there were two variables (dose and sex) when
compared with male controls. It would be interesting to investigate the effects of CPA on liver
growth in female rats.
   
Figure 3.12 Effects of PXR ligands in male and female rats: pilot study .  Three groups of male F-344/
NHsd rats aged 14-15 weeks were treated with 100mg kg-1 PCN, CPA or corn oil and a group of females were treated
with 100 mg kg-1 CPA. They were then killed after 24 hours. Two hours before killing they were dosed intraperito-
neally with BrdU (Section 2.2). A shows liver weight to body weight ratio. B shows the hepatic DNA synthesis (as
determined by immunocytochemical localization of BrdU) (n=2).
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Section 3.1.2.2.2 Effects of CPA in male F-344/NHsd rats
The aim of this experiment was to investigate more rigorously the effects of CPA on liver
growth and DNA synthesis in male F-344NHsd rats. 
Rats were dosed with 100 mg kg-1 CPA or corn oil (vehicle), then killed after 24 hours. Two
hours before killing, they were dosed intraperitoneally with BrdU. The liver was then processed
and stained by immunohistochemical protocol (Section 2.2.3). Liver weight to body weight ra-
tio is shown in Figure 3.13A. 
Analysis with Student’s t- test showed no significant difference between liver weight to body
weight ratio for the control (3.8±0.5%) and treated group (4.2±0.3%). There was a significant
difference in the labelling index between the control group (0.1±0.1%) and the group dosed with
CPA (7.8±2.9%) Figure 3.13B.
This result revealed that CPA in male F-344NHsd rats had no significant effect on liver weight
to body weight ratio after 24 hours, but has a significant effect on the labelling index. 
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Figure 3.13 Effects of CPA on liver growth in F-344NHsd rats. Male F-344NHsd rats aged 14-15 weeks,
were dosed with 100 mg kg-1 CPA or corn oil (vehicle), and killed after 24 hours (Section 2.2.1). A shows liver weight
to body weight ratio. B shows the immunocytochemical localization of BrdU (as in Section 2.2.4.1) for the control and
CPA treated group. All data are expressed as mean±SD of 6 animals, Statistically significant difference from the control
group is indicated by an asterisk, Statistics done was with Student’s t- test (P<0.05).
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Section 3.2Zonal distribution of DNA synthesis in liver
The experiments below were designed to establish if the replicating hepatocytes are found most-
ly in the periportal or centrilobular regions for F-344NHsd rats and different strains of mice
dosed with different treatments. Table 3.1 shows the strains of mouse or rat, which had been
studied dosed with different treatments. It should be noted that some of the slides used were tak-
en from (Al Kholaifi, 2008). Al Kholaifi dosed the animals and stained the slides with immu-
nohistochemical technique. I then read the slides and determined the zonation of the BrdU-
labelled hepatic nuclei in the periportal and perivenous zones as described in Section 2.2.4.2:
Table 3.1 Zonal distribution study. 
No Receptor Treatment Species/strain Reference
1 PPARα ciprofibrate F-344NHsd rats Section 3.1.2.1
2 PXR CPA F-344NHsd rats Section 3.1.2.2.2
3 CAR TCPOBOP 129S4/SvJae mice (Al Kholaifi, 2008)
4 PPARα ciprofibrate 129S4/SvJae mice (Al Kholaifi, 2008)
5 PPARα ciprofibrate 129S4/SvJae PPARα-null mice (Al Kholaifi, 2008)
6 PPARα ciprofibrate C57BL/6JCrl mice Section 3.1.1.3
7 PPARα ciprofibrate DBA/2JCrl mice Section 3.1.1.2.2
8 PPARα MCP 129S4/SvJae mice (Al Kholaifi, 2008)
9 PPARα MCP AP mice (Al Kholaifi, 2008)
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Section 3.2.1 Zonation studies in F-344/NHsd rats
Section 3.2.1.1 Induction of hepatic DNA synthesis by PPARα ligands (ciprofibrate)
This experiment was designed to determine the lobular distribution of hepatocellular prolifera-
tion in liver of F-344/NHsd rats treated with ciprofibrate. Figure 3.14 shows immunohistochem-
ical localization of hepatic DNA synthesis in F-344/NHsd rats treated with 50mg kg-1
ciprofibrate for 4 days (Section 2.2.4.1).
Figure 3.14A and B show central veins (CV) on the right hand side. Hepatocytes closest to the
(CV) are not BrdU-stained. In Figure 3.14C a portal space (PS) is on the right hand side and the
stained hepatic nuclei are mostly gathered around the (PS). Closer examination of immunohis-
tochemical-stained slides on higher power (X400) show a clear distribution of labelled nuclei
Figure 3.15. The hepatocytes around the central vein show little labelling as shown in Figure
3.15A and B. While several labelled cells gather around the portal space (Figure 3.15C and D)
upon visual inspection. 
From this it established that the zonal distribution of hepatic replication in male F-344/NHsd
rats dosed with ciprofibrate is not randomly distributed and was more situated at the periportal
zone than at the central veins, and this is consistent with the results established from (Barrass et
al., 1993) on Sprague-Dawley rats treated with MCP and clofibric acid.
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Figure 3.14 Zonal distribution of hepatic replication in F-344/NHsd rats. Immunohistochemical sec-
tions of livers from male Fisher 344/NHsd rats aged 14-15 weeks and treated with BrdU in orange juice as described
in Section 2.2.1.2. Then gavaged with 50 mg kg -1day-1 ciprofibrate for 4 days. A and B show central veins (CV); he-
patocytes in the area closest to the CV are not BrdU stained. C shows a portal space (PS) on the right hand side, and
the hepatocytes are mostly stained in the area around the PS. Sections were examined under a light microscope at X40.
Photos were taken with a gray scale camera. The scale bar=100µm. Slides were from (Al Kholaifi, 2008) (personal
communication).
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The distribution of labelled hepatocytes was determined in periportal and centrilobular zones,
as described in Section 2.2.4.2. There was a significant difference between the incidence of la-
belled hepatocytes between centrilobular and periportal regions in the control (Figure 3.16A)
and treated animals according to Student’s t- test (p< 0.05) (Figure 3.16B), with the number of
labelled cells being larger in the periportal region by 4, 12 and 20 fold in the rats treated with
ciprofibrate for 1, 2 and 4 days. 
Figure 3.15 Central vein and portal space of liver sections in F-344/NHsd rats. Liver sections in
male Fisher 344/NHSd rats aged 14-15 weeks and treated with BrdU. Then gavaged with 50 mg kg-1 day-1 cipro-
fibrate for 4 days Section 2.2.1. A and B panels show central veins CV and the area around it. C and D show portal
spaces PS and the area around it. Sections were examined under a light microscope at X400. Photos were taken
with a gray scale camera. In A, B and C the scale bar=10µm. In D the scale bar=5µm. Slides were a kind gift from
(Al Kholaifi et al., 2008) (personal communication).
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These results show the hepatic zonal distribution of F-344/NHsd rats liver is periportal rather
than centilobular, and that treatment with ciprofibrate emphasises this result.
Figure 3.16 Hepatic zonal distribution of cell proliferation in rats treated with ciprofibrate. 
Male F-344/NHsd rats aged 14-15 weeks and treated with BrdU (Section 2.2.1). Visualization of BrdU-stained
hepatocyte nuclei was undertaken using the method of (Barrass et al., 1993) described in Section 2.2.4.2. The
number of cells labelled in periportal (PS- gray bars) or centrilobular (CV- black bars) is shown in A for vehicle
control rats orally treated with corn oil for 1 and 4 days (the number of animals is 6 & 4 respectively) and in B
animals treated orally with 50 mg kg-1 day-1 ciprofibrate for 1, 2 and 4 days (the number of animals is 6, 5 and 5
respectively). The bars show the mean value, and the error bars depict one standard deviation. Statistically sig-
nificant difference from the control group is indicated by an asterisk. Statistics done was with Student’s t- test
(P<0.05).
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Section 3.2.1.2 Induction of DNA synthesis by the PXR ligand cyproterone acetate 
(CPA) 
The aim of this experiment was to determine lobular distribution of hepatocellular proliferation
in liver of F-344/NHsd rats treated with cyproterone acetate (CPA). 
Male F-344/NHsd rats were treated with 100 mg kg-1 CPA as described in Section 3.1.2.2.2.
Immunohistochemical staining was applied on the liver tissue and the distribution of labelled
hepatocytes was determined in periportal and centrilobular zones, as described in Section
2.2.4.2. 
There was a significant difference in the number of labelled hepatocytes between centrilobular
and periportal regions as in Figure 3.17 with the number of labelled cells being larger in the peri-
portal region, comparable to the results that were achieved from the previous experiments on F-
344/NHsd rats treated with corn oil or ciprofibrate (the statistic used was Student’s t- test,
P<0.05, the number of animals is 6).
From these results we can establish that the hepatic zonal distribution of F-344/NHsd rats liver
has a periportal distribution when treated with CPA, and this is consistent with the result found
by (Barrass et al., 1993) and the results found earlier for ciprofibrate (Section 3.2.1.1).
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Figure 3.17 Hepatic zonal distribution of cell proliferation in rats treated with CPA.  Male F-
344NHsd rats aged 14-15 weeks old were dosed with 100 mg kg-1 CPA and killed after 24 hours. Two hours before
killing they were dosed intraperitoneally with BrdU. Immunohistochemical protocol and visualization of BrdU-
stained hepatocyte nuclei was undertaken as described in Section 2.2.4.2. The figure shows the number of cells la-
belled in the periportal region (PS- gray bar) or in the centrilobular region (CV- black bar) (the number of amimals
is 6). Statistically significant difference is indicated by an asterisk with Student’s t- test between the PS and the CV(P
< 0.05).
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Section 3.2.2 Zonation studies in mouse
These experiments were designed to establish if the replicating hepatocytes are found mostly in
the periportal or centrilobular regions for different strains of mice dosed with different hapatic
inducing chemicals.
Section 3.2.2.1 Induction of hepatic DNA synthesis by the constitutive androstane 
receptor (CAR) agonist TCPOBOP in 129S4/SvJae mice
This experiment was designed to determine the lobular distribution of hepatocellular prolifera-
tion in male and female 129S4/SvJae wild type mice, treated with a CAR agonist TCPOBOP,
as a hepatocyte mitogen, to determine if this caused differential lobular zonation of hepatocyte
labelling. 129S4/SvJae mice were dosed with BrdU added to the orange juice as their sole
source of fluid. After at least one day on BrdU, the animals were dosed by gavage with 3 mg
kg-1 TCPOBOP and killed after 2 days. Immunohistochemical staining was done on the liver
tissue as in Section 2.2.3.2. Visualization of BrdU-stained hepatocyte nuclei was undertaken,
essentially as described in Section 2.2.4.1. 
Figure 3.18 shows immunohistochemical localization of hepatic DNA synthesis in liver sec-
tions. Figure 3.18A and B show central veins on the right hand side and portal spaces on the left.
Figure 3.18C shows a CV in the middle top of the liver section. All the slides when examined
on low power did not show any zonation for the BrdU-stained hepatocytes and the labelled he-
patocytes were evenly distributed in the liver lobule. Examination of mice slides on higher pow-
er (X400) corroborated a homogeneous distribution of labelled nuclei. The BrdU-stained
hepatocytes around the central veins and the portal spaces do not show any preferential lobular
distribution as shown in Figure 3.19A, B, C and D. From this it established that the zonal dis-
tribution of hepatic replication in male 129S4/SvJae mice has no discernible difference between
the periportal and the perivenous zones.
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Figure 3.18 Zonal distribution of hepatic replication in 129S4/SvJae mice. Male 129S4/SvJae mice
aged 9-10 weeks were dosed with BrdU then gavaged with 3 mg kg-1 TCPOBOP and killed after 2 days. Immunohis-
tochemical protocol and visualization of BrdU-stained hepatocyte nuclei was undertaken on liver sections as described
in Section 2.2.3.2 and Section 2.2.4.2. A- C sections were examined under a light microscope at 40X. Photos were
taken with a gray scale camera. The scale bar=100µm. Slides were a gift from (Al Kholaifi et al., 2008).
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There was no significant difference in the hepatic zonation between the periportal and the
perivenous regions according to Student’s t- test (P>0.05) for male groups (control and treated)
and the control female group, as shown in Figure 3.20. However, for the female group treated
with TCPOBOP there was a significant zonation (P=0.005). 
Figure 3.19 Central veins and portal spaces of liver sections in 129S4/Svae mouse. Immunohis-
tochemical staining of liver from 129S4/SvJae male mice, the animals were dosed with BrdU and TCPOBOP as
in Figure 3.18, slides were a kind gift from (Al Kholaifi et al., 2008). Visualization of BrdU-stained hepatocyte
nuclei was undertaken as in Section 2.2.4.2. The scale bar represents 10µm. Sections A-D were examined under
a light microscope at 400X. Photos were taken with a gray scale camera. 
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In this case, the labelled cells were preferentially perivenous (CV), although the magnitude of
the effect was relatively small, with the number of labelled cells in the perivenous region being
less than two times greater than those in the periportal region. The total labelling index was
strongly increased by TCPOBOP.
From these results it was found there was no significant difference in the number of labelled
hepatocytes between the periportal and the perivenous zones in male and female 129S4/SvJae
control mice and the male mice treated with TCPOBOP, but there was a significant effect for
treated female mice where the labelled cells were preferentially perivenous.
Figure 3.20 Zonal distribution of hepatic DNA synthesis in 129S4/SvJae mice treated with 
TCPOBOP.  Male and female 129S4/SvJae mice were treated with BrdU then gavaged with a single dose of 3
mg kg-1 TCPOBOP and killed after 2 days. Livers were subjected to the immunohistochemical protocol as de-
scribed in (Section 2.2.3.2). The number of cells labelled in periportal (PS- gray bars) or centrilobular (CV- black
bars) is shown for the control (n=4) and treated (n=5) group for males and females. The bars show the mean val-
ue, and the error bars depict one standard deviation. Statistically significant difference between the CV and the
PS is indicated by an asterisk. Statistic was done with Student’s  t- test (P < 0.05).
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Section 3.2.2.2  Induction of hepatic DNA synthesis by PPAR ligands (ciprofibrate)
Section 3.2.2.2.1 Zonation in 129S4/SvJae mice treated with ciprofibrate.
This experiment was designed to determine the lobular distribution of hepatocellular prolifera-
tion in the liver of 129S4/SvJae mice treated with ciprofibrate. 
129S4/SvJae male mice were stained for BrdU labelling and treated with 100mg kg-1 day-1 cip-
rofibrate or corn oil as shown in Section 2.2.1.2 and Section 2.2.1.3. The number of labelled
cells in the periportal or centrilobular areas was determined as described earlier in Section
2.2.4.2. Dosing with corn oil was for two days and ciprofibrate was 3, 4 and 6 days Figure
3.21A. There was no significant difference in the number of labelled hepatocytes between the
portal space zone and the central vein zone for all the groups. There was also no significant dif-
ference in a separate experiment, where mice were administered 300 mg kg-1 ciprofibrate for 5
days Figure 3.21B. 
In different experiments of animals treated with corn oil for 4 and 6 days there was no signifi-
cant difference between the periportal region and the centrilobular. When all the control data (2,
4, 5, and 6 days) were pooled together there still was no significant difference in lobular distri-
bution of labelled hepatocytes (data not shown). Statistics done with Student’s t- test (P<0.05).
These results show that hepatic zonal distribution of DNA synthesis in 129S4/SvJae mice treat-
ed with corn oil (vehicle)/ ciprofibrate is consistent throughout the liver zones and does not ac-
cumulate in any of the periportal or perivenous zones, and there is no effect of time (2, 4, 5 and
6 days) or different doses of ciprofibrate 100, 300 mg kg-1 day-1 on the distribution.
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Figure 3.21 Lobular distribution of hepatic DNA synthesis in ciprofibrate-treated 129S4/SvJae 
mice.  Male 129S4/SvJae mice aged 9-10 weeks were treated with BrdU and the liver processed and visualization of
BrdU-stained hepatocyte nuclei was undertaken as in Section 2.2.4.2. The number of cells labelled in periportal (PS-
gray bars) or centrilobular (CV- black bars) is shown, in A for animals treated orally with corn oil for the control group
and with 100 mg kg-1 Ciprofibrate for 3, 4 and 6 days (the mean is for 5 animals). B shows animals treated orally with
corn oil (control) or 300 mg kg-1 Ciprofibrate for 5 days (the mean is for 4 animals). There was no significant differ-
ence between the number of labelled hepatocytes in portal space and central vein areas for all groups. The bars show
the mean value, and the error bars depict one standard deviation. Statistics done was with Student’s t- test (P<0.05).
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Section 3.2.2.2.2 Zonation in 129S4/SvJae PPARα-null (129S4/SvJae-Pparatm1Gonz/
tm1Gonz) mice treated with ciprofibrate.
This experiment was designed to determine the lobular distribution of hepatocellular prolifera-
tion in liver of male 129S4/SvJae nullizygous for PPAR (the tm1Gonz allele) mice which were
treated with 100 mg kg-1 day-1 ciprofibrate. 
Male 129S4/SvJae PPARa-null mice were stained for BrdU labelling and orally dosed with 100
mg kg-1 day-1 ciprofibrate or corn oil (vehicle) for two and four days, as shown in Section
2.2.1.2 and Section 2.2.1.3. The number of labelled cells in the periportal or centrilobular areas
were determined as described in Section 2.2.4.2. Figure 3.22 shows that there was no significant
difference in the number of labelled hepatocytes between portal space and central vein zones
for all the control and treated groups, although the mean value is higher in the PS for the treated
groups and the control for 4 days. Statistics were done with Student’s t- test P<0.05.
These results indicate that the hepatic zonal distribution of male 129S4/SvJae PPARa-null mice
treated with corn oil (vehicle) or 100 mg kg-1day-1 ciprofibrate is consistent through out the liv-
er lobule zones and does not significantly accumulate in any of the periportal or perivenous re-
gions.
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Section 3.2.2.2.3 Zonation in C57BL/6JCrl mice treated with ciprofibrate.
The above results did not show a significant preferential periportal distribution of hepatocyte
labelling in 129S4/SvJae mice. However, it is possible that there could be zonal distribution of
labelling in a different mouse strain, so this experiment was designed to determine the lobular
distribution of hepatocellular proliferation in the liver of male C57BL/6JCrl mice treated with
ciprofibrate. Male C57BL/6JCrl mice were stained for BrdU labelling as shown in Section
3.1.1.3. 
The number of labelled cells in the periportal or centrilobular areas were determined as de-
scribed in Section 2.2.4.2. The mice were dosed orally with 100 mg kg-1day-1 ciprofibrate or
Figure 3.22 Lobular localization of DNA labelling in 129S4/SvJae (Pparatm1Gonz/tm1Gonz) male 
mice. Male 129S4/SvJae (Pparatm1Gonz/tm1Gonz) mice aged 9-10 weeks were treated with BrdU (Section 2.2.1.2).The
number of cells labelled in periportal (PS- gray bars) or centrilobular (CV- black bars) is shown for control or animals
treated orally with 100 mg kg-1 ciprofibrate for 2 and 6 days (for the control the mean is for 2 and 5 animals), for the
treated the number of animals is 3 and 5 for days 2 and 6 respectively). The bars show the mean value, and the error
bars depict one standard deviation. There was no difference between portal space and central vein for all the groups
with Student’s t- test (P<0.05).
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corn oil for two and four days Figure 3.23. There was no significant difference in the number of
labelled hepatocytes found around the portal space and central vein zones for all the groups, al-
though the mean value is higher in the PS for all the groups. Statistics were done with Student’s
t- test, P<0.05. (n=6). 
These results show that the hepatic zonal distribution of DNA synthesis in C57BL/6JCrl male
mice treated with corn oil/ ciprofibrate for 2 and 4 days is consistent throughout the liver zones
and does not significantly accumulate in any of the periportal or perivenous zones.
Figure 3.23 Lobular localization of hepatic DNA labelling in C57BL/6JCrl mice treated with 
ciprofibrate. Male C57BL/6JCrl mice aged 9-10 weeks were treated with BrdU as in Section 2.2.1.2. The num-
ber of cells labelled in periportal (PS- gray bars) or centrilobular (CV- black bars) is shown for animals treated
orally with control (corn oil) or 100 mg kg-1 day-1 ciprofibrate for 2 or 4 days. The bars show the mean value, and
the error bars depict one standard deviation is for 6  animals. There was no difference between portal space and
central vein for all the groups with Student’s t- test (P<0.05).
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Section 3.2.2.2.4 Zonation in DBA/2JCrl mice treated with ciprofibrate.
This experiment was designed to determine the lobular distribution of hepatocellular prolifera-
tion in the liver of male DBA/2JCrl mice treated with ciprofibrate. 
Male DBA/2JCrl mice were stained for BrdU labelling as shown in Section 3.1.1.2.2. The num-
ber of labelled cells in the periportal or centrilobular areas were determined as described in Sec-
tion 2.2.4.2. The mice were dosed orally with corn oil for two and six days or 100 mg kg-1day-
1 ciprofibrate for two, four and six days Figure 3.24. There was no significant difference in the
number of labelled hepatocytes found around the portal space and central vein zones for all the
groups.
These results show the hepatic zonal distribution of DNA synthesis in DBA/2JCrl male mice
treated with corn oil (vehicle)/ ciprofibrate for two, four and six days is consistent throughout
the liver zones and does not accumulate significantly in any of the periportal or perivenous
zones.
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Section 3.2.2.3 Induction of hepatic DNA synthesis by the PPARα methylclofenapate.
From the results before, it was possible that the failure to observe lobular localization of hepa-
tocyte DNA synthesis was due to an idiosyncratic response to ciprofibrate. Therefore, the per-
oxisome proliferator methylclofenapate (MCP) was used, as an agent that has previously been
shown to lead to zonated DNA synthesis induction in rats (Barrass et al., 1993).
Section 3.2.2.3.1 Zonation in 129S4/SvJae mice treated with MCP
This experiment was designed to determine the lobular distribution of hepatocellular prolifera-
tion in the liver of male 129S4/SvJae mice treated with 25 mg kg-1day-1 MCP for 3 and 4 days.
Male 129S4/SvJae mice aged 9-10 weeks were stained for BrdU labelling as shown in Section
Figure 3.24 Lobular localization of hepatic DNA labelling in DBA/2JCrl mice treated with cip-
rofibrate. Male DBA/2JCrl mice aged 9-10 weeks were treated with BrdU as in Section 2.2.1.2. The number of
cells labelled in periportal (PS- gray bars) or centrilobular (CV- black bars) is shown for animals treated orally with
control (corn oil) for 2 and 6 days or 100 mg kg-1day-1 ciprofibrate for 2, 4 or 6 days. The bars show the mean
value, and the error bars depict one standard deviation for 6 animals. No difference between portal space and cen-
tral vein for all the groups with Student’s t- test (P<0.05).
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2.2.1.2. The number of labelled cells in the periportal or centrilobular areas were determined (as
described in Section 2.2.4.2). 
The mice were dosed orally with corn oil for four days or 25 mg kg-1day-1 MCP for 3 and 4 days
Figure 3.25. There was no significant difference in the number of labelled hepatocytes found
around the portal space and the central vein zones for all the 129S4/SvJae male mice groups
when treated with 25 mg kg-1day-1 MCP for 3 and 4 days.
Figure 3.25 Zonal distribution of hepatic DNA synthesis in 129S4/SvJae mice treated with MCP.  
Male 129S4/SvJae mice aged 9-10 weeks were treated with BrdU as in Section 2.2.1.2 The number of cells labelled
in periportal (PS- gray bars) or centrilobular (CV- black bars) is shown for control for 4 days (the number of animals
is 5),or treated with 25 mg kg-1day-1 MCP methylclofenapate for 3 and 4 days (the number of animals is 6). Visual-
ization of BrdU-stained hepatocyte nuclei was undertaken as mentioned in Section 2.2.4.2. The bars show the mean
value, and the error bars depict one standard deviation. There was no significant difference between portal space and
central vein for all the groups according to Student’s t- test (P<0.05).
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Section 3.2.2.3.2 Zonation in Alderley park (AP) mice treated with MCP.
This experiment was designed to determine the lobular distribution of hepatocellular prolifera-
tion in liver of male Alderley park [AP] mice treated orally with 25 mg kg-1day-1 MCP for 3
and 4 days. 
Male Alderley park mice aged 9-10 weeks were stained for BrdU labelling as shown in Section
2.2.1.2. The number of labelled cells in the periportal or centrilobular areas were determined. 
It was found in male AP mice treated with 25 mg kg-1day-1 MCP that there was a significant
difference in the number of labelled hepatocytes between the periportal and the perivenous
zones (statistics used was with Student’s t- test, P< 0.005) for the control and the treated group
for 4 days with MCP. The results show a larger distribution of hepatic DNA synthesis at the
periportal. As for the group treated for 3 days, there was no significant difference between the
number of labelled cells situated around the PS and CV (Figure 3.26). 
From this result it is established that the hepatic zonal distribution between the periportal and
perivenous regions is not significantly different for male AP mice dosed with 25 mg kg-1day-1
MCP for 3 days. As for the AP mice dosed for 4 days with MCP and the control group, the dis-
tribution of hepatic DNA synthesis was primarily periportal.
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Figure 3.26 Zonal distribution of hepatic DNA synthesis in AP mice treated with MCP. Male
AP mice aged 14-15 weeks old were treated with BrdU as described earlier in Figure 3.25. The number of cells
labelled in periportal (PS- gray bars) or centrilobular (CV- black bars) is shown for control (4 days) or treated
with 25 mg kg-1 day-1 MCP methylclofenapate for 3 and 4 days (the number of animals is 6). Visualization of
BrdU-stained hepatocyte nuclei was undertaken as mentioned in Section 2.2.4.2. The bars show the mean value,
and the error bars depict one standard deviation. Statistically significant difference from the control group is in-
dicated by an asterisk according to Student’s t- test (P < 0.05). 
Abeer Amer   Section 3.2.2
Page 119
Section 3.3Microarray analysis
Knowledge from the previous results Section 3.1.2 that hepatic DNA synthesis occurs 24 hours
after dosing, and the fact that cells need from 18-20 hours to undergo DNA synthesis, suggests
that the transcriptional signal is sensed within the first five hours after dosing. From this, the 1-
5 hour window was targeted in order to specify the early genes that may be induced, and which
could be responsible for hepatic DNA synthesis at 24 hours. 
The microarray analysis was applied as in Section 2.2.5 to measure the expression levels of
genes induced by 50 mg kg-1 ciprofibrate in livers of F-344NHsd rats after 1, 3, 5 and 24 hours
in comparision with the control. 
A number of controls were used;
 Corn oil (vehicle) dosed rats were used as negative controls. 
 Rats dosed with PXR ligands (cyproterone acetate CPA) were used as positive controls, to
compare genes that are involved in hepatic DNA synthesis, but which might not be specific
for the PPARα ligands (ciprofibrate). 
 24 hour points were used to confirm the induction happens at 24 hours by the immunohis-
tochemical protocol and to rule out genes that would be induced after 24 hours as these
genes are not of our interest.
 A general or common reference/control which is the most commonly used design of
microarray experiments. This also has the benefit of a competent comparison of samples
(Cherkaoui-Malki et al., 2001).
In Figure 3.27 is a diagram that clarifies the experiment design. This experiment was done in
parallel with the time course done in Section 3.1.2.
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Figure 3.28 shows that in this experiment there was a statistically significant induction of he-
patic DNA synthesis after 24 hours for the group treated with ciprofibrate and even higher for
the group treated with cyproterone acetate, according to the measurements of hepatic labelling
index with immunohistochemistry.
Liver weight to body weight ratios were calculated for all the time points (Figure 3.29), and
there was no significant difference between the control and treated (ciprofibrate/ CPA) groups
for all the time points (1, 3, 5, and 24 hours). 
Figure 3.27 Time course of hepatic DNA synthesis in F-344NHsd rats. Groups of F-344NHsd rats were
dosed by gavage with 50 mg kg-1 ciprofibrate or 100mg kg-1 cyproterone acetate or corn oil, then killed after 1, 3, 5
and 24 hours. The groups killed after 24 hours were dosed intraperitoneally two hours before killing with BrdU and
immunohistochemical protocol was undertaken (Section 2.1.3). Each point represents the number of animals is 4 for
the time points 1, 3 and 5 hours and the number of animals is 5 for the group treated with ciprofibrate after 24 hour.
The number of animals used is 6 for the groups treated with CPA and corn oil killed after 24 hours. Microarray analysis
was done on all the time points at 1, 3, 5 and 24 hours in 4 biological replicates and 2 technical replicates.
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Figure 3.28 Effects of ciprofibrate and CPA on hepatic DNA synthesis in F-344NHsd rats 
after 24 hours of dosing. Male F-344NHsd rats aged 14-15 weeks were dosed with corn oil (vehicle), 50
mg kg-1 ciprofibrate or 100 mg kg-1 cyproterone acetate CPA, then killed and assayed after 24 hours (Section
2.1.1). All data are expressed as mean±SD for 6 animals. Statistically significant differences from the control
group are indicated by an asterisk. Statistics were performed with Dunnett's multiple comparison test (P<0.05).
exception for the number of animals in the ciprofibrate group was 5.
Figure 3.29 Effects of ciprofibrate and CPA on liver weight in F-344NHsd rats.  Male F-344NHsd rats
aged 14-15 weeks were dosed with corn oil (vehicle), 50 mg kg-1 ciprofibrate or 100 mg kg-1 cyproterone acetate (CPA),
then killed after 1, 3, 5 and 24 hours. Liver weight to body weight ratio was determined as in Section 2.2.2. All data are
expressed as mean±SD. There was no significant difference between the treated and control groups with Dunnett's mul-
tiple comparison test (P<0.05). n=4 for the time points 1, 3 and 5 hours, n=6 for time point 24 hours corn oil and CPA,
n=5 for the time point 24 hours treated with ciprofibrate (n=number of animals).
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Section 3.3.1 Assessment of RNA quality and quantity 
The liver tissue sampled at intervals after dosing was snap frozen in liquid nitrogen and stored
in a -80oC freezer until use. RNA isolation was processed with TRI reagent as in Section 2.2.5.1
for all the liver tissues. Preliminary experiments with a mini prep method and the TRI reagent
method showed that the higher quality RNA preparations were established with the TRI reagent,
as shown in Figure 3.30A where the 28S and 18S rRNA bands are sharper in lanes 3 and 4 while
the RNA in lanes 6 and 7 (the mini prep) was more smeared. Also the TRI reagent method
(when overloading the RNA on the agarose gel; Figure 3.30B) showed the 5S band indicating
that the microRNA was intact. 
The quality of the total RNA for all the samples was assessed by the relative intensities of the
28S and 18S rRNA bands visualized by electrophoresis on 2% agarose gels with a 1kb Plus
DNA ladder and stained with ethidium bromide. Figure 3.31 and Figure 3.32 show intact total
RNA with sharp 28S and 18S ribosomal RNA bands. The 28S rRNA band is approximately
twice as intense as the 18S rRNA band. The 5S rRNA was determined by comparing with the
literature and with the ladder and appears as a faint band (in most of the lanes that have been
slightly overloaded) indicating the microRNAs. 
The yield of the RNA was measured by a CECIL CE9500 spectophotometer, and the total yield
of each of the RNAs from the liver tissues were in a range between 8.2±3.9 µg mg-1. A reference
RNA control was made by mixing aliquots of all the RNAs to be used in the microarray hybrid-
ization -to remove any bias from the 555 and 647 Alexa dyes. 
From the above analysis it was established that the TRI reagent method works well, yielding
intact microRNAs. All the RNAs used were of good quality and had a yield sufficiently high for
microarray analysis.
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Figure 3.30 Optimizing RNA isolation from rat liver.  Agarose gels (2%) stained with ethidium bromide as
shown in Section 2.2.8. In A, the ladder is a 1kb Plus DNA ladder, lanes 3 and 4 have RNA made by the TRI reagent pro-
cedure; lanes 6 and 7 have RNA made with the mini prep procedure. In B, the ladder is a 1kb Plus DNA ladder, RNAs in
lanes 1, 2 and 3 were made with TRI reagent method. A larger amount of the RNA was loaded to show the microRNA band
at 5S as a faint band. The major RNA bands are shown at 28S and 18S.
A          B
mini prep
procedure
TRI reagent
procedure
Figure 3.31 Agarose gel with RNA from F-344NHsd rat liver.  Agarose gel electrophoresis (2%) was per-
formed as described in Section 2.2.8 with a 1kb Plus DNA ladder to mark the nuclear weight of the RNA and dyed with
ethidium bromide. The lanes were loaded with RNA samples from F-344NHsd rat liver treated with ciprofibrate for 24
hours.
28S
18S --->
5S --->
 --->
Figure 3.32 More examples of agarose gels loaded with RNAs from F-344NHsd rats. Agarose gel electro-
phoresis was made as described in Figure 3.30 with a 1kb Plus DNA ladder to mark the nuclear weight of the RNA and dyed
with ethidiome bromide. Intact total RNA with sharp 28S and 18S ribosomal RNA bands are shown. The lanes were loaded
with RNA samples from F-344NHsd rat liver treated with CPA.
28S
28S
28S
18S --->
18S --->
18S --->
 --->
 --->
 --->
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Section 3.3.2 Incorporation of Alexa dyes in the cDNA
RNAs were made to cDNAs labelled with Alexa dyes 555 and 647. The Amino allyl cDNA la-
belling used a two step process, and all the steps were made with a negative control (sample with
no RNA) and a positive control (RNA supplied in the kit). All the samples’ incorporation of the
Alexa dyes and the cDNA quantities were determined using a nanodrop machine, and the cDNA
amounts were around 80±20 ng µl-1 (and might go up to 200 ng µl-1), and the incorporated dye
was approximately 8±4 pmol ul-1 (and might go up to 20 pmol ul-1) for each of the Alexa dye
555 and 647 (Appendix I). The Amino allyl cDNA labelling kit -from Ambion- was used for
the rest of the analysis, and optimizing was done to dilute the cDNA, and also to decrease the
costs as will be described in Section 3.3.3.
Section 3.3.3 Optimization of the microarray technique
Figure 3.33 shows a typical outcome of the scanned “MEEBO” -Mouse genome set- microarray
slide. The scanner functions using sequential scanning to create 3 images: the slide is scanned
twice; first using the green 532 nm laser that scans the 555 Alexa dye (Figure 3.33A), and then
the red 635 nm laser and this scans the 647 Alexa Dye (Figure 3.33B). The third slide with a
ratio image where the second wavelength image is composed on the first as in Figure 3.33C,
where a green spot indicates the treatment for this specific gene has less activity than the refer-
ence control; a red spot indicates the treatment would have more activity than the reference con-
trol; and a yellow spot means that there is no change in the level of activity between the two
populations of test and reference control would be where the control and treated are the same.
Notice for each of the red and the green scans there are white spots indicating saturating fluo-
rescence.
Abeer Amer   Section 3.3.3
Page 125
Figure 3.33 Images of the scanned microarray slide.  Outcome of the Axon 4200 scanner, A shows the im-
age with the green 555 fluorescent. B shows the image with the red 674 fluorescent. C+D shows the combined colours,
where a green spot indicates the treatment for this specific gene has less activity than the reference control; a red spot
indicates the treatment would have more activity than the reference control; and a yellow spot means that there is no
change in the level of activity between the two groups control and treated. Notice for each of the red and the green
scans there are white spots indicating a large intensity of the fluorescent.
A B C
D
red spot
yellow spot
green spot
white spot
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It was of importance to validate the microarray technique to ensure the results are reliable and
repeatable with the least expense possible. So, the following issues were addressed in an inde-
pendent experiment: (1) Section 3.3.3.1- Reproducibility of the scanning. (2) Section 3.3.3.2-
Reproducibility of the hybridizating. (3) Section 3.3.3.3- Testing of the concentration of cDNA.
For optimizing the microarray technique, RNA extracted from liver of F-344NHsd rats treated
with ciprofibrate at 24 hours was used. Groups of the same cDNA were labelled and hybridized
as described in Section 2.1.4.2. They were then all scanned. A random group was chosen to be
scanned repeatedly. All groups then went through the analyzing process, then normalised using
the NORTT program, and then compared against each other.
Section 3.3.3.1 Reproducibility of scanning
The aim of this experiment was to determine that the scanning section of the microarray tech-
nique is reliable and the results are repeatable. Slides were chosen at random and each slide was
scanned twice. The data from the scanner was normalised and one set of scan results was com-
pared against the other. 
The results in Figure 3.34 shows the linear regression between the first and the second scan at
a 1:1 ratio, which means that a specific gene that is high in one scan is also high in the other
scan, and the ones that are low in one, would be low in the other scan. As the r2= from 0.9 to
0.6, it can be said that the two scans of the same slide are 60-90% reproducible.
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Figure 3.34 Reproducibility of scanning.  Each plot shows a comparison between two set of genes of the same
slide when scanned twice. On the Y axis is a set of the fold-inducion of the normalised log2 ratio of median for the first
scan, and the X axis is the same for the second scan, the linear regression line is at a angle at ~45o, r2=0.8±0.1. The 2 green
arrows are pointing to the same spot (gene) indecating that this gene’s fold induction is just under 2 in both of the scans,
and this is the same for most of the genes.
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Section 3.3.3.2 Reproducibility of hybridization
It was necessary to ensure that the hybridization in this protocol was repeatable. In this section
cDNAs were hybridized on three different sets of slides, then the slides were scanned, and the
results from the scans were normalised as shown in Section 2.2.5. The results were then com-
pared. Preliminary experiments showed that, when the same cDNA is hybridized on different
slides, they did not give repeatable results as in Figure 3.35. The r2=0.2±0.1 meaning; when
comparing a gene from slide 1 against the same gene in slide 2 it gives a different fold induction.
Thus the same cDNA when hybridized on different slides gives a 20-30% similarity. This was
a problem, and results from this hybridizations were not reliable.
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Figure 3.35 Reproducibility of hybridization. Each plot shows two sets of genes from the same cDNA hybridized
on different microarray slides, processed as in Figure 3.34. The genes then plotted, the Y axis is a set of the fold-inducion
of the normalised log2 ratio of median for the first slide, and the X axis is the same for the second slide. The line presents
the linear regression line, the r2=0.2±0.1. The green arrows are pointing to the same spot (gene) indecating that the genes
fold induction is different in each of the slides (under 1 in the first slide and over 4 in the second slide).
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It was essential to address the issue of not being able to get the same results from the same
cDNA hybridized on different slides before being able to consider using the microarray tech-
nique for further analysis. Therefore looking into the microarray procedure systematically by
checking all the steps (hybridizing, scanning and fitting features) was a reliable technique and
the results were comparable to each other and gave a higher r2 (Figure 3.36).
The main area where the error could be made was misplacing the gene names on the gene spots
of the slides (human error) when featuring the scan to the GAL file. The improvement here is
that when fitting the features greater care was taken and there were also some markers on the
slides to indicate where exactly each gene is situated. From the above information it was decid-
ed that all the hybridizations have to have technical replicates that were at least 60% similar to
be considered in the analysis.
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Figure 3.36 Reproducibility of hybridization (improved). Each of the figures show two sets of genes of the
same cDNA hybridized on different slides, then processed as in Figure 3.34. The genes were then plotted; on the Y axis
is a set of the fold-inducion of the normalised log2 ratio of median for the first slide, and on X the same for the second
slide. The linear regression line is shown in red and had a r2=0.6±0.1. The improvement here is when fitting the features
more care was taken and there were also some markers on the slides to indicate where exactly each gene is situated on
the slide.
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Section 3.3.3.3 Testing of the cDNA concentration
Because of the expense of the cDNA labelling kit it was desirable to try to decrease these ex-
penses to make it possible to continue with the rest of the planned experiments. So, it was de-
cided to cut the costs in half by diluting the cDNA and spreading what is usually spread on one
set of slides to be spread on two sets of slides (to be used as technical replicates). Figure 3.37
shows a comparison between the undiluted cDNA (concentrated 50:1:50µl of 80ng µl-1 la-
belled-cDNA: tRNA: hybridization buffer) and the diluted cDNA (50:30:2:80µl of 80ng µl-1 la-
belled-cDNA:DEPC H2O:tRNA: hybridization buffer). 
An experiment was designed where 4 replicates of the same cDNA was labelled (the cDNA was
from a sample of liver treated with ciprofibrate and killed after 24 hours). cDNA 1, 2 and 3 were
hybridized as concentrated, cDNA 4 was diluted and hybridized on 2 sets of slides. The slides
were then compared, the diluted against the undiluted. 
When comparing the technical replicates, diluted vs. diluted, non-diluted vs. non-diluted and di-
luted vs. non-diluted, they all gave a similar results of 60% similarity (the mean and standard
deviation of all the r2=0.6±0.1). This means that the dilution of the cDNA sample did not affect
its quality. This dilution method was used for the rest of the experiments.
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Figure 3.37 Testing of the cDNA concentration.  Each of the figures shows a comparison between the di-
luted cDNA and undiluted cDNA. Hybridized on different slides, then processed as in Figure 3.34. The genes were
then plotted as in Figure 3.36. The linear regression line is shown in red and the mean and standard deviation of all
the samples is r2=0.6±0.1. 
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From these results, it was found that the optimal way to resolve inconsistently issues in microar-
ray procedures was to:
1- Use more replicates, so 4 biological replicates and 2 technical replicates were used.
2- Compare the technical replicates against each other and accept only the results that the r2 is
more that 0.6. 
Figure 3.38 Examples of technical replicates . Each plot shows a comparison of technical replicates
from the same diluted cDNA. The samples were hybridized on different slides, then processed as in Figure 3.34.
The genes were then plotted as in Figure 3.36. The linear regression line is shown in red and the mean and standard
deviation of the r2=0.6±0.1. 
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Section 3.3.4 Microarray analysis of dosed rats after 24 hours
In order to measure the expression levels of early genes that may be up- regulated after dosing
of ciprofibrate, and might be responsible for the induction of hepatic DNA synthesis, microar-
ray analysis was applied as in Section 2.2.5 on F-344 fisher rats dosed with 50 mg kg-1 ciprofi-
brate, or 100 mg kg-1 CPA, or corn oil and killed after 1, 3, 5 and 24 hours in comparison with
the control. 
Preliminary results were established from microarray analysis done on F-344 fisher rats treated
with ciprofibrate, CPA and corn oil for 24 hours. This was to help ensure that the analysis and
processing of the data is reliable, by checking for induction of specific genes (used as markers)
that are known from the literature to be induced after 24 hours of dosing with ciprofibrate and
CPA. 
Analysis of the 24 hour groups with R software revealed 1597 genes whose expression was sig-
nificantly changed (FDR p-value <0.05). The whole list is attached in a CD at the end of the
Thesis. Table 3.2 shows a list of up- regulated genes for samples treated with ciprofibrate for 24
hours, that have a fold induction of >1.2 fold change. These include Cyp4A1 (CYP4A10), a
gene that is a known marker for PPARα agonists treatments. Also an up- regulation of GstYb4
(Gstm3) gene was detected for the F-344HNsd rats dosed with CPA as shown in Table 3.3. This
gene is known to be induced by CPA (Krebs et al., 1998). Significantly down- regulated genes
for the samples treated with ciprofibrate for 24 hours are listed in Table 3.4, and the samples
treated with CPA for 24 hours are listed in Table 3.5. The cut-off for choosing the fold change
depended on the number of genes in each group. From this we can say that the microarray meth-
od and the analysis used to achieve these results were all reliable and reproducible, and that we
could proceed with the analysis of the early hour samples at 1, 3 and 5 hours treated with cip-
rofibrate and CPA.
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Table 3.2 Known up- regulated genes at 24 hour in ciprofibrate dosed Fisher rats.  The list of up- regulated
genes for male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 24 hours. Microarray
analysis was carried out as in Section 2.2.5. 
Description Name
Mean fold 
change
FDR p-
value
Mus musculus 3-ketoacyl-CoA 
thiolase B
MGC29978 3.51 0.000001
Cytochrome P450, family 4, 
subfamily a, polypeptide 1
Cyp4A1 (CYP4A10) 2.97 0.00001
Cytosolic thioesterase 1 Cte1 2.39 0.000001
Member RAS oncogene family Rab19 2.26 0.00001
Solute carrier family 9 (sodium/
hydrogen exchanger), member 2
Slc9a2 1.78 0.00001
Tensin 1 E030037J05Rik 1.70 0.000001
Mitochondrial ribosomal pro-
tein S18A
18S 1.62 0.00001
Lactate dehydrogenase C Ldh3 1.61 0.00001
NMDA receptor regulated 1 Narg1 1.53 0.0001
RIKEN cDNA 5430402E10 
gene
5430402E10Rik 1.46 0.00001
Polymerase (RNA) II (DNA 
directed) polypeptide A
Polr2a 1.46 0.00001
Succinate-CoA ligase, alpha 
subunit
Suclg1 1.41 0.0001
LOC14433 1.39 0.00011
Talin TIn 1.37 0.0001
RIKEN cDNA 2300009N04 
gene
2300009N04Rik 1.33 0.0001
Heat shock protein 90, alpha 
(cytosolic), 
Hspca 1.28 0.000001
UDP glucuronosyltransferase 1 
family, polypeptide A5
Ugt1A5 1.27 0.000001
Adenosine A2B receptor Adora2b 1.26 0.000001
Putative homeodomain tran-
scription factor 1
Phtf1 1.21 0.00001
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Table 3.3 Known up- regulated genes at 24 hour in CPA dosed Fisher rats. The list of up- regulated genes 
for male F-344NHsd rats aged 14-15 weeks dosed with 100 mg kg-1 CPA then killed after 24 hours. Microarray analysis was 
carried out as in Section 2.2.5
Description Name
Mean fold 
change
FDR p-
value
Glutathione S-transferase Alpha 
1
Gsta1 2.01 0.0001
Heat Shock Protein A8 Hspa8 1.88 0.0001
Glutathione S-transferase Mu 3 GstYb4 (Gstm3) 1.87 0.0001
Udp Glucuronosyltransferase 1 
Family, Polypeptide A5
Ugt1a5 1.67 0.0001
Major Urinary Protein 3 Mup3 1.47 0.0001
Eukaryotic Translation Elonga-
tion Factor 1 Alpha 1
Eef1a1 1.42 0.0001
Ribosomal Protein S6 Rps6 1.27 0.0001
Metallothionein 1a Mt1 1.26 0.0001
Ubiquitin C Ubc 1.18 0.00001
Apolipoprotein A-i Apoa1 1.16 0.0001
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Table 3.4 Known down- regulated genes at 24 hour in ciprofibrate dosed Fisher rats. The list of the down-
regulated genes for male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate, then killed after 24 hours. Mi-
croarray analysis was determined as in Section 2.2.5. 
Description Name
Mean fold 
change
FDR p-
value
Major urinary protein 2 Mup2 -2.47 0.0001
Zinc finger protein 598 Zfp598 -1.85 0.002
Fibrinogen gamma chain Fgg -1.77 0.0001
Murinoglobulin 2 Mug2 -1.54 0.0001
Cytochrome P450, family 2, subfamily 
c, polypeptide 29
CYP2c29 -1.44 0.0001
Polymerase (RNA) II (DNA directed) 
polypeptide A
Polr2a -1.38 0.0001
Brain protein 44-like Brp44l -1.27 0.0001
Cysteine dioxygenase, type I Cdo1 -1.23 0.0001
Ornithine carbamoyltransferase Otc -1.21 0.0001
Sepina3a -1.21 0.0001
Table 3.5 Known down- regulated genes at 24 hour in CPA dosed Fisher rats. The list of the down- regulat-
ed genes for male F-344NHsd rats aged 14-15 weeks dosed with 100 mg kg-1 CPA, then killed after 24 hours. Microarray anal-
ysis was determined as in Section 2.2.5. 
Description Name
Mean fold 
change
FDR p-
value
RIKEN cDNA 2300009N04 gene 2300009N04Rik -1.52 0.00001
Major urinary protein 2 Mup2 -1.29 0.00001
Ribonuclease, RNase A family 4 Rnase4 -1.27 0.00001
Transferrin Trf -1.19 0.00001
Cytochrome P450, family 2, subfamily 
d, polypeptide 26
CYP2d26 -1.14 0.00001
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Figure 3.39 shows a heatmap depicting the hepatic genes that were affected by the ciprofibrate
after 24 hour treatment: red indicates highly- induced, and blue indicates down- regulation of
the genes. These were established with High-Throughput GoMiner (Zeeberg, 2005)). Also the
Figure shows the different pathways that are changed with the ciprofibrate dose after 24 hours.
The main changed pathways are the fatty acid metabolic process where 5 genes from 14 total
genes involved in this process were over expressed (35.7%), and the monocarboxylic acid met-
abolic process with 5 out of 19 genes (26.3%), also, fatty acid β oxidation and acyl-CoA meta-
bolic process had both 50% up- regulation.
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Figure 3.39 Effect of ciprofibrate on gene expression after 24 hour. Male F-344NHsd rats aged 14-15
weeks were dosed with 50 mg kg-1 ciprofibrate, then killed after 24 hours. Microarray analysis was carried out as in Sec-
tion 2.2.5, this heatmap was established with High-Throughput GoMiner (Zeeberg, 2005). Red demonstrates up- regulat-
ed, and blue demonstrates down- regulated (-1 down- regulated, +1 up- regulated).
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In Figure 3.40 is a heatmap showing the affected hepatic genes up/down- regulated with the
CPA after 24 hours: red describes highly induced, and blue demonstrates down- regulated in-
duction of the genes. The Figure shows the different pathways that are changed with the CPA
dose after 24 hours. Nevertheless, the highly changed processes are the glutathione transferase
activity where 2 of 3 genes are over expressed (66.7%), the other process is related to the inter-
phase of mitotic cell cycle which is also 2 out of 3 over expressed genes (66.7%).
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Figure 3.40 Effect of CPA after 24 hour on gene expression. Male F-344NHsd rats aged 14-15 weeks dosed
with 100 mg kg-1 CPA, then killed after 24 hours. Microarray analysis was carried out as in Section 2.2.5, this heatmap was
established with High-Throughput GoMiner (Zeeberg, 2005). Red demonstrates up- regulated, and blue demonstrates
down- regulated (-1 down- regulated, +1 up- regulated).
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Section 3.3.5 Microarray analysis of ciprofibrate dosed rats after 1, 3, and 5 
hours
Having performed preliminary analysis at 24 hours (Section 3.3.4). The microarray analysis of
the early hour samples was undertaken. This was done collectively at 1, 3 and 5 hours for the
hepatic samples from F-344NHsd fisher rats dosed with 50 mg kg-1 ciprofibrate, 100 mg kg-1
CPA, or corn oil (Section 2.2.5).
The analysis of the 1, 3 and 5 hour groups with R software revealed 1377 significant genes for
each of the groups (FDR p-value <0.05) out of 5826 genes, (the whole list is attached in a CD
at the end of the Thesis). A list of the up- regulated genes for the samples treated with ciprofi-
brate for 1 hour with a fold induction of >2.6 fold change is presented in Table 3.6 which include
Igf1, Sstr4, Abcc2, mup1, mmu and Adamts, and the down- regulated genes after 1 hour is found
in Table 3.7, while a list of up and down- regulated genes for 3 hour samples are shown in Table
3.8 (fold change >1.7) and Table 3.9 respectively which include, a number of the up- regulated
for 3 hours are Seprina1b, mup4, Mug2, Gsta1 and Atp8b3. A list of the genes up and down-
regulated with ciprofibrate after 5 hours are listed in Table 3.10 (fold change >2.0) and Table
3.11 respectively, the up- regulated genes include Seprina1b, Mug1, Sema5a, My16, Mup4, and
Mug4. The different cut-off for the fold changes depends on the number of genes in each of the
groups.
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Table 3.6 Up- regulated genes at 1 hour in ciprofibrate dosed Fisher rats.  The list of up- regulated genes for
male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 1 hours. Microarray analysis was
carried out as in Section 2.2.5. 
Description Name
Mean fold 
change
FDR p-
value
FXYD domain-containing ion transport 
regulator 2
Fxyd2 3.86 0.0001
Insulin-like growth factor 1 Igf1 3.39 0.005
Olfactory receptor 976 Olfr976 3.37 0.0001
Serine/threonine kinase 3 Stk3 3.29 0.0001
N-myc downstream regulated gene 1 Ndrg1 3.19 0.0001
Somatostatin receptor 4 Sstr4 3.18 0.003
Adaptor-related protein complex 1, sigma 
1 subunit
Ap1s1 3.13 0.0001
Thymidylate synthetase Tyms 3.09 0.0001
Carboxypeptidase A5 Cpa5 3.08 0.001
Zinc finger protein 64 Zfp64 3.07 0.006
Complement factor H Cfh 3.06 0.002
Zinc finger protein 180 Zfp180 2.99 0.0001
PDZ domain containing 3 Pdzk2 2.92 0.003
DNA segment, Chr 11, Brigham & 
Women's Genetics 0517 expressed
D11Bwg0517e 2.91 0.0001
CD68 antigen Cd68 2.90 0.0001
Sema domain, seven thrombospondin 
repeats, transmembrane domain and short 
cytoplasmic domain 5A
Sema5a 2.89 0.00011
Serum amyloid A 3 Saa3 2.89 0.0001
Chloride intracellular channel 1 Clic1 2.86 0.008
Dihydropyrimidinase-like 2 Dpysl2 2.86 0.008
Proteolipid protein 1 Plp1 2.85 0.0001
Otoancorin Otoa 2.82 0.0001
Kinesin family member 9 Kif9 2.82 0.0001
Deoxynucleotidyltransferase, terminal Dntt 2.79 0.0001
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Transmembrane protein 140 1110007F12Rik 2.77 0.0001
Telomeric repeat binding factor 2 Terf2 2.77 0.003
PWWP domain containing 2A mmu 2.76 0.001
Chemokine-like receptor 1 Cmklr1 2.74 0.008
Galactosyltransferase I B4galt7 2.73 0.0001
Phosphoinositide binding specific) mem-
ber 3
Plekha3 2.73 0.0001
Ganglioside-induced differentiation-asso-
ciated protein 1-like 1
Gdap1l1 2.73 0.001
BTB (POZ) domain containing 9 Btbd9 2.72 0.0001
ATP-binding cassette, sub-family C 
member 2
Abcc2 2.72 0.0001
Major urinary protein 1 Mup1 2.71 0.001
ADAM metallopeptidase with thrombos-
pondin type 1 motif, 2
Adamts2 2.71 0.0001
Mucin 13, cell surface associated Ly64 2.70 0.003
Endoplasmic reticulum protein 44 Txndc4 2.70 0.005
Table 3.6 Up- regulated genes at 1 hour in ciprofibrate dosed Fisher rats.  The list of up- regulated genes for
male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 1 hours. Microarray analysis was
carried out as in Section 2.2.5. 
Description Name
Mean fold 
change
FDR p-
value
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Table 3.7 Down-down- reg regulated genes at 1 hour in ciprofibrate dosed Fisher rats.  The list of down-
regulated genes for male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 1 hours. Mi-
croarray analysis was carried out as in Section 2.2.5. 
Description Name
Mean fold 
change
FDR p-
value
Fibroblast growth factor 21 Fgf21 -6.62 0.0001
Regulator of G-protein signalling like 2 Rgsl2 -5.89 0.0001
Ubiquitin specific peptidase 28 Usp28 -5.74 0.0001
Chloride channel 6 Clcn6 -5.48 0.0001
Aspartyl-tRNA synthetase Dars -5.28 0.0001
Zinc finger, DHHC-type containing 9 Zdhhc9 -5.20 0.0001
ArfGAP with RhoGAP domain, ankyrin 
repeat and PH domain 1
Centd2 -4.99 0.0001
Origin recognition complex, subunit 6 like Orc6l -4.36 0.0001
Vanin 3 Vnn3 -4.03 0.0001
Zinc finger protein 212 Zfp212 -4.03 0.0001
Poliovirus receptor-related 4 Pvrl4 -3.98 0.0001
Frizzled homolog 7 Fzd7 -3.93 0.00011
Transforming growth factor, beta 1 Tgfb1 -3.90 0.0001
Proprotein convertase subtilisin/kexin type 4 Pcsk4 -3.85 0.022
UDP glucuronosyltransferase 1 family, 
polypeptide A6
Ugt1a6 -3.84 0.0001
Rho GDP dissociation inhibitor (GDI) alpha Arhgdia -3.83 0.0001
PRP4 pre-mRNA processing factor 4 
homolog 
Prpf4 -3.75 0.0001
Immunoglobulin superfamily, DCC sub-
class, member 3
Punc -3.65 0.0001
MAP/microtubule affinity-regulating kinase 
2
Mark2 -3.65 0.012
WD repeat and HMG-box DNA binding 
protein 1
Wdhd1 -3.60 0.0001
Tubulin folding cofactor B Ckap1 -3.32 0.0001
Keratinocyte associated protein 2 Krtcap2 -3.29 0.0001
Homeobox A3 Hoxa3 -3.22 0.0001
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Cystathionase (cystathionine gamma-lyase) Cth -3.09 0.0001
ASF1 anti-silencing function 1 homolog B 
(S. cerevisiae)
Asf1b -3.02 0.001
E2F transcription factor 2 E2f2 -2.84 0.002
Rho-related BTB domain containing 2 Rhobtb2 -2.82 0.004
Uracil DNA glycosylase Ung -2.75 0.001
CD97 antigen Cd97 -2.74 0.0001
Pro-platelet basic protein Cxcl7 -2.72 0.0001
Mannosyl (alpha-1,6-)-glycoprotein beta-
1,2-N-acetylglucosaminyltransferase
GnT -2.69 0.005
Glucosamine-6-phosphate deaminase 2 Gnpda2 -2.69 0.019
Jagged 2 Jag2 -2.64 0.016
Immunoglobulin kappa chain variable 28 IGKV2 -2.64 0.008
HIV-1 Rev binding protein 2 Hrb2 -2.55 0.003
Antigen identified by monoclonal antibody 
Ki-67
Mki67 -2.55 0.0001
Vomeronasal 1 receptor, H3 V1rh3 -2.47 0.001
Ubiquitin-like modifier activating enzyme 1 Ube1x -2.34 0.0001
Formiminotransferase cyclodeaminase Ftcd -2.30 0.0001
Phenylalanyl-tRNA synthetase 2, mitochon-
drial
Fars1 -2.26 0.001
Zinc finger protein 364 Zfp364 -2.24 0.0001
RAR-related orphan receptor B Rorb -2.20 0.0001
TNFAIP3 interacting protein 1 Tnip1 -2.17 0.035
Cas-Br-M (murine) ecotropic retroviral 
transforming sequence b
Cblb -2.16 0.001
Splicing factor, arginine/serine-rich 9 Sfrs9 -2.12 0.0001
Papillary renal cell carcinoma Prcc -2.04 0.007
Receptor-interacting serine-threonine kinase 
2
Ripk2 -2.04 0.003
Table 3.7 Down-down- reg regulated genes at 1 hour in ciprofibrate dosed Fisher rats.  The list of down-
regulated genes for male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 1 hours. Mi-
croarray analysis was carried out as in Section 2.2.5. 
Description Name
Mean fold 
change
FDR p-
value
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Phosphate regulating endopeptidase 
homolog, X-linked
Phex -2.02 0.021
Xylosyltransferase II Xylt2 -2.02 0.045
Pumilio homolog 1 Pum1 -2.01 0.001
Phosphodiesterase 4D interacting protein 
(myomegalin)
Usmg4 -2.01 0.003
Table 3.7 Down-down- reg regulated genes at 1 hour in ciprofibrate dosed Fisher rats.  The list of down-
regulated genes for male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 1 hours. Mi-
croarray analysis was carried out as in Section 2.2.5. 
Description Name
Mean fold 
change
FDR p-
value
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Table 3.8 Up- regulated genes after 3 hours in ciprofibrate dosed Fisher rats.  The list of up- regulated genes
for male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 3 hours. Microarray analysis
was carried out as in Section 2.2.5. 
Description Name
Mean fold 
change
FDR p-
value
Proteasome (prosome, 
macropain) subunit, beta type 9 
Psmb9 3.65 0.0001
Inositol polyphosphate phos-
phatase-like 1
Inppl1 3.07 0.001
Opioid growth factor receptor Ogfr 2.95 0.0001
Serum amyloid A 3 Saa3 2.71 0.0001
Transmembrane protein 222 D4Ertd196e 2.47 0.0001
Otoancorin Otoa 2.43 0.0001
Histone cluster 1, H2af Hist1h2af 2.40 0.0001
Hemopexin Hpxn 2.24 0.005
Olfactory receptor 1395 Olfr1395 2.23 0.000
Serine/threonine kinase 25 Stk25 2.17 0.003
UDP-GlcNAc:betaGal beta-1,3-
N-acetylglucosaminyltrans-
ferase 7
B3gnt7 2.17 0.0001
Iroquois homeobox 1 Irx1 2.06 0.001
WW domain binding protein 1 Wbp1 2.05 0.002
Serine (or cysteine) preptidase 
inhibitor, clade A, member 1B
Serpina1b 2.05 0.001
Major urinary protein 4 Mup4 2.03 0.006
Insulin 1 Ins1 2.02 0.000
Group specific component Gc 2.02 0.000
FLYWCH-type zinc finger 1 E030034P13Rik 2.01 0.000
Extracellular matrix component; 
may play a role in fibrosis and 
tumour metastasis
Fn1 1.96 0.000
Testis expressed 264 Tex264 1.92 0.005
Metallothionein 1, pseudogene 1 Mt1 1.90 0.001
DAZ associated protein 1 Dazap1 1.89 0.000
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DNA (cytosine-5-)-methyltrans-
ferase 3-like
Dnmt3l 1.87 0.007
Serpin peptidase inhibitor, clade 
A 1
Serpina1 1.87 0.001
Ventral anterior homeobox 2 Vax2 1.87 0.0001
Receptor (G protein-coupled) 
activity modifying protein 2
Ramp2 1.83 0.0001
Deiodinase, iodothyronine, type 
III
Dio3 1.81 0.006
Coiled-coil domain containing 
146
4930528G09Rik 1.80 0.004
Ribosomal protein S17 Rps17 1.78 0.001
Cathepsin Z Ctsz 1.76 0.0001
Glutathione S-transferase alpha 
1
Gsta1 1.75 0.0001
Murinoglobulin 2 Mug2 1.75 0.0001
ATPase, Class I, type 8B, mem-
ber 3
Atp8b3 1.74 0.0001
RIKEN cDNA 1700048F04 
gene
1700048F04Rik 1.74 0.002
Interferon, alpha-inducible pro-
tein 27 like 1
D12Ertd647e 1.74 0.004
Coiled-coil domain containing 
89
1700019B01Rik 1.72 0.001
Synaptogyrin 4 Syngr4 1.70 0.0001
Table 3.8 Up- regulated genes after 3 hours in ciprofibrate dosed Fisher rats.  The list of up- regulated genes
for male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 3 hours. Microarray analysis
was carried out as in Section 2.2.5. 
Description Name
Mean fold 
change
FDR p-
value
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Table 3.9 Down- regulated genes after 3 hours in ciprofibrate dosed Fisher rats.  The list of down- regulat-
ed genes for male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 3 hours. Microarray
analysis was carried out as in Section 2.2.5. 
Discription Name
Mean fold 
change
FDR p-
value
6-phosphofructo-2-kinase/fructose-
2,6-biphosphatase 2
Pfkfb2 -3.55 0.0001
Intraflagellar transport 122 homolog Wdr10 -2.97 0.0001
Cystathionase (cystathionine gamma-
lyase)
Cth -2.62 0.0001
KH domain containing, RNA binding, 
signal transduction associated 2
Khdrbs2 -2.45 0.0001
C-type lectin domain family 4, mem-
ber e
Clecsf9 -2.39 0.011
Casein kinase 2, alpha 1 polypeptide Csnk2a1 -2.37 0.025
Transportin 1 Tnpo1 -2.04 0.002
Potassium voltage-gated channel, 
KQT-like subfamily, member 2
Kcnq2 -2.02 0.008
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Table 3.10 Up- regulated genes after 5 hours in ciprofibrate dosed Fisher rats.  The list of up- regulated genes
for male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 5 hours. Microarray analysis
was carried out as in Section 2.2.5. 
Description Name
Mean fold 
change
FDR p-
value
Group specific component Gc 3.64 0.0001
Apolipoprotein B Apob 2.92 0.0001
Dual specificity phosphatase 14 Dusp14 2.88 0.0001
Mucin 2, oligomeric mucus/gel-form-
ing
Muc2 2.88 0.0001
Glucosidase, alpha; neutral C 5830445O15Rik 2.86 0.004
Serine (or cysteine) preptidase inhibi-
tor, clade A, member 1B
Serpina1b 2.81 0.001
Kininogen 1 Kng1 2.79 0.0001
Murinoglobulin 1 Mug1 2.76 0.0001
Hemopexin Hpxn 2.57 0.005
Metallothionein 1 Mt1 2.55 0.001
Microtubule-associated protein 7 
domain containing 1
BC019977 2.54 0.0001
Potassium voltage-gated channel, sub-
family H, member 1
Kcnh1 2.48 0.001
Hyaluronan and proteoglycan link pro-
tein 4
Hapln4 2.42 0.0001
Per-hexamer repeat gene 5 Phxr5 2.41 0.003
Peptidylprolyl isomerase A (cyclophi-
lin A)
Ppia 2.41 0.0001
Sortilin-related VPS10 domain con-
taining receptor 2
Sorcs2 2.40 0.002
Serine (or cysteine) proteinase inhibi-
tor, clade A, member 3M
Serpina3m 2.39 0.001
Gulonolactone (L-) oxidase Gulo 2.39 0.0001
Transmembrane protein 41a 5730578N08Rik 2.37 0.001
RIKEN cDNA 1700001G17 gene 1700001G17Rik 2.32 0.0001
RIKEN cDNA 4930543D07 gene 4930543D07Rik 2.31 0.005
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Sema domain, seven thrombospondin 
repeats transmembrane domain 5B
Sema5b 2.31 0.004
Sema domain, seven thrombospondin 
repeats transmembrane domain 5A
Sema5a 2.29 0.0001
Fructose-1,6-bisphosphatase 1 Fbp1 2.27 0.0001
Myosin, light chain 6 Myl6 2.27 0.001
Collagen, type XI, alpha 2 Col11a2 2.26 0.005
Major urinary protein 4 Mup4 2.26 0.006
Human immunodeficiency virus type I 
enhancer binding protein 1
Hivep1 2.26 0.0001
Serum amyloid P-component Apcs 2.24 0.0001
B9 protein domain 1 Eppb9 2.22 0.0001
Ankyrin repeat domain 40 Gcap15 2.22 0.00011
Propionyl-coenzyme A carboxylase, 
alpha polypeptide
Pcca 2.20 0.001
Murinoglobulin 2 Mug2 2.17 0.0001
Metallothionein 4 Mt4 2.17 0.009
Ubiquitin A-52 residue ribosomal pro-
tein fusion product 1
Uba52 2.16 0.002
Ceruloplasmin Cp 2.16 0.0001
Prostaglandin E synthase 2 Ptges2 2.16 0.0001
Fetuin B Fetub 2.16 0.001
Glutathione transferase zeta 1 Gstz1 2.13 0.0001
RIKEN cDNA 4930444A02 gene 4930444A02Rik 2.13 0.0001
Vitamin K epoxide reductase complex, 
subunit 1
Vkorc1 2.12 0.006
RIKEN cDNA 2010107G23 gene 2010107G23Rik 2.11 0.007
Olfactory receptor 123 Olfr123 2.11 0.003
Table 3.10 Up- regulated genes after 5 hours in ciprofibrate dosed Fisher rats.  The list of up- regulated genes
for male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 5 hours. Microarray analysis
was carried out as in Section 2.2.5. 
Description Name
Mean fold 
change
FDR p-
value
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Table 3.11 Down- regulated genes after 5 hours in ciprofibrate dosed Fisher rats.   The list of down- 
regulated genes for male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 5 hours. 
Microarray analysis was carried out as in Section 2.2.5.
Description Name
Mean fold 
change
FDR p-
value
NmrA-like family domain containing 1 1110025F24Rik -4.91 0.00001
Neural precursor cell expressed, develop-
mentally down-regulated 4
Nedd4 -4.49 0.00001
Zinc finger, MIZ-type containing 1 BC065120 -4.31 0.00001
RAS (RAD and GEM)-like GTP-binding 
1
Rem1 -3.79 0.00001
Adenylate cyclase 8 (brain) Adcy8 -3.57 0.00001
Taste receptor, type 2, member 116 Tas2r116 -3.50 0.026
Phosphofructokinase, platelet Pfkp -3.41 0.0001
Rab40c, member RAS oncogene family Rab40c -3.35 0.027
Mucin 5AC, oligomeric mucus/gel-form-
ing
Muc5ac -3.19 0.0001
Tubulin folding cofactor B Ckap1 -3.16 0.0001
Cas-Br-M (murine) ecotropic retroviral 
transforming sequence b
Cblb -3.10 0.005
Acyl-Coenzyme A dehydrogenase, short/
branched chain
Acadsb -2.93 0.0001
Cyclin B3 Ccnb3 -2.89 0.00001
RAN binding protein 1 Ranbp1 -2.89 0.004
RAB interacting factor Rabif -2.87 0.001
Usher syndrome 1C binding protein 1 Ushbp1 -2.81 0.0001
Zinc finger protein 212 Zfp212 -2.70 0.0001
Diazepam binding inhibitor-like 5 Dbil5 -2.70 0.030
Immunoglobulin lambda chain complex Igl -2.68 0.00011
Minichromosome maintenance complex 
component 5
Mcm5 -2.55 0.0001
TPX2, microtubule-associated, homolog Tpx2 -2.50 0.004
Olfactory receptor 609 Olfr609 -2.46 0.026
Casein kinase 2, alpha 1 polypeptide Csnk2a1 -2.43 0.025
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Figure 3.41 shows a heatmap of the hepatic genes that were highly induced with ciprofibrate
after 5 hours. Inaddition, the trees at the top and right show how these genes and pathways clus-
ter together. Apparently there was not enough data to be able to generate figures for the other
time points (as indicated by the software). Genes of the acute phase response were found to be
up- regulated in both the 3 and 5 hour treated groups. For the 3 hour group there was 4 out of
23 genes responsible for the acute phase response (17.4%) and in the 5 hour group there was 8
out of 23 genes (34.8%). 
This also was the case for the genes of the acute inflammatory response, where for the 3 hour
group there was 4 out of 43 genes and for the 5 hours there was 9 out of 43 genes (20.9%). As
for the genes of the response to wounding in the 3 hour samples there was 7 out of 193 (3.6%)
and 19 out of 193 genes (9.8%) for the 5 hour samples.
Sonic hedgehog Shh -2.38 0.005
Transglutaminase 5 Tgm5 -2.25 0.012
Nuclear transcription factor-Y alpha Nfya -2.15 0.00001
Poly (ADP-ribose) polymerase family, 
member 12
Zc3hdc1 -2.13 0.036
Table 3.11 Down- regulated genes after 5 hours in ciprofibrate dosed Fisher rats.   The list of down- 
regulated genes for male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 5 hours. 
Microarray analysis was carried out as in Section 2.2.5.
Description Name
Mean fold 
change
FDR p-
value
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Figure 3.41 Heatmap for microarray analysis of ciprofibrate gene expression after 5 hours. 
Male F-344/NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate, then killed after 24 hours. The num-
bers at the left side refer to genes 1= SERPINA1A, 5= HP, 10= SERPINC1, 15= UCN2, 20= STATG, 25= TUBB4,
30=CDC20, 35=RPS27. Microarray analysis was carried out as in Section 2.2.5, this heatmap was established with
High-Throughput GoMiner (Zeeberg, 2005). Red demonstrates up- regulated, and blue demonstrates down- regu-
lated (-1 down- regulated, +1 up- regulated).
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Section 3.3.6 Microarray analysis of CPA dosed rats after 1, 3, and 5 hours
Microarray analysis was performed with hepatic samples from F-344NHsd fisher rats dosed
with 100 mg kg-1 CPA (Section 2.2.5). A list of the up- regulated genes for the samples treated
with CPA for 1 hour with a fold induction of >1.2 fold change is presented in Table 3.12 includ-
ing Cd97, Sstr4 and Rnf141. A list of down- regulated genes after 1 hour is presented in Table
3.13, while a list of up- regulated genes for 3 hour samples were found in Table 3.14 (fold
change >1.0) including Hpxn, Cyp2c29, and Seprina3m and Table 3.15 lists the down- regulated
genes after 3 hours CPA treatment. The genes up- regulated with ciprofibrate after 5 hours were
listed in Table 3.16 (fold change >1.5) including Scd1, Mug2, Ppp1cb and Hspd1, and the
down- regulated genes were listed in Table 3.17.
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Table 3.12 Up- regulated genes at 1 hour in CPA dosed Fisher rats.  A list of up- regulated genes for male F-
344NHsd rats aged 14-15 weeks dosed with 100 mg kg-1 CPA then killed after 1 hours. Microarray analysis was determined as
in Section 2.2.5. 
Description Name
Mean fold 
change
FDR p-
value
CD97 molecule Cd97 2.50 0.0001
Lix1-like D130027M04Rik 1.47 0.005
Somatostatin receptor 4 Sstr4 1.47 0.003
Transient receptor potential cation 
channel, subfamily C, member 4 asso-
ciated protein
Trpc4ap 1.29 0.003
E2F transcription factor 3 E2f3 1.86 0.039
Sirtuin (silent mating type information 
regulation 2 homolog) 2 
Sirt2 1.80 0.013
MCF.2 cell line derived transforming 
sequence-like
Mcf2l 1.22 0.042
Kinesin family member 3B Kif3b 1.39 0.010
Dual specificity phosphatase 28 0710001B24Rik 1.16 0.002
Neurexin 3 Nrxn3 1.71 0.038
Ring finger protein 141 Rnf141 1.22 0.0001
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Table 3.13 Down- regulated genes at 1 hour in CPA dosed Fisher rats.  A list of down- regulated genes for 
male F-344NHsd rats aged 14-15 weeks dosed with 100 mg kg-1 CPA then killed after 1 hours. Microarray analysis was 
determined as in Section 2.2.5.
Description Name
Mean fold 
change
FDR p-
value
Phospholipase A2, group IIC Pla2g2c -3.09 0.006
RIKEN cDNA 4930507D10 gene 4930507D10Rik -3.03 0.021
Caspase recruitment domain family, 
member 10
Card10 -2.62 0.001
Kruppel-like factor 15 Klf15 -2.60 0.002
Protein phosphatase 1, regulatory 
(inhibitor) subunit 14A
Ppp1r14a -2.58 0.021
Retinoic acid induced 1 Rai1 -2.38 0.006
RIKEN cDNA 4933433G15 gene 4933433G15Rik -2.31 0.012
RIKEN cDNA 7030407O06 gene 7030407O06Rik -2.30 0.015
Hepatocyte nuclear factor 4, alpha Hnf4a -2.25 0.021
GS homeobox 1 Gsh1 -2.23 0.0001
RIKEN cDNA 9530085L11 gene 9530085L11Rik -2.13 0.0001
RIKEN cDNA 1810046J19 gene 1810046J19Rik -2.05 0.033
Abeer Amer   Section 3.3.6
Page 160
Table 3.14 Up- regulated genes after 3 hours in CPA dosed Fisher rats.  A list of up- regulated genes for male 
F-344NHsd rats aged 14-15 weeks dosed with 100 mg kg-1 CPA then killed after 3 hours. Microarray analysis was determined 
as in Section 2.2.5. 
Description Name
Mean fold 
change
FDR p-
value
RIKEN cDNA E130101E03 gene E130101E03Rik 1.16 0.003
Hemopexin Hpxn 1.14 0.005
COP9 constitutive photomorphogenic 
homolog subunit 4 
Cops4 1.30 0.012
Hairy/enhancer-of-split related with 
YRPW motif 1
Hey1 1.12 0.028
Cytochrome P450, family 2, subfamily 
c, polypeptide 29
Cyp2c29 1.08 0.039
Serine (or cysteine) proteinase inhibi-
tor, clade A, member 3M
Serpina3m 1.12 0.001
Table 3.15 Down- regulated genes after 3 hours in CPA dosed Fisher rats.  A list of down- regulated genes for 
male F-344NHsd rats aged 14-15 weeks dosed with 100 mg kg-1 CPA then killed after 3 hours. Microarray analysis was 
determined as in Section 2.2.5
Description Name
Mean fold 
change
FDR p-
value
Membrane-associated ring finger Axot -2.35 0.006
Aminolevulinate, delta-, synthase 1 Alas1 -1.84 0.0001
Cytochrome P450, family 3, subfamily 
a, polypeptide 44
Cyp3a44 -1.46 0.001
UDP glycosyltransferase 1 family, 
polypeptide A10
Ugt1a13 -1.13 0.002
ER degradation enhancer, mannosi-
dase alpha-like 1
Edem1 -1.01 0.002
Serum induced transcript 1 Sif1 -1.01 0.020
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Table 3.16 Up- regulated genes after 5 hours in CPA dosed Fisher rats.  A list of up- regulated genes for male 
F-344NHsd rats aged 14-15 weeks dosed with 100 mg kg-1 CPA then killed after 5 hours. Microarray analysis was determined 
as in Section 2.2.5
Description Name
Mean fold 
change
FDR p-
value
Cathepsin E C920004C08Rik 3.48 0.0001
Metallothionein mt 2.87 0.0001
Murinoglobulin 1 Mug1 2.47 0.0001
Stearoyl-Coenzyme A desaturase 1 Scd1 2.21 0.0001
ADAM metallopeptidase with throm-
bospondin type 1 motif, 1
Adamts1 2.17 0.001
Group specific component Gc 2.18 0.0001
RIKEN cDNA 2810455D13 gene 2810455D13Rik 2.12 0.003
Frizzled homolog 7 Fzd7 2.10 0.0001
Murinoglobulin 2 Mug2 2.09 0.0001
Zinc finger protein 335 1810045J01Rik 2.02 0.006
Beta-2 microglobulin B2m 2.01 0.004
cDNA sequence BC018242 BC018242 1.95 0.006
RIKEN cDNA 2600006L11 gene 2600006L11Rik 1.91 0.0001
Protein phosphatase 1, catalytic sub-
unit, beta isoform
Ppp1cb 1.91 0.002
Predicted gene IGKV12 1.87 0.0001
Transmembrane BAX inhibitor motif 
containing 6
Tegt 1.81 0.003
C-type lectin domain family 5, mem-
ber a
Clecsf5 1.80 0.0001
SET binding protein 1 Setbp1 1.66 0.005
RIKEN cDNA 4930538K18 gene 4930538K18Rik 1.64 0.0001
Ribosomal protein L5 Rpl5 1.63 0.006
Sulfotransferase family 2A,member 2 Sult2a2 1.61 0.008
Pregnancy upregulated non-ubiqui-
tously expressed CaM kinase
Pnck 1.59 0.0001
Heat shock protein 1 Hspd1 1.58 0.005
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Figure 3.42 shows a heatmap of the hepatic genes that were highly induced with CPA after 3
hours. In addition, the trees at the top and right show how these genes and pathways cluster to-
gether. There was not enough data to be able to generate figures for the other time points, or for
the down- regulated genes, and there was not any related pathways that were repeated with the
1, 3 and 5 hour time points.
Table 3.17 Down- regulated genes after 5 hours in CPA dosed Fisher rats.  A list of down- regulated genes for 
male F-344NHsd rats aged 14-15 weeks dosed with 100 mg kg-1 CPA then killed after 5 hours. Microarray analysis was 
determined as in Section 2.2.5
Description Name
Mean fold 
change
FDR p-
value
Acyl-Coenzyme A dehydrogenase, 
short/branched chain
Acadsb -3.56 0.0001
Diazepam binding inhibitor-like 5 Dbil5 -2.76 0.030
Splicing factor, arginine/serine-rich 16 Sfrs16 -2.53 0.007
Inositol polyphosphate phosphatase-
like 1
Inppl1 -2.50 0.001
ArfGAP with dual PH domains 1 Centa1 -2.43 0.027
RIKEN cDNA 1700034B16 gene 1700034B16Rik -2.37 0.001
Calcineurin-like phosphoesterase 
domain containing 1
C530044N13Rik -2.23 0.033
RIKEN cDNA 1700126L10 gene 1700126L10Rik -2.22 0.006
Mitochondrial ribosomal protein S18A 18S -2.19 0.0001
RIKEN cDNA 2300009N04 gene 2300009N04Rik -2.16 0.0001
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Figure 3.42 Heatmap for microarray analysis of CPA treated samples after 3 hours. Male F-344NHsd
rats aged 14-15 weeks dosed with 100 mg kg-1 CPA, then killed after 24 hours. Microarray analysis was determined as
in Section 2.2.5, this heatmap was established with High-Throughput GoMiner (Zeeberg et al., 2005). Red demonstrates
up- regulated, and blue demonstrates down- regulated (-1 down- regulated, +1 up- regulated).
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Section 3.4Transcriptome sequencing analysis
To study the early genes whose expression may be linked to the induction of hepatic DNA syn-
thesis, RNA sequencing (whole transcriptome sequencing) was applied to the mRNAs isolated
from F-344 fisher rats dosed with 50mg kg-1 ciprofibrate or corn oil and killed after 3 hours.
This was done with the Next Generation sequencing facilities, at the Deep seq research facility
at the University of Nottingham (The AB SOLID 3 platform) as described in Section 2.2.6. The
number of genes that resulted from this analysis was 24962 genes, with 705 genes that have a
FDR p-value correction of <0.05, and 4245 genes that have the p-value is <0.05. In this analysis
reads per kilobase of exon model per million mapped reads (RPKM) was used, which norma-
lises for the difference in number of mapped reads between the samples (4 treated and 4 control
samples).
Section 3.4.1 Comparing the data in a scatter plot
To show the effect of the ciprofibrate against the control on the genes a scatter plot was applied,
this represents the number and distribution of the genes after the analysis. Shown in Figure 3.43
the spread of the control normalised genes against the treated normalised genes is illustrated The
original data can be found at http://spldeepseq.nottingham.ac.uk/~aziz/wtp_rat/.
The points closest to the linear regression plot (the x=y line in the plot) are the genes which are
least affected by the treatment. Genes of interest would be represented by the points that are
most dispersed along an axis perpendicular to the linear regression plot. It is clarified in Figure
3.43 that the genes are behaving in a similar way because most of the genes are close to the x=y
line, but if they are affected by the ciprofibrate as there is a drift away from the main line, and
these should be the differently induced genes that are of interest.
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Figure 3.43 Scatter plot view of transcriptome data.  A scatter plot view of the treated normalised
mean data for each gene against the control normalised means, from the liver-RNA of F-344NHsd fisher rats
dosed with 50 mg kg-1 ciprofibrate (or corn oil) for 3 hours. Shown in red is a linear regression plot of the
points. Each point indicates the relationship between the control and treated samples. (Software used The CLC
Genomics Workbench).
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Section 3.4.2 Checking between and within the groups variability
The objective here is to compare and examine the general distributions of the data within the
same group. This is important to exclude any flaws in the preparation or other defects in the con-
trol and treated groups, so box plots were used. 
The normalised expression values of the control data are shown in Figure 3.44 where the 4 sam-
ples are similar in spread (the upper and lower bars are aligned) and the median lines in all the
boxes are aligned. Similar results were observed in the normalised treated data (Figure 3.45) and
the data for the whole experiment (when comparing the treated against the control) (Figure
3.46). 
From the spread of the samples in the figures it can be concluded that the samples are equally
distributed within the control/ treated groups and in the whole experiment, and this indicates that
the preparation and processing of the samples were correctly labelled and assigned in each of
the groups.
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Figure 3.44 Analysing distributions of the control data. Four box plots of the normalised expression val-
ues of each of the 4 samples from control livers of F-344 fisher rats dosed with corn oil for 3 hours. Each box plot
refers to the distribution of the data, and includes a square box indecating the IQR (Inter quartile Range 25%) value
for each sample’s distribution (from the lower to the upper quartile), the lines displayed in the square boxes are the
median and the upper and lower bars extend 1.5 (75%) the height of the box.(Software used The CLC Genomics
Workbench).
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Figure 3.45 Analysing distributions of the treated data. Four box plots of the normalised expression val-
ues of each of the 4 samples from livers of F-344 fisher rats treated with 50 mg kg-1 ciprofibrate for 3 hours. Each
box plot refers to the distribution of the data, and includes a square box indecating the IQR (Inter quartile Range 25%)
value for each sample’s distribution (from the lower to the upper quartile), the lines displayed in the square boxes are
the median and the upper and lower bars extend 1.5 (75%) the height of the box (Software used The CLC Genomics
Workbench).
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Section 3.4.3 A volcano plot view of the data
This was done to see the genes on the basis of the p-value and the fold change differences be-
tween the control and the ciprofibrate treated samples for 3 hours, by applying the volcano plot
view of the data.
A volcano plot of the results from the RNAseq analysis is illustrated in Figure 3.47 showing the
log10 of the p-value (of the Student’s t- test of the difference between the control and treated
samples) and the log2 of the fold change difference between the control and treated samples.
The plots closest to the zero value for log2 fold change are the genes with least change in ex-
pression, while the genes with significantly changed expression are indicated within the plots in
Figure 3.46 Analysing distributions of all the transcriptome data. 8 box plots of the normalised ex-
pression values of all 8 samples from livers of F344 fisher rats treated with 50 mg kg-1 ciprofibrate/corn oil for 3
hours. Red are the 4 control (corn oil) samples and green are the 4 treated samples. Each box plot refers to the dis-
tribution of the data, and includes a square box indecating the IQR (Inter quartile Range 25%) value for each sam-
ple’s distribution (from the lower to the upper quartile), the lines displayed in the square boxes are the median and
the upper and lower bars extend 1.5 (75%) the height of the box. (Software used The CLC Genomics Workbench).
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red (statistics done was with Students' t- test) data used, and had a false discovery rates FDR p-
values of < 0.05, and a fold change of ± 2. 
The volcano plot shows the relationship between the p-values and the variation in expression
values of the control and treated groups. Points for gene expressions with statistically significant
differences will be positioned in the upper left and upper right of the volcano plot specified in
red in Figure 3.47. This shows that the samples are mostly similar with only a small number of
genes that are differently (up or down) regulated. These genes are the genes of interest for this
study. 
Figure 3.47 volcano plot view of transcriptome data (Students t- test).  A volcano plot view of the log10 p-
value versus the log2 fold change difference between the control and treated samples, from the hepatic RNA of F-
344NHsd fisher rats dosed with 50 mg kg-1 ciprofibrate (or corn oil) for 3 hours. Red points are the features with false
discovery rates (FDR) p-values of < 0.05, and a fold change of ±2. (Software used The CLC Genomics Workbench).
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Section 3.4.4 Hierarchical clustering of samples
Hierarchical clustering was presented to see the comparative similarities of the control and
treated samples, and to check if they cluster homogeneously or not. 
The hierarchical cluster is a heat map with the clustering of the samples at the bottom. The tree
was arranged by placing each group of related genes as a cluster and calculating the pair-wise
space between all clusters, then combining each two closest clusters to be made into one new
cluster and then the next closest joined and so on until there was only one cluster left (which
contains all samples). In the tree the spaces between the clusters reflect the distance of the
branches in the tree. Therefore, samples that have closely resembled gene expressions have
short distances between them, and those that are more different are separated further. 
In Figure 3.48 the samples on the left are the treated samples and the samples on the right are
the controls, the red and blue colours express the induction of the genes in the groups (red indi-
cates high gene expression and blue presents low expression of the genes), the hierarchical clus-
tering of the samples clarifies the relationship in between the groups, and shows that the
treatment has affected the gene induction and that it is different from the untreated. 
The tree cluster at the bottom of Figure 3.48 shows that the samples similar in their gene expres-
sion are together, and also indicates that the ciprofibrate treatment replicates had a similar effect
on the genes at 3 hours (the red colour is more abundant than the blue). This is different from
the control replicates that are all clustered together.
As a conclusion the treated replicates show similar effects on genes that appear highly induced,
and the same for the control replicates, which also show a difference between the treated and
control groups.
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Figure 3.48 A hierarchical cluster of samples. Male Fisher rats were treated with 50mg kg-1 ciprofibrate or
corn oil for 3 hours, then RNAseq analysis was applied on the hepatic RNA samples as described in Section 2.2.6. At the
top of the figure are listed the names of the samples the treatments (4 groups) on the left and the controls (4 groups) on
the right. The horizontal lines present the features (genes) and are coloured according to the expression level. Red pres-
ents the maximum level of expression and blue shows the minimal level of expression. The tree at the bottom of the heat-
map visualizes the clustering. The features are sorted by the expression intensity in the first sample on the left. (Software
used The CLC Genomics Workbench).
treatments                                                         controls
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Section 3.4.5 Hierarchical and K-means clusters of features
Feature clustering was performed with the results from the RNAseq analysis to recognize and
cluster together genes with related gene expression values from the controls or samples treated
with 50 mg kg-1 ciprofibrate for 3 hours. Features that are clustered together are expected to be
involved in similar biological procedures.
Hierarchical clustering of features was a tree arrangement of the similar expressed genes over
the set of control and treated samples (or groups). In the hierarchical cluster each feature is a
cluster. Then the pairwise distance between the clusters was evaluated and the two closest clus-
ters combined into one new cluster. Then the clusters were grouped together depending on the
relationship of the gene induction until there was only one cluster left. This feature clustering
was performed on a subset of the data after filtering away the genes that have low fold difference
values or have little difference between the samples (large p-value).
With the hierarchical clustering a number of the genes were found by the feature clustering to
be more expressed in the treated than that in the control group, e.g. Cyp4A1, G0/G1switch 2 and
Scd1 genes (sterol-Coenzyme A desaturase 1), and the last two genes are more closely clustered
together than the Cyp4A1 gene.
The feature clustering was also performed as a k-means clustering, where the features (gene ex-
pressions) are clustered together in groups depending on the expression response to the control
and treated samples. This clustering resulted in presenting how some genes were down-regulat-
ed in the control samples and up-regulated in the treated samples, or presenting how the gene
expression behaves in a different way, where the genes were up-regulated in the control samples
then the same gene expression goes down in the treated samples, or how the gene expression in
the control and treated samples have similar expression values. 
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Section 3.4.6 Induced genes by ciprofibrate after 3 hours with RNAseq
The objective from this is to find genes that are differential expressed in hepatic cells of
F344NHsd Fisher rats dosed with 50mg kg-1 ciprofibrate after 3 hours see (Section 2.2.1). This
should highlight genes whose expression is correlated with the hepatic DNA synthesis that oc-
curs at 24 hours.
This was done by Transcriptome Sequencing analysis of the hepatic RNA detailed in Section
2.2.6. Stastical analysis was done with Student t- test and genes were defined as significant if
the FDR p-value was < 0.05. A whole list of all the ~25000 genes and associated data analysis
is provided in the CD at the end of this thesis.
Section 3.4.6.1 Down- regulated genes with RNAseq
Genes were considered down- regulated if the FDR p-value was > 0.05 and there was a fold
change in expression of < -1.5 (0.67 fold). Table 3.18 shows a list of down- regulated known
(named) genes (e.g. Igfbp2, ppargcla, Cyp1a2, AhR.....), and in Table 3.19 is a list of the novel
genes that have not been named to date.
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Table 3.18 Named down- regulated genes in ciprofibrate dosed rats treated for 3 hours.  A list of down-
regulated genes for male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 3 hours.
RNAseq analysis was done as described in Section 2.2.6. Expressed genes with a fold change of <-1.5 and a FDR p-value of
<0.05 were listed.
Description
Gene 
name
Ensembl 
Feature ID
Fold 
Change 
<-1.5
FDR 
p-
value 
<0.05
Insulin-like growth factor-binding protein 2 Precursor 
(IGF-binding protein 2)
lgfbp2 ENSRNOT00000023068 -5.0 0.01
Peroxisome proliferator-activated receptor gamma, 
coactivator 1 alpha
Ppargc1a ENSRNOT00000006071 -2.1 0.01
Cytochrome P450, family 1, subfamily a, polypeptide 2 
Gene
Cyp1a2 ENSRNOT00000058571 -1.7 0.03
Acyl-CoA synthetase medium-chain family member 2 Acsm2 ENSRNOT00000020587 -3.3 0.02
Hepatocyte nuclear factor 6 (One cut domain family 
member 1)
HNF-6 ENSRNOT00000010738 -2.2 0.03
Aryl hydrocarbon receptor Ahr ENSRNOT00000006618 -2.0 0.04
Immediate early response 2- immediate early response 
gene 2 protein
Ier2 ENSRNOT00000003793 -1.8 0.02
Forkhead box D1 (mediates the coordinated expression 
of hepatocyte-specific genes)
Foxd1 ENSRNOT00000010201 -1.9 0.04
 Death-associated kinase 2 dapk2 ENSRNOT00000023372 -1.7 0.04
Solute carrier family 2 (facilitated glucose transporter), 
member 1
Slc2a1 ENSRNOT00000064452 -2.4 0.04
Protein kinase-like protein SgK493 Sgk493 ENSRNOT00000005664 -2.2 0.04
Oncogene-serine threonine protein kinase pim-1 ENSRNOT00000000637 -2.0 0.03
Claudin 9 (predicted); LOC287099; protein-coding Cldn9 ENSRNOT00000004848 -2.1 0.03
Claudin 6 (protein binding) Cldn6 ENSRNOT00000004845 -1.9 0.03
Claudin 4 Cldn4 ENSRNOT00000002003 -2.0 0.04
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Sialidase 2 (cytosolic enzyme that cleaves sialic acid; 
involved in the degradation of glycolipids and glycopro-
teins)
Neu2 ENSRNOT00000022818 -2.1 0.02
Proline rich 16 similar to mesenchymal stem cell protein 
DSC54 (predicted)
Prr16 ENSRNOT00000026724 -1.9 0.04
Zink finger protein 36-acts as a transcriptional activator Zfp36 ENSRNOT00000026661 -1.9 0.03
SH3-domain binding protein 5 (BTK-associated)-may 
bind c-Jun N-terminal kinase (JNK); may play a role in 
JNK and Bruton's tyrosine kinase (Btk) mediated signal-
ling pathways
Sh3bp5 ENSRNOT00000026389 -1.8 0.03
UDP-Gal:betaGlcNAc beta 1,3-galactosyl transferase, 
polypeptide 1 
B3galt1 ENSRNOT00000010018 -1.8 0.01
Lipopolysaccharide binding protein-binds lipopolysac-
charide on outer membrane of gram negative bacteria; 
involved in immune response 
Lbp ENSRNOT00000019787 -1.8 0.04
Leukocyte cell-derived chemotaxin 2 Lect2 ENSRNOT00000016252 -1.8 0.04
Small nuclear ribonucleoprotein 25 (U11/U12) Snrnp25 ENSRNOT00000067079 -1.8 0.03
 Tripartite motif-containing 36 Trim36 ENSRNOT00000022294 -1.8 0.04
Sprouty homolog 2 (Drosophila) Spry2 ENSRNOT00000013342 -1.7 0.04
Sec61 gamma subunit, pseudogene 1 gama subunit-like 
Q7Tq10_RAT
SEC61g-
ps1
ENSRNOT00000043104 -1.7 0.02
Phosphodiesterase 4C, cAMP-specific (phosphodi-
esterase E1 dunce homolog, Drosophila- putative nucle-
otide phosphodlerase E1 dunce homolog, drosophila)
Pde4c ENSRNOT00000026457 -1.6 0.04
UDP-N-acteylglucosamine pyrophosphorylase 1-like 1. Uap1/1 ENSRNOT00000017373 -1.6 0.02
Table 3.18 Named down- regulated genes in ciprofibrate dosed rats treated for 3 hours.  A list of down-
regulated genes for male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 3 hours.
RNAseq analysis was done as described in Section 2.2.6. Expressed genes with a fold change of <-1.5 and a FDR p-value of
<0.05 were listed.
Description
Gene 
name
Ensembl 
Feature ID
Fold 
Change 
<-1.5
FDR 
p-
value 
<0.05
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Hermansky-Pudlak syndrome 4 homolog (human)- 
human homolog is involved in the biogenesis of lyso-
somes and related cellular vesicles; mutations in the 
human gene are associated with Hermansky-Pudlak syn-
drome
Hps4 ENSRNOT00000000824 -1.6 0.02
Sodium-dependent phosphate transport protein 1 Slc17a1 ENSRNOT00000066313 -1.6 0.04
Translocase of outer mitochondrial membrane 7 homolog 
(yeast)
Tomm7 ENSRNOT00000065962 -1.6 0.02
Transmembrane protein 38a Tmem38a ENSRNOT00000015877 -1.5 0.01
High mobility group uncleosomeal binding domain 3 Hmgn3 ENSRNOT00000039917 -1.5 0.04
ADP- ribosylation factor- like 4A - may play role in GTP 
binding and hydrolysis
arl4a ENSRNOT00000005800 -1.6 0.04
ADP- ribosylation factor-like arl11 ENSRNOT00000019646 -1.5 0.04
Ribosomal protein S27-ribosomal protein subunit Rps27 ENSRNOT00000022897 -1.7 0.02
Ribosomal protein S14-structural component of the 40S 
subunit of the ribosome, the organelle responsible for 
protein synthesis
Rps14 ENSRNOT00000059501 -1.8 0.05
Ribosomal protein L10A 60S ribosomal subunit protein Rpl10a ENSRNOT00000000603 -1.5 0.02
Ribosomal protein L11 Rpl11 ENSRNOT00000030043 -1.5 0.01
Ribosomal protein L23a Rpl23a ENSRNOT00000035657 -1.5 0.03
SnoRNA no protein product U8 ENSRNOT00000054056 -5.3 0.01
Table 3.18 Named down- regulated genes in ciprofibrate dosed rats treated for 3 hours.  A list of down-
regulated genes for male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 3 hours.
RNAseq analysis was done as described in Section 2.2.6. Expressed genes with a fold change of <-1.5 and a FDR p-value of
<0.05 were listed.
Description
Gene 
name
Ensembl 
Feature ID
Fold 
Change 
<-1.5
FDR 
p-
value 
<0.05
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Table 3.19 Novel down- regulated genes in rats dosed with ciprofibrate for 3 hours.  A list of novel down-
regulated genes for male F-344NHsd rats aged 14-15 weeks, dosed with 50 mg kg-1 ciprofibrate then killed after 24 hours.
RNAseq analysis was done as described in Section 2.2.6. Expressed genes with a fold change of <-1.5 and a FDR p-value of
<0.05 are shown. 
Description Gene name
Ensembl 
Feature ID
Fold 
change 
>1.5
FDR 
p-
value 
<0.05
Pseudogene (a noncoding sequence similar to an 
active protein) no protein product
novel ENSRNOT00000011532 -9.0 0.05
Pseudogene (no protein product) novel ENSRNOT00000025854 -1.9 0.04
Novel MiRNA microarray (a single-stranded 
RNA, typically 21-23 base pairs long), thought to 
be involved in gene regulation (especially inhibi-
tion of protein expression)
novel ENSRNOT00000054415 -1.7 0.04
Protein coding- a protein coding transcript is a 
spliced mRNA that leads to a protein product
novel ENSRNOT00000002046 -1.8 0.05
Protein coding novel ENSRNOT00000065817 -1.6 0.03
Protein coding novel ENSRNOT00000060517 -1.6 0.04
Protein coding novel ENSRNOT00000004213 -1.5 0.03
Protein coding transcript RGD1563551 ENSRNOT00000047507 -3.1 0.04
Protein coding transcript RGD1562755 ENSRNOT00000051559 -2.5 0.01
Protein coding transcript LOC691255 ENSRNOT00000036330 -1.9 0.03
Pseudogene gene a noncoding sequence similar to 
an active protein (no protein product)
LOC365595 ENSRNOT00000000346 -2.1 0.03
Pseudogene LOC367016 ENSRNOT00000030115 -1.8 0.05
Ribosomal protein P1-like LOC10036522 ENSRNOT00000015893 -1.5 0.03
Similar to ribosomal protein L30 RGD1562397 ENSRNOT00000044756 -1.5 0.04
Similar to 60S acidic ribosomal protein P1 RGD1565054 ENSRNOT00000034714 -1.6 0.01
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Section 3.4.6.2 Up- regulated genes with RNAseq
Genes were considered up- regulated if the FDR p-value was more than 0.05 and there was a
fold change in expression of > 2.5 (because the interest is in the up-regulated genes). Table 3.20
shows a list of up- regulated known (named) genes and in Table 3.21 is a list of the novel genes
that have not been named to date. 
Similar to dystonin isoform 1 LOC680875 ENSRNOT00000014191 -1.5 0.04
Similar to 60S ribosomal protein L23a LOC689899 ENSRNOT00000040647 -1.5 0.01
Similar to ribosomal protein S27a RGD1564290 ENSRNOT00000027780 -1.6 0.03
Similar to ribosomal protein S27a RGD1560997 ENSRNOT00000051805 -1.6 0.01
Table 3.19 Novel down- regulated genes in rats dosed with ciprofibrate for 3 hours.  A list of novel down-
regulated genes for male F-344NHsd rats aged 14-15 weeks, dosed with 50 mg kg-1 ciprofibrate then killed after 24 hours.
RNAseq analysis was done as described in Section 2.2.6. Expressed genes with a fold change of <-1.5 and a FDR p-value of
<0.05 are shown. 
Description Gene name
Ensembl 
Feature ID
Fold 
change 
>1.5
FDR 
p-
value 
<0.05
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Table 3.20 Named up- regulated genes in ciprofibrate dosed rats treated for 3 hours.  A list of up- regulated
genes for male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 3 hours. RNAseq anal-
ysis was done as described in Section 2.2.6. Expressed genes with a fold change of >2.5 and a FDR p-value of <0.05 were listed.
Description
Gene 
name
Ensembl 
Feature ID
Fold 
Change 
>2.5
FDR 
p-
value 
<0.05
Cytochrome P450, family 4, subfamily a, polypeptide 
10-member of the cytochrome P450 monoxygenase 
enzyme superfamily; plays a role in lipid metabolism; 
involved in androgen mediated signalling
Cyp4a10 ENSRNOT00000051385 3.2 0.01
Cytochrome P450 4X1 cytochrome P450 protein; may 
play a role in neurovascular function cytochrome P450, 
family 4, subfamily x, polypeptide 1- cytochrome P450 
protein; may play a role in neurovascular function
Cyp4x1 ENSRNOT00000011985 3.1 0.04
Peroxisome proliferator-activated receptor gamma, 
coactivator 1 beta
Ppargc 1b ENSRNOT00000023661 2.9 0.03
G0/G1switch 2 G0s2 ENSRNOT00000007879 5.8 0.01
Arylacetamide deacetylase-like 1 - exhibits catalytic 
activity and hydrolase activity; involved in metabolism 
Aadacl1 ENSRNOT00000017805 6.1 0.02
Acyl-CoA thioesterase 5 Acot5 ENSRNOT00000013760 2.8 0.01
Acyl-CoA thioesterase 6 Acot6 ENSRNOT00000058101 4.0 0.01
Acid phosphatase, prostate- Acpp ENSRNOT00000016222 3.2 0.03
Angiopoietin-like 4 -a circulating protein which causes 
an increase in plasma very low density lipoprotein by 
inhibition of lipoprotein lipase activity
Angptl4 ENSRNOT00000010031 2.7 0.01
Apolipoprotein L 9a Apol9a ENSRNOT00000031951 2.8 0.02
Arrestin domain containing 4 Arrdc ENSRNOT00000051402 3.5 0.01
Calcium channel, voltage-dependent, alpha 2/delta sub-
unit 4
Cacna2d4 ENSRNOT00000010746 3.3 0.01
Chemokine binding protein 2 CC-chemokine receptor; 
may have a role in placental immunity or hematopoiesis
Ccbp ENSRNOT00000026343 4.5 0.05
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Cyclin D1 a cell cycle protein involved in the regulation 
of cell proliferation; associated with many cancers and 
other diseases
Ccnd1 ENSRNOT00000028411 2.9 0.03
Carnitine palmitoyltansferase 1b, muscle - muscle iso-
form of enzyme that catalyses the transfer of long chain 
fatty acids to carnitine for translocation across the mito-
chondrial inner membrane
Cpt1b ENSRNOT00000013985 4.2 0.02
Carnitine palmitoyltransferase 2 - inner mitochondrial 
membrane protein that converts acylcarnitine to acyl-
CoA
Cpt2 ENSRNOT00000016954 2.6 0.01
Eph receptor A2 Epha2 ENSRNOT00000066072 3.3 0.04
Ets variant 3-like Etv3I ENSRNOT00000057490 2.9 0.04
Ets variant 6 human homolog is an ETS family tran-
scription factor; may be involved in hematopoiesis and 
maintenance of the vascular network
Etv6 ENSRNOT00000007889 4.6 0.01
Fin bud initiation factor homolog (zebra fish) Fiin ENSRNOT00000006203 3.2 0.04
Inhibin beta E cytokine; involved in cell fate determina-
tion
Inhbe ENSRNOT00000010106 3.7 0.03
Kelch repeat and BTB (POZ) domain containing 11 Kbtbd11 ENSRNOT00000016420 6.5 0.01
Known pseudogene potassium channel tetramerisation 
domain containing 12
Kctd12 ENSRNOT00000037179 2.9 0.02
Keratin 23 (histone deacetylase inducible) Krt23 ENSRNOT00000016657 3.9 0.01
MHC I like leukocyte 2 Mill2 ENSRNOT00000048149 3.7 0.01
Myotubularin related protein 7 Mtmr7 ENSRNOT00000065327 4.2 0.03
Myeloblastosis oncogene-like 1 Mybl1 ENSRNOT00000066911 2.6 0.01
Table 3.20 Named up- regulated genes in ciprofibrate dosed rats treated for 3 hours.  A list of up- regulated
genes for male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 3 hours. RNAseq anal-
ysis was done as described in Section 2.2.6. Expressed genes with a fold change of >2.5 and a FDR p-value of <0.05 were listed.
Description
Gene 
name
Ensembl 
Feature ID
Fold 
Change 
>2.5
FDR 
p-
value 
<0.05
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Myc myelocytomatosis viral oncogene homolog 1, lung 
carcinoma derived (avian) mouse lung carcinoma myc 
related oncogene 1 (Lmyc1) is a DNA binding protein 
with cell cycle related transcriptional activities
Mycl1 v ENSRNOT00000019101 3.6 0.02
Nuclear receptor subfamily 4, group A, member 2- 
nuclear receptor and transcription factor; plays a role in 
development and maintenance of neurons synthesizing 
the neurotransmitter dopamine
Nr4a2 ENSRNOT00000041394 2.8 0.01
Progestin and adipo Q receptor family member VII Paqr7 ENSRNOT00000022713 5.7 0.01
Peptidase M20 domain containing 2; aminoacylase 1-
like 2; aminoacylase 1-like 2 (predicted); acy1l2; 
LOC313130; Acy1l2; Acy1l2_predicted
Pm20d2 ENSRNOT00000060914 3.8 0.05
Protein phosphatase 1K (PP2C domain containing) Ppm1k ENSRNOT00000009202 2.5 0.03
PR domain containing 6 Prdm6 ENSRNOT00000047755 2.6 0.03
Prospero homeobox 2 Prox2 ENSRNOT00000006704 3.2 0.04
Proline rich Gla (G-carboxyglutamic acid) 4 (trans 
membrane)
Prrg4 ENSRNOT00000038464 7.9 0.02
Putative neuronal cell adhesion molecule Punc ENSRNOT00000051353 6.3 0.04
RAS, dexamethasone-induced 1- interacts with neuronal 
NO synthase adaptor protein CAPON and is involved in 
nitric oxide mediated signalling
Rasd1 ENSRNOT00000004475 2.6 0.03
Ras responsive element binding protein 1 Rreb1 ENSRNOT00000021007 2.5 0.02
Sterile alpha and TIR motif containing 1 Sarm1 ENSRNOT00000013639 2.8 0.04
Stearoyl-Coenzyme A desaturase 1-enzyme involved in 
the synthesis and regulation of unsaturated fatty acids
Scd1 ENSRNOT00000051086 13.2 0.01
Stearoyl-coenzyme A desaturase 4 Scd4 ENSRNOT00000017834 15.6 0.02
Table 3.20 Named up- regulated genes in ciprofibrate dosed rats treated for 3 hours.  A list of up- regulated
genes for male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 3 hours. RNAseq anal-
ysis was done as described in Section 2.2.6. Expressed genes with a fold change of >2.5 and a FDR p-value of <0.05 were listed.
Description
Gene 
name
Ensembl 
Feature ID
Fold 
Change 
>2.5
FDR 
p-
value 
<0.05
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Solute carrier family 16, member 6 (monocarboxylic 
acid transporter 7) - human homolog is a monocarboxy-
late transporter 
Slc16a6 ENSRNOT00000000262 6.4 0.03
Solute carrier family 22 (organic cation/carnitine trans-
porter), member 5 mediates high-affinity sodium-depen-
dent carnitine transport and sodium-independent organic 
cation transport
Slc22a5 ENSRNOT00000011340 2.7 0.01
Solute carrier family 25, member 30 kidney mitochon-
drial carrier protein 1; solute carrier family 25 member 
30; solute carrier family 25, member 30, Kidney mito-
chondrial carrier protein 1
Slc25a30 /
KMCP1_r
at
ENSRNOT00000040316 3.0 0.04
Solute carrier family 34 (sodium phosphate), member 2- 
a sodium dependent phosphate transporter that may pro-
vide inorganic phosphate for the synthesis of lung sur-
factant and is associated with aging 
Slc34a2 ENSRNOT00000048509 5.6 0.04
T-box 3 - human homolog acts as a transcriptional 
repressor and plays a role in the development of several 
organ systems
Tbx3 ENSRNOT00000011552 3.1 0.03
Table 3.20 Named up- regulated genes in ciprofibrate dosed rats treated for 3 hours.  A list of up- regulated
genes for male F-344NHsd rats aged 14-15 weeks dosed with 50 mg kg-1 ciprofibrate then killed after 3 hours. RNAseq anal-
ysis was done as described in Section 2.2.6. Expressed genes with a fold change of >2.5 and a FDR p-value of <0.05 were listed.
Description
Gene 
name
Ensembl 
Feature ID
Fold 
Change 
>2.5
FDR 
p-
value 
<0.05
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Table 3.21 Novel up- regulated genes in rats dosed with ciprofibrate for 3 hours with RNAseq analysis.  
A list of novel down- regulated genes for male F-344NHsd rats aged 14-15 weeks, dosed with 50 mg kg-1 ciprofibrate then
killed after 24 hours. RNAseq analysis was done as described in Section 2.2.6. Expressed genes with a fold change of >2.5 and
a FDR p-value of <0.05 are shown. 
Description Gene name
Ensembl 
Feature ID
Fold 
Change 
>2.5
FDR p-
value 
<0.05
Fer-1-like 5 (C. elegans) Gene novel ENSRNOT00000059806 2.6 0.03
XIAP associated factor 1 Gene novel ENSRNOT00000056551 2.6 0.04
Known protein coding novel ENSRNOT00000061062 3.5 0.02
Known protein coding novel ENSRNOT00000041253 2.6 0.02
Protein coding novel ENSRNOT00000061064 3.1 0.04
Protein coding novel ENSRNOT00000061065 3.1 0.04
Protein coding novel ENSRNOT00000016611 3.5 0.03
Known protein coding similar to serine/threonine 
kinase Synonyms: LOC296256; 
RGD1565143_predicted; similar to serine/threonine 
kinase (predicted);
RGD1565143 ENSRNOT00000065773 3.3 0.05
rCG62747-like LOC1003615
82
ENSRNOT00000050476 3.3 0.01
mCG140381-like LOC1003630
13
ENSRNOT00000005583 2.9 0.03
Similar to ras homolog gene family, member f LOC690130 ENSRNOT00000064390 2.8 0.03
Similar to hypothetical protein MGC42105 RGD1308116 ENSRNOT00000021964 2.9 0.01
Ab2-060 LOC501038 ENSRNOT00000045455 2.7 0.04
RGD1560010 RGD1560010 ENSRNOT00000013356 3.6 0.02
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Section 3.4.7 Pathways for over-representative genes
The identification of a number of up- regulated genes calls for characterisation of common path-
ways or functions in this gene subset. This was achieved by manual comparison of the up-reg-
ulated genes with pathways found at these websites http://rgd.mcw.edu/wg/pathway?100 and
http://www.ensembl.org/Rattus_norvegicus/Info/Index.
The pathways with relationship with DNA synthesis, cell cycle or PPAR signalling were stud-
ied. 16 genes were induced out of 73 PPAR signalling pathway genes (21.9%), when compared
with KEGG website. Also, 12 up-regulated genes out of 43 fatty acid metabolic pathway genes
(27.9%), and 10 out of 103 genes (9.7%) were engaged in the cell cycle. Other smaller groups
of genes (5-6 genes) were involved in sodium ion transport, oxidation reduction and palmitoyl-
CoA hydrolase activity as demonstrated in Table 3.22. 
Pathways that are not listed in the table but have a number of up- regulated genes are metabolic
process and bioactivation pathway via cytochrome P450.
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Table 3.22 Some pathways represented by named up- regulated genes in ciprofibrate dosed rats for 3 
hours.  A list of pathways and the related genes are shown for up- regulated genes for male F-344NHsd rats aged 14-15 
weeks dosed with 50 mg kg-1 ciprofibrate then killed after 3 hours. RNAseq analysis was done as described in Section 2.2.6. 
Expressed genes with a fold change of >1.5 and a FDR p-value of <0.05 were listed.
Description gene 
name
fold 
change
PPAR signalling pathway:
Acetyl-Coenzyme A acyl transferase 1/peroxisomal 3-ketoacyl-CoA 
thiolase
Acaa1 1.9
Acyl-CoA synthetase long-chain family member 1 Acsl1 1.8
Acyl-CoA synthetase long-chain family member 3 Acsl3 2.0
Angiopoietin-like 4 Angptl4 2.7
Apolipoprotein L 9a Apol9a 2.8
Carnitine palmitoyltransferase 1a, liver Cpt1a 1.7
Carnitine palmitoyltansferase 1b, muscle Cpt1b 4.2
Carnitine palmitoyltransferase 2 Cpt2 2.6
Cytochrome P450, family 4, subfamily a, polypeptide 1 Cyp4a1 3.3
Cytochrome P450, family 4, subfamily a, polypeptide 2 Cyp4a2 2.3
Cytochrome P450, family 4, subfamily a, polypeptide 3 Cyp4a3 2.3
Cytochrome P450, family 4, subfamily b, polypeptide 1 Cyp4b1 1.8
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 Hmgcs2 1.7
Peroxisome proliferator-activated receptor gamma, coactivator 1 beta Ppargc 
1b
2.9
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Stearoyl-Coenzyme A desaturase 1 Scd1 13.2
Stearoyl-coenzyme A desaturase 4 Scd4 15.6
Fatty acid metabolic pathway:
Acetyl-Coenzyme A acyltransferase 1 Acaa1 1.9
Acyl-CoA synthetase long-chain family member 1 Acsl1 1.8
Acyl-CoA synthetase long-chain family member 3 Acsl3 2.0
Aldehyde dehydrogenase 3 family, member A2 Aldh3a2 1.7
Carnitine palmitoyltransferase 1a, liver Cpt1a 1.7
Carnitine palmitoyltansferase 1b, muscle Cpt1b 4.2
Carnitine palmitoyltransferase 2 Cpt2 2.6
Cytochrome P450, family 4, subfamily a, polypeptide 10 Cyp4a10 3.3
Cytochrome P450, family 4, subfamily a, polypeptide 2 Cyp4a2 2.3
Cytochrome P450, family 4, subfamily b, polypeptide 1 Cyp4b1 1.8
Hydroxyacyl-Coenzyme A dehydrogenase, alpha subunit Hadha 1.6
Stearoyl-Coenzyme A desaturase 1 Scd1 13.2
Table 3.22 Some pathways represented by named up- regulated genes in ciprofibrate dosed rats for 3 
hours.  A list of pathways and the related genes are shown for up- regulated genes for male F-344NHsd rats aged 14-15 
weeks dosed with 50 mg kg-1 ciprofibrate then killed after 3 hours. RNAseq analysis was done as described in Section 2.2.6. 
Expressed genes with a fold change of >1.5 and a FDR p-value of <0.05 were listed.
Description gene 
name
fold 
change
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Cell cycle:
Cell cycle associated protein 1 Gene Caprin1 1.8
CC-chemokine receptor Ccbp 4.5
Cyclin D1 Ccnd1 2.9
Cyclin T1 Ccnt1 1.8
G0/G1switch 2 G0s2 5.8
Nicotinamide phosphoribosyltransferase Nampt 2.3
Nibrin Nbn 2.0
Par-6 (partitioning defective 6) homolog beta Pard6b 2.0
Retinoblastoma 1 Rb1 1.6
Salt-inducible kinase 1 Sik1 2.2
Sodium ion transport:
Solute carrier family 13 (sodium/sulfate symporters), member 4 Slc13a4 2.2
Solute carrier family 22 (organic cation/carnitine transporter), member 
5
Slc22a5 2.7
Solute carrier family 23 (nucleobase transporters), member 2 Slc23a2 2.0
Solute carrier family 34 (sodium phosphate), member 2 Slc34a2 5.6
Table 3.22 Some pathways represented by named up- regulated genes in ciprofibrate dosed rats for 3 
hours.  A list of pathways and the related genes are shown for up- regulated genes for male F-344NHsd rats aged 14-15 
weeks dosed with 50 mg kg-1 ciprofibrate then killed after 3 hours. RNAseq analysis was done as described in Section 2.2.6. 
Expressed genes with a fold change of >1.5 and a FDR p-value of <0.05 were listed.
Description gene 
name
fold 
change
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Solute carrier family 4 (anion exchanger), member 4 Slc4a4 1.8
Palmitoyl-CoA hydrolase activity:
Acyl-CoA thioesterase 5 Acot5 2.8
Acyl-CoA thioesterase 6 Acot6 4.0
Acyl-CoA thioesterase 7 Acot7 1.6
Acyl-CoA synthetase long-chain family member 1 Acaa1 1.8
Acyl-CoA synthetase long-chain family member 3 Acsl3 2.0
Acetyl-Coenzyme A acyltransferase 1 Acaa1 1.9
Oxidation reduction:
Cytochrome P450, family 4, subfamily a, polypeptide 10 Cyp4a1 3.3
Cytochrome P450, family 4, subfamily a, polypeptide 2 Cyp4a2 2.3
Cytochrome P450, family 4, subfamily a, polypeptide 3 Cyp4a3 2.3
Cytochrome P450, family 4, subfamily b, polypeptide 1 Cyp4b1 1.8
Jumonji domain containing 1C Jmjd1c 1.5
Table 3.22 Some pathways represented by named up- regulated genes in ciprofibrate dosed rats for 3 
hours.  A list of pathways and the related genes are shown for up- regulated genes for male F-344NHsd rats aged 14-15 
weeks dosed with 50 mg kg-1 ciprofibrate then killed after 3 hours. RNAseq analysis was done as described in Section 2.2.6. 
Expressed genes with a fold change of >1.5 and a FDR p-value of <0.05 were listed.
Description gene 
name
fold 
change
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Section 3.5Confirmation of results with real- time PCR
This section was set out to confirm the results found by the RNAseq and microarray analysis
with real- time PCR by choosing some genes and measuring the levels of mRNA. Samples from
male F-344 fisher rats treated with 50 mg kg-1 ciprofibrate, 100 mg kg-1 CPA and the control/
vehicle corn oil for 1, 3, 5 and 24 hours were analysed with real- time PCR as shown in Section
2.2.7. These samples were in 4 biological replicates and 2 technical replicates.
Primers and probes were designed for chosen genes. The genes used were CYP4A1, CYP3A1,
G0s2, Ccnd1, AhR, β-actin and Scd1. AhR and β-actin genes were chosen as normalization
genes as they were found to have a minimal induction change with the RNAseq results and they
are also well known housekeeping genes regularly used for this purpose (Bazzi et al., 2009). 
Cytochrome P450, family 4, subfamily a, polypeptide 1 (CYP4A1) was used as a positive con-
trol for the samples treated with ciprofibrate, as it is known to be induced by PPARα agonists
(Bell et al., 1991)(Bars et al., 1993)(Morris and Davila, 1996). The induction of CYP4A1 was
also noted in the microarray analysis for the 24 hour samples. Cytochrome P450, family 3, sub-
family a, polypeptide 1 (CYP3A1) was used as a positive control for CPA treated samples, as
this is known to be highly induced by PXR agonists (Lehmann et al., 1998)(Hosoe et al., 2005).
The other genes tested were G0/G1switch 2 (G0s2) and cyclin D1 (Ccnd1) as they are involved
in cell cycle pathway. Stearoyl-Coenzyme A desaturase 1 (Scd1) is involved in the PPAR sig-
nalling pathway. As for the Aryl hydrocarbon receptor (AhR) it was found to be down- regulated
in the ciprofibrate samples treated for 3 hours. 
Abeer Amer   Section 3.5.1
Page 191
Section 3.5.1 Efficiency of primers and probes
To test the efficiency of the real- time PCR primers and probes, standard curves were produced
for the CYP4A1, CYP3A1, G0s2, Ccnd1, AhR, β-actin and Scd1 genes by amplifying a 5 fold
serial dilution of cDNA prepared from the rat samples treated with corn oil. This was done in
triplicate and the negative controls used were NTC, -RT and -RNA as explained in Section
2.2.7.2.
Figure 3.49 shows the Cycle-Threshold (Ct) (the cycle at which the fluorescence from the sam-
ples cross the threshold) against the log10 cDNA concentrations for the genes AhR, Scd1 and
CYP3A1. Figure 3.50 shows the standard curves for the genes Ccnd1, CYP4A1 and G0s2. While
the standard curves for the gene β-actin are shown in Figure 3.51. 
The amplification efficiency(%) and regression coefficient (r2) of the standard curves for the
genes are represented in Table 3.23. Amplification efficiencies of the standard curves for all
seven genes (CYP4A1, CYP3A1, G0s2, Ccnd1, AhR, β-actin and Scd1) were within 9% of 100%
and a regression coefficient of 0.996±0.003. This is ideal, as the amplification efficiency for
PCR reactions should be 100% ±10%, and the r2 should be close to 1. 
These results show that the genes and the method used, as described in Section 2.2.7, are reliable
and can be applied to analyse the samples from male F-344 fisher rats treated with 50 mg kg-1
ciprofibrate, 100 mg kg-1 CPA and the control/vehicle corn oil for 1, 3, 5 and 24 hours.
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Figure 3.49 Amplification efficiencies for AhR, Scd1 and CYP3A1.  cDNA from rat hepatic RNA
treated with corn oil for 30 hours was diluted 5 fold and amplified separately with each of AhR-with dye HEX
(blue squares), Scd1-with dye HEX (red circles) and CYP3A1- with dye FAM (green triangles), then detected
with real-time RT-PCR using TaqMan probe as described in Section 2.2.7. Each point represents the mean for
triplicate samples. The efficiencies of each of the genes were obtained separately.
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Figure 3.50 Amplification efficiencies for Ccnd1, CYP4A1 and G0s2.  cDNA from rat hepatic RNA treated
with corn oil for 30 hours was diluted to 5 fold and amplified separately with each of Ccnd1-with dye HEX (blue
squares), CYP4A1- with dye FAM (red circles) and G0s2- with dye At0647N (green triangles), then detected with real-
time RT-PCR using TaqMan probe as described in Section 2.2.7. Each point represents the mean for triplicate samples.
The efficiencies of each of the genes were obtained separately.
Figure 3.51 Amplification efficiencies for β-actin.  cDNA from rat hepatic RNA treated with corn oil for
30 hours was diluted to 5 fold and amplified with β-actin- with dye Cy5 (green triangles), then detected with real-
time RT-PCR using TaqMan probe as described in Section 2.2.7. Each point represents the mean for triplicate sam-
ples. 
Abeer Amer   Section 3.5.2
Page 194
Section 3.5.2 Real- time PCR analysis of the samples
The aim of this section was to measure the levels of mRNA of the genes CYP4A1, CYP3A1,
G0s2, Ccnd1 and Scd1 with real- time PCR. To correct for loading differences, AhR and β-actin
were both used as reference genes to normalise the measurements of mRNA. 
F344 Fisher rats were treated with 50 mg kg-1 ciprofibrate, 100 mg kg-1 CPA or corn oil/vehicle
for 1, 3, 5 and 24 hours. Hepatic RNA was extracted from frozen livers and reverse transcribed
into cDNA as explained in Section 2.2.5.1 and. The cDNA was amplified with real- time PCR
and the Ct levels were determined as shown in Section 2.2.7.3.
Table 3.23 Quantitation data of real- time RT-PCR for the genes used.  Regression and 
efficiencies of CYP4A1, CYP3A1, G0s2, Ccnd1, AhR, beta actin and Scd1. The regression correlation 
coefficient value r2 were determined from the equation line. The amplification efficiencies were derived as 
percentages and were calculated from the slope. 
Gene r2 Efficiency%
CYP3A1 0.998 102.3
CYP4A1 0.997 104.1
G0s2 0.998 93.4
Scd1 1.0 97.7
Ccnd1 0.992 94.98
AhR 0.992 95.1
β-actin 0.998 97.9
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Section 3.5.2.1 Effects of ciprofibrate and CPA on CYP4A1
This experiment was done to test the induction levels of CYP4A1 mRNA at different time points
on ciprofibrate/CPA treated samples in comparison with controls, the CYP4A1 was used as a
positive control because it was known to be one of the first markers to the induction with PPA-
Rα agonists (Bell et al., 1991)(Bars et al., 1993)(Morris and Davila, 1996). 
The results for the samples treated with ciprofibrate showed statistically significant induction
of CYP4A1 after 3, 5 and 24 hours of treatment, as shown in the time course in Figure 3.52 (red
line). The samples from the 24 hour treatment showed a mean of ~30 fold induction higher than
the control at the same time point. These results were consistent with the results from RNAseq
analysis of the 3 hour samples treated with ciprofibrate which showed 3.2 fold induction of
CYP4A1, while the real- time PCR gave a 2.4 fold induction at 3 hours (Section 3.4.6.2). 
The induction of CYP4A1 in fisher rats treated with CPA was not affected at all the time points
as demonstrated as a blue line in Figure 3.52. Statistics was done with one-way analysis of vari-
ance (Bonferroni’s multiple comparison test), P<0.05.
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Figure 3.52 Effect of treatments on CYP4A1 mRNA expression. The effects of treatments on
CYP4A1 mRNA expression, on cDNA from hepatic RNA of rats treated for 1, 3, 5 and 24 hours with 50 mg kg -1
ciprofibrate (red circles), 100 mg kg-1 CPA (blue squares) or corn oil (black triangles). Real- time PCR was per-
formed as in Section 2.2.7.3 and analysed as in Section 2.2.7.4. Points are the mean value, and the error bars depict
one standard deviation. Statistically significant difference from the control group was indicated by an asterisk. Sta-
tistics was done with one-way analysis of variance (Bonferroni’s multiple comparison test), P<0.05.
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Section 3.5.2.2 Effects of ciprofibrate and CPA on CYP3A1 
The objective of this section was to test the induction levels of CYP3A1 in ciprofibrate and CPA
treated samples in comparison with control samples at different time points. CYP3A1 was used
as a positive control for CPA treated samples, because the CYP3A1 was reported to be highly
induced by PXR agonists (Lehmann et al., 1998)(Hosoe et al., 2005). 
The results for the samples treated with CPA showed a statistically significant induction of
CYP3A1 after 24 hours treatment; > 30 fold difference as shown in Figure 3.53/ blue line. 
In contrast, the expression of CYP3A1 in Fisher rats treated with ciprofibrate was not different
from the control at any of the 1, 3, 5 and 24 hour samples. 
Abeer Amer   Section 3.5.2
Page 198
 
Figure 3.53 Effect of treatments on CYP3A1 mRNA expression. The effects of treatments on
CYP3A1 mRNA expression, on cDNA from hepatic RNA of rats treated for 1, 3, 5 and 24 hours with 50 mg kg-1
ciprofibrate (red circles), 100 mg kg-1 CPA (blue squares) or corn oil (black triangles). Real- time PCR was per-
formed as in Section 2.2.7.3 and analysed as in Section 2.2.7.4. Points are the mean value, and the error bars depict
one standard deviation. Statistically significant difference from the control group is indicated by an asterisk. Sta-
tistics was done with one-way analysis of variance (Bonferroni’s multiple comparison test), P<0.05.
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Section 3.5.2.3 Effects of ciprofibrate and CPA on G0s2 
This experiment was carried out to test the effects of ciprofibrate/CPA on the induction levels
of G0/G1switch 2 (G0s2) mRNA (involved in cell cycle control), at the early time points and at
24 hours after treatment in comparision with the control samples.
Figure 3.54 shows the results for the samples treated with ciprofibrate (in red) where the expres-
sion of G0s2 at 3 hours was significantly higher (5.4- fold) than the control at the same time
point but declines by 24 hours. This result was similar to the results from RNAseq at 3 hours
where the G0s2 gene was found to be 5.8 fold higher than control samples (Section 3.4.6.2).
The induction of G0s2 in fisher rats treated with CPA showed no significant difference from the
control in all the samples treated at 1, 3 and 5 hours, as shown in Figure 3.54 blue line. Statistics
was done with one-way analysis of variance (Bonferroni’s multiple comparison test), P<0.05.
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Figure 3.54 Effect of treatments on G0s2 mRNA expression. The effects of treatments on G0s2
mRNA expression, on cDNA from hepatic RNA of rats treated for 1, 3, 5 and 24 hours with 50 mg kg -1 cip-
rofibrate (red circles), 100 mg kg-1 CPA (blue squares) or corn oil (black triangles). Real- time PCR was per-
formed as in Section 2.2.7.3 and analysed as in Section 2.2.7.4. Points are the mean value, and the error bars
depict one standard deviation. Statistically significant difference from the control group is indicated by an as-
terisk. Statistics was done with one-way analysis of variance (Bonferroni’s multiple comparison test), P<0.05.
Abeer Amer   Section 3.5.2
Page 201
Section 3.5.2.4 Effects of ciprofibrate and CPA on Ccnd1 
This part of the experiment was prepared to determine the effects of ciprofibrate and CPA on
the induction levels of cyclin D1 (Ccnd1) (also involved in the cell cycle), with real- time PCR
analysis.
The results for the samples treated with ciprofibrate, show a significant induction of Ccnd1 at 3
hours (1.8 fold change) when compared with the control at the same time point (Figure 3.55/
red line). This result is comparable with the results from RNAseq at 3 hours where the Ccnd1
gene was induced 2.9 fold (Section 3.4.6.2).
The induction of Ccnd1 in Fisher rats treated with CPA is significantly higher than the control
at 5 hours, while the 1, 3 and 24 hour samples treated with CPA have no significant difference
when compared with the control as shown in (Figure 3.55). 
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Figure 3.55 Effect of treatments on Ccnd1 mRNA expression. The effects of treatments on Ccnd1
mRNA expression, on cDNA from hepatic RNA of rats treated for 1, 3, 5 and 24 hours with 50 mg kg -1 cipro-
fibrate (red circles), 100 mg kg-1 CPA (blue squares) or corn oil (black triangles). Real- time PCR was performed
as in Section 2.2.7.3 and analysed as in Section 2.2.7.4. Points are the mean value, and the error bars depict one
standard deviation. Statistically significant difference from the control group is indicated by an asterisk. Statis-
tics was done with one-way analysis of variance (Bonferroni’s multiple comparison test), P<0.05.
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Section 3.5.2.5 Effects of ciprofibrate and CPA on Scd1 
This experiment was done to test the induction levels of the Scd1 gene expression, which en-
codes stearoyl-coenzyme A desaturase 1 engaged in the PPARα pathway) with real- time PCR.
The results for the samples treated with ciprofibrate (Figure 3.56) showed a significant induc-
tion of Scd1 at 1 hour, and at other time points Scd1 expression in the ciprofibrate samples was
slightly higher than in the control. 
On the other hand the expression of Scd1 in CPA- treated Fisher rats was lower than in the con-
trol albeit not significantly different (Figure 3.56).
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Figure 3.56 Effect of treatments on Scd1 mRNA expression. The effects of treatments on Scd1 mRNA
expression, on cDNA from hepatic RNA of rats treated for 1, 3, 5 and 24 hours with 50 mg kg -1 ciprofibrate (red
circles), 100 mg kg-1 CPA (blue squares) or corn oil (black triangles). Real- time PCR was performed as in Section
2.2.7.3 and analysed as in Section 2.2.7.4. Points are the mean value, and the error bars depict one standard devi-
ation. Statistically significant difference from the control group is indicated by an asterisk. Statistics was done with
one-way analysis of variance (Bonferroni’s multiple comparison test), P<0.05.
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Chapter 4 Discussion
Section 4.1Induction of hepatic DNA synthesis
The main goal of this thesis was to identify the genes induced by peroxisome proliferators (pri-
marily ciprofibrate), which may be involved in the induction of hepatic DNA synthesis, and
consequently, play an important role in hepato-carcinogenesis. First it was essential to demon-
strate the effects of ciprofibrate on hepatic DNA synthesis. 
Section 4.1.1 Effect of ciprofibrate on hepatic DNA synthesis in mice
To study the hepatic response to ciprofibrate in different strains of mice, two inbred strains of
mice were chosen: C57BL/6JCrl which is a strain resistant to liver carcinogenesis and DBA/
2JCrl which is fairly vulnerable to liver carcinogenesis (Diwan et al., 1986). 
This was done with an immunohistochemical protocol, as has been used by many in the detec-
tion of proliferating cells in vivo with BrdU (deFazio et al., 1987)(Beyer et al., 2008)(Menegazzi
et al., 1997)(Peters et al., 1997a). The validity of the immunohistochemical procedure in the de-
tection of incorporated BrdU in the replicating hepatocytes has been broadly tested (e.g., (El-
dridge et al., 1990) (Ledda-Columbano et al., 2003)). 
The toxicity of BrdU to the DBA/2JCrl mouse strain was assessed by testing the gross effect on
the animals’ body weight, which showed there was no negative effect from the BrdU on the
mice for the duration of the experiment (Section 3.1.1.2.1). This was consistent with results of
(Al Kholaifi, 2008). 
Also, the results showed there was no toxic effect from the ciprofibrate indicated by the body
weight study, and that the induction of hepatic DNA synthesis did not start until after 4 days of
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exposure to ciprofibrate in DBA/2JCrl mice (Figure 3.5). This was substantively the same as
previous results established by (Al Kholaifi et al., 2008) with MCP in 129S4/SvJae mice, where
he found that induction of hepatic DNA synthesis occurs 3- 4 days after dosing. 
On the contrary, (Styles et al., 1990) showed that when dosing C57BL/6J mice with MCP, the
induction of hepatic DNA synthesis started at 24 hours. This discrepancy could be the result of
strain differences as this could affect liver function (Akiyama et al., 2001), although no previous
evidence indicates that strain differences affect the response to peroxisome proliferators
(Budroe et al., 1992). 
Because of the above issues, the same experiment was repeated in C57BL/6JCrl mouse strain
(Section 3.1.1.3), and this established that there were no toxic effects from the ciprofibrate or
BrdU, and the induction of hepatic DNA synthesis did not start until after 4 days of exposure to
ciprofibrate. The C57BL/6JCrl mice are inbred mice, so genetic variability is very small. Con-
sequently, the difference between this study and the Styles study is less likely to relate to genetic
differences. The present result was consistent with the findings for DBA/2JCrl mice (Section
3.1.1.2.2) AP mice and 129S4/SvJae mice (Al Kholaifi et al., 2008). 
The difference in the kinetics of induction of DNA synthesis between this and the Styles study
could be due to the fact that this and the Al Kholaifi studies (Al Kholaifi et al., 2008) used an
immunohistochemical detection of incorporated BrdU protocol, whereas Styles detected incor-
porated BrdU by isolation of hepatocytes and flow cytometry (Styles et al., 1987).
Miller (Miller et al., 1996) also tried to reproduce the same results that were from Styles but
with the same flow cytometry procedure, and failed to produce the same results indicating that
the results produced with the flow cytometry procedure are not fully reproducible. 
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As a conclusion, the induction of hepatic DNA synthesis was delayed until after 4 days dosing
of ciprofibrate in the C57BL/6JCrl and the DBA/2JCrl mouse strain. This result demonstrates
a confirmation of earlier studies on other strains with different peroxisome proliferators (Ledda-
Columbano et al., 2003)(Al Kholaifi et al., 2008). 
Section 4.1.2 Effect of ciprofibrate on hepatic DNA synthesis in rats
The large time window of 4 days between the dosing of the ciprofibrate and the hepatic DNA
synthesis makes it difficult to indicate when exactly the regulation of the genes responsible for
the induction of DNA synthesis occurred. Thus, it was desirable to try an alternative system, and
the rat liver was chosen.
It was known from previous in vivo and in vitro studies in Wistar and Fisher344 rats dosed with
peroxisome proliferators (nafenopin and Wyeth-14,643) that the hepatic induction of DNA syn-
thesis starts as early as 24 hours (Miller et al., 1996)(Menegazzi et al., 1997)(Al Kholaifi, 2008)
(Al Kholaifi et al., 2008)(Bell and Elcombe, 1991a)(Bell et al., 1991). 
In the current study a time course of the hepatic DNA synthesis revealed similar results. Hepatic
DNA synthesis in male F-344/NHsd rats was induced by ciprofibrate within 10 to 30 hours,
which peaks at 24 hours and again at 48 hours. This was consistent with (Plant et al., 1998) who
demonstrated that PPARα ligands cause rapid induction of DNA synthesis in rat hepatocytes in
vitro (~24 hours). The second peak at 48 hours was probably related to the fact that the dose was
given each day, meaning that the first peak would be a response to the first dose and the second
peak would be a response to the second dose. 
These results were similar to (Aboshofa’s data) who also found two peaks of hepatic DNA syn-
thesis at 24 and at 48 hours, using two labelling methods (BrdU and EdU). Aboshofa’s data also
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found that the induced hepatocytes at 24 hours are different from the hepatocytes induced at 48
hours (not the exact same hepatocyte). This was achieved by dosing the rats with ciprofibrate at
0 and 24 hours and dosing the animals with BrdU at 22 hours to label the proliferating cells at
22- 26 hours (as a response to the first ciprofibrate dose), and then giving the animals a dose of
EdU at 46 hours to label the cells dividing at 46- 50 hours (as a response to the second ciprofi-
brate dose) (Aboshofa). After examining the hepatocytes with immunohistochemistry (to detect
the BrdU labelled cells) and with fluorescent microscopy (to indicate the cells labelled with
EdU), the images were merged together. Aboshofa found that the cells labelled with BrdU were
different from the cells labelled with EdU, this suggests that the hepatocytes that divide at 24
hours are different from the hepatocytes that divide at 48 hours (Aboshofa personal communi-
cations).
Al Kholaifi’s (Al Kholaifi et al., 2008) results with F-344/NHsd rats showed that hepatic DNA
synthesis started to rise at 24 hours and continued after 48- 96 hours. This was consistent with
the results found in this study (Figure 3.9). However, Al Kholaifi used the chronic dosing sys-
tem for BrdU labelling which gives the cumulative number of BrdU-labelled hepatocytes,
whereas this study used the acute dosing system, showing what happened at each time point
within a 2- 4 hour window. 
It was desirable to determine the optimal dose of ciprofibrate in F-344/NHsd rats that gave the
highest hepatic replicative DNA synthesis. Al Kholaifi (Al Kholaifi, 2008) used 50 mg kg-1day-
1 but did not test the effects of higher doses. This information was not available in the literature,
so this study demonstrated (with a dose response experiment of 0, 50, 100, 200, 300 mg kg-1
body weight for 24 hours), that the liver labelling index increased significantly at 50, 100 and
200 mg kg-1 ciprofibrate, but the labelling index was low at 300 mg kg-1. The reduced response
at 300 mg kg-1 suggests a possible toxic reaction suppressing the liver growth response (Section
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3.1.2.1.1). The concentration of 50 mg kg-1 was selected for the assay as an optimal dose of cip-
rofibrate for F-344NHsd rats, because it was deemed sufficiently low to avoid toxicity but gave
a reasonably good labelling index.
(Woods et al., 2007) suggested that PPARα ligands mediate chronic oxidative DNA damage,
therefore, it was of importance to test the serum ALT concentrations as an indicator of liver cell
damage. A single dose of 50-300 mg kg-1 ciprofibrate did not increase serum ALT levels (Fig-
ure 3.11), indicating that there is no gross hepatotoxicity, and consequently no potential for re-
generative DNA synthesis. Also the body weight of the animals was tested on a daily basis and
this showed that there was no growth inhibition, indicating no toxic effects from the ciprofi-
brate. In addition the examination of histological sections revealed no necrosis in the liver tis-
sue.
The immunohistochemical protocol yielded satisfactory staining of intestinal nuclei with BrdU
as a positive control for labelling. Ciprofibrate-induced hepatocyte DNA synthesis was at its
peak for rats at 24 hours after dosing, in contrast to the mouse strains where there was no sig-
nificant induction until 4 days after treatment. These results demonstrate a species difference
between mouse and rat in the kinetics of induction of hepatocyte DNA synthesis by PPARα li-
gands. 
The early induction of hepatic DNA synthesis in rat by PPARα ligands unlocks doors of oppor-
tunity to study the mechanism of induction of the liver growth response, by linking early mea-
surements of altered gene regulation to subsequent hepatic DNA synthesis. 
Section 4.1.3 Effects of CPA on hepatic DNA synthesis in rats
The anti-androgen cyproterone acetate (CPA) is known to cause liver tumours in rats, and it
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strongly enhances hepatic DNA synthesis of male and female Wistar rats (Schulte-Hermann et
al., 1980), with it being more strongly inducing in female F-344 rats (Aboshofa). This drug was
used to compare the genes that were induced with the CPA (PXR) with those that were induced
by ciprofibrate (PPAR-α). 
Although female rats gave higher induction than males from the preliminary tests, and from the
literature (Topinka et al., 2004a) (Topinka et al., 2004b), it was reasonable to use male rats, as
male rats had been used for the ciprofibrate dosing in this study. It might be expected that sim-
ilar genes are induced in the male and the female rats, just more strongly in the latter (it would
be interesting to follow up on this).
The doses used for the CPA (or PCN used in the preliminary experiment) were chosen from the
literature (Topinka et al., 2004a) (Topinka et al., 2004b) and (Guzelian et al., 2006), at 100 mg
kg-1. The time was fixed to 24 hours so it would be comparable to the ciprofibrate experiment.
The results showed a significantly high labelling index in the treated over the control group and
over the groups treated with ciprofibrate at 24 hours (Figure 3.13B) and this was similar to re-
sults from previous studies (Topinka et al., 2004a).
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Section 4.2Zonal distribution of DNA synthesis in liver
The fact that the zonal distribution of DNA synthesis in the rat liver is known (Barrass et al.,
1993) and that Barrass has established a reliable method to study this, gave reason to make sim-
ilar studies on mouse liver, as there are no directly comparable data in mice (Burkhardt et al.,
2004). 
The main objective was to study the hepatic zonal distribution of cell proliferation in the liver
of mice treated with ciprofibrate. Rats liver (used as a positive control) treated with ciprofibrate
or CPA or corn oil (control) showed a significant zonal distribution of the labelled nuclei, with
~20 fold more labelled cells in the periportal region than in the perivenous region. This was in
agreement with the literature (Barrass et al., 1993). Equally, the preferential periportal distribu-
tion of hepatic labelling in ciprofibrate treated rats was consistent over a dose range of 50-200
mg kg -1 body weight (because of the low number of labelled cells in the 300 mg kg -1 it was
not possible to study the zonation in these slides.).
The zonal distribution of hepatic labelling index in male mouse showed no statistically signifi-
cant difference between the periportal or perivenous zones in most of the mouse strains studied
(1294S/SvJae wild type, PPARα null male mice, C57BL/6JCrl and DBA/2JCrl), with the dif-
ferent doses of PPAR agonist, or choice of drug PPARα (ciprofibrate, methylclofenapate) or
CAR (TCPOBOP) (Section 3.2.2). 
Exceptions were female 129S4/SvJae mice when treated with TCPOBOP as they showed a sig-
nificantly perivenous preference (Figure 3.20), but the magnitude of the effect is relatively
small, with the number of labelled cells in the perivenous region less than two times greater than
those in the periportal region. Also AP mice when treated with MCP showed a similar zonal
reaction to the rats, as the control and the group treated for 4 days had a periportal preference,
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but for the group treated for 3 days the difference was not significant.
Of the total liver volume, 20% is made up of non-parenchymal cells, which are stellate cells,
Kupffer cells, pit cells and endothelial cells (Oinonen and Lindros, 1998). These types of cells
display modest quantitative zonal differentiation, in general being more abundant in the peri-
portal area (Sasse, 1986). This could be related to the periportal/perivenous zonal behaviour no-
ticed in the hepatic DNA induction in the liver population. It is observed furthermore that the
periportal zonation of the hepatic labelling index in rat is different from the centrilobular induc-
tion of peroxisomal enzymes, cytochrome P450 and acyl CoA oxidase induced by PPARα li-
gands, suggesting that the factors that mediate the induction mechanisms are located to specific
zones of the liver lobule (Bell and Elcombe, 1991b)(Bars et al., 1993). 
However, the induction of both enzymes and DNA synthesis are dependent on the PPARα, this
suggests that the zonation of the peroxisomal enzymes is via a PPARα independent means (Al
Kholaifi et al., 2008). Candidates that may intervene with these PPARα-independent zonal ef-
fects are the zonal distribution of the PPARα-associated microRNAs, or co-activators that are
known to be required for the induction of hepatic DNA synthesis (Matsumoto et al., 2007) (Shah
et al., 2007a).
Whereas it is acknowledged in mice that the Apc gene is the liver zonation keeper (Ben-
hamouche et al., 2006), it is unknown if similar pathways apply for rat hepatocytes. Generally,
however, the zonation of the hepatic induction of DNA synthesis is less studied, especially in
mice.
These results illustrate species differences in zonation and kinetics of liver growth between rat
and mouse, and predict species differences in zonation and timing of the regulatory factors re-
sponsible for the liver growth. These differences are similar in extent to those seen in extensive
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zonation studies on the induction of enzymes by various xenobiotics in isolated rat cells (Oino-
nen et al., 1994). 
Bars (Bars et al., 1992) reported that the induction and expression of the cytochrome P4502B1/
2 iso enzyme has a hepatic zonal pattern in the intact liver, whereas different reaction to PPARα
occurred in vitro, where they found that P4502B1/2 hepatic immunostaining was stronger in
cells isolated from the perivenous liver region than in hepatocytes isolated from the periportal
region. They also suggested that periportal and perivenous hepatocytes are assigned differen-
tially to maintain regio- specific factors.
The diversity in inter species and inter strain response to the peroxisome proliferators could be
most likely as a result of a difference in PPAR and/or PPRE structure, but this needs to be stud-
ied further and more data is required (Aldridge et al., 1995).
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Section 4.3Gene expression analysis
It has been acknowledged that the hepatic DNA synthesis induced by ciprofibrate in rat occurs
after 24 hours (Section 3.1.2), and it is known that cells need ~19 hours to undergo hepatic DNA
synthesis (Alberts et al., 2002). This implies that the RNA signal is increased within the first
five hours after dosing. To determine the immediate early genes that may be induced the first 1-
5 hours post induction were examined, as these genes could be responsible for the hepatic DNA
synthesis at 24 hours. 
This was done with cDNA microarray, RNA transcriptome sequencing and quantitative real-
time PCR. Studies have shown that two or more different methodologies used to measure gene
expression change have a tendency to agree when the magnitude of change in gene expression
is large (Draghici et al., 2006). 
cDNA microarrays can concurrently measure the expression intensity of thousands of genes
within a specific mRNA sample (Schena et al., 1995)(Schena et al., 1998). The microarray anal-
ysis was applied to measure the expression levels of genes induced by 50 mg kg-1 ciprofibrate
in livers of F-344NHsd rats after 1, 3, 5 and 24 hours in comparison with the control. 
The microarray analysis was carefully controlled with usage of: (1) vehicle/ corn oil as a nega-
tive control, (2) rats dosed with PXR ligands (CPA) as positive controls, to compare genes that
are involved in hepatic DNA synthesis, but which might not be specific for the PPAR ligands
(ciprofibrate), (3) the 24 hour samples were used to exclude the genes that are generally regu-
lated by ciprofibrate but might not be specifically related to the early-immediate reaction that
might be involved in the hepatic DNA synthesis, (4) a common reference/control (a sample con-
taining an aliquot from each of the corn oil, CPA and ciprofibrate samples) was used which is
the most commonly used design of microarray experiments, for a complete comparison of sam-
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ples and to remove any bias from the 555 and 647 Alexa dyes (Cherkaoui-Malki et al., 2001).
The cDNA microarray analysis was optimized and each step controlled and assessed, beginning
with the RNA quality and quantity measurements (Section 3.3.1). The incorporation of Alexa
dyes 555 and 647 in the cDNA were also made with a negative control (sample with no RNA)
and a positive control (RNA supplied in the kit). 
Section 4.3.1 Optimization of the microarray technique
Optimization of the microarray technique was essential to ensure the results are reliable and re-
peatable. So, the following issues were addressed: (1) reproducibility of the scanning, (2) repro-
ducibility of hybridization, and (3) the testing of different concentrations of cDNA. The
reproducibility of scanning (60- 90%) was good (Section 3.3.3.1). However, initial experiments
on the reproducibility of hybridization were not as successful, since the same cDNA when hy-
bridized on three different sets of slides did not give repeatable results. This was a problem, and
results from these hybridizations were not reliable. Therefore, it was essential to address this
issue before being able to consider using the microarray technique for further analysis (Section
3.3.3.2). Subsequently, by considering all the microarray procedures systematically, it was re-
vealed that the gene names were misplaced on the gene spots of the slides (human error) when
placing the features from the GAL file on the slides. This issue was resolved by using slides with
markers indicating where the genes were situated. 
It was also essential that all the hybridizations were replicated at least twice with data giving a
minimum of 60% similarity to be considered in the analysis. A 60% similarity in the reproduc-
ibility of the technical replicates was proposed acceptable in other studies, and it has been re-
ported that the correlation coefficient can range between 0.5 and 0.95 (this corresponds to 50 -
95%) (Bammler et al., 2005)(Jarvinen et al., 2004)(Jenssen et al., 2002)(Carter et al, 2005). 
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This variability issue with microarrays could be related to the fact that they do not measure with
great accuracy the genes expressed at low levels (Tarca et al., 2006). Also fluorescence from the
extremely highly induced genes may surpass the saturation limit of the detector. These factors
may have contributed to the differences evident in this study between data from the microarray
analysis and the transcriptome sequencing, as the latter would detect all the genes.
From this study the measures used to improve the quality of microarray results were to use four
biological replicates and two technical replicates with the technical replicates being accepted
only where r2 > 0.6.
Section 4.3.2 Microarray analysis of rats dosed with ciprofibrate 
The 24 hour samples were initially tested to measure the expression levels of genes associated
with induction of hepatic DNA synthesis, because this time point has been thoroughly investi-
gated in the literature and a large number of genes have been detected to be highly induced. This
was to ensure that the analysis and processing of the data were acceptable and reliable, and that
specific genes used as markers were discovered.
Microarray analysis of rats dosed with ciprofibrate after 24 hours revealed 1597 significantly
changed genes. In the samples treated with ciprofibrate for 24 hours 39 genes were up- regulated
by double or more and 23 genes down- regulated by half or less. Up- regulated genes included
Cyp4a1, Cte1, Rab19, Slc9a2, 18A, Ldh3, Narg1 and Polr2a. Genes recently reported to be up-
regulated after 14 days of orally repeated dosing of WY-14,643 were Apex1, Xrcc5, Gadd45 and
A1h1 (Suzuki et al., 2010). Down- regulated genes included Mup2, Zfp598, Fgg, Cyp2c29 and
Sepina3a (a list of all the genes are found in a CD at the end of the Thesis). 
Cyp4A1 is a known marker for PPARα agonists (Morris and Davila, 1996)(Hardwick et al.,
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1987)(Bell and Elcombe, 1991a)(Bell and Elcombe, 1991b)(Orton and Parker, 1982)(Baker et
al., 2004). The induction of CYP4A1 via the PPARα receptor has been reported in hepatocytes
both in vitro (Yaacob et al., 1997) and in vivo (Correia, 1995)(Simpson, 1997). Furthermore,
clofibrate exposure induced CYP4A1 with both RNA microarrays and quantitative real-time
PCR (Baker et al., 2004). The induction of CYP4A1 with ciprofibrate here, while not proof, sup-
ported the validity of the present microarray analyses. 
The microarray analysis of ciprofibrate dosed F-344NHsd fisher rats after 1, 3, and 5 hours
showed 1377 significant genes analysed for each of the time points. Some of the up- regulated
genes were Fxyd2, Igf1, cpa5, Cd68, Abcc2, Mup1, Cmklr1, mmu and Ndrg1 for the 1 hour sam-
ples, while Psmb9, Inppl1, Saa3, Serpina1b, Ins1 and Gsta1 were up- regulated for the 3 hour
samples. The genes Gc, Apob, Dusp14 Mug1, Serpina 1b, Kcnh1, Apcs and Gcap15 were up-
regulated in the 5 hour samples. These are all novelty findings for the immediate early genes.
Later genes have been reported to be induced by clofibrate after 3 days of treatment: Hcd,
Cyp4a1, 3kcta, 3kctb, ACox, Cyp17 and Adh1(Baker et al., 2004).
Down- regulated genes can be just as informative as up- regulated genes when studying the
mechanism of action of liver growth induced by ciprofibrate. After 1 hour treatment with cip-
rofibrate a number of the down- regulated genes were Fgf21, Rgsl2, Usp28, Dars, Vnn3 and
Fzd7, some of the down- regulated genes after 3 hours were Pfkfb2, Wdr10, Clecsf9, Kcnq2,
Mylc2pl and Rgsl2, while genes down- regulated at 5 hours were Nedd4, Rem1, Adcy8, Rab40c,
Acadsb and Ccb3. Other genes that have been reported to be down- regulated after 24 hours of
dosing with ciprofibrate are Apo-A1, CYP1A2, CPT1 and tumour necrosis factor receptor 1
(Baker et al., 2004).
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Section 4.3.3 Transcriptome sequencing of rats dosed with ciprofibrate for 
3 hours 
Transcriptome sequencing analysis uses high- efficiency high- throughput sequencing to mea-
sure gene expression (Marioni et al., 2008). Transcriptome sequencing analysis was used to help
find differently expressed genes in hepatic cells of F344/NHsd Fisher rats dosed with 50 mg kg-
1 ciprofibrate for 3 hours. A key advantage of the transcriptome sequencing analysis procedure
is the number of genes that could be detected in this study, at just under 25000 genes. This was
because the transcriptome analysis was sincere and was used against a complete rat genome data
base. The microarray analysis had only 5826 genes because a large number of genes were
missed when spreading the cDNA on the slides, or the cDNA does not hybridize well enough
to be able to be scanned, or just washes off at the washing stages, also the microarray slides were
specified for mice, so only the rat genes that match the mouse genome are included. 
The different outcomes from the microarray results and the transcriptome sequencing results
and real-time PCR measurements are expected, and could reflect the fact that the microarray
analysis excluded the extremely high induced genes and the very low expressed genes (Tarca et
al., 2006) (Gerhold et al., 2001). While the transcriptome sequencing data were more inclusive,
and real- time PCR detects smaller changes in gene expressions, that are undetectable with mi-
croarrays (Baker et al., 2004). Hence the recommendation that microarrays are used to screen
thousands of genes, whereas quantitative real-time PCR could be used to validate observations
with chosen genes of interest (Baker et al., 2004). 
The trancriptional sequencing was carefully monitored, with the samples confirmed to be as-
signed to their original groups and the hierarchical and k-means clustering showing that the con-
trol and treatment groups were clustered together. 
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Up- regulated genes included CYP4A1, G0s2 (G0/G1 switch 2), Aadacl1, Acot5+ 6 (Acyl-CoA
thioesterase 5+6) Acpp, Apol9a, Ccnd1, Epha2, Prrg4, Myc11, Etv6 and Scd1, and the down-
regulated known/ named genes were Igfbp2, ppargcla, Cyp1a2, AhR, Acsm2, Cldn9 +4 +6,
Hps4 and Rps14. These were similar to results found by Peters who revealed that the Aco, and
c-myc alongside other genes were up- regulated when mice were dosed with Wy-14,643 for 5
weeks and 11 months (Peters et al., 1997a). He also concluded that the peroxisome proliferators
contribute to the hepato-carcinogenicity effects.
Section 4.3.4 Ciprofibrate pathways of over-represented genes
The acute phase response pathway was over-represented among the functions of up- regulated
genes in both the 3 and 5 hour groups treated with ciprofibrate and analysed with microarray
analysis. At 3 hours 4 up- regulated genes out of 23 (of all genes in the genome) that are in-
volved in the acute phase response (17.4%) and 8 out of 23 genes (34.8%) in the 5 hour group.
The acute inflammatory response and the wounding response were over-represented at 3 and 5
hours post-treatment. These results were not unexpected, as these responses, and especially the
acute phase response, are a complex chain of reactions that are known to be the initial response
to infections, or malignancy, which prevent further damage to the tissue (Baumann and Gauldie,
1994).
Hierarchical clustering was also used in these experiments to clarify different pathways that
were over-represented, among up- regulated genes after ciprofibrate treatment for 24 hours.
These functional categories included the fatty acid metabolic process, the monocarboxylic acid
metabolic process, the long chain fatty acid metabolic process (100%), fatty acid β oxidation
and acyl-CoA metabolic process. Among the changes documented to occur during liver growth
after treatment with peroxisome proliferators in rats are β-oxidation of fatty acids and very long-
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chain fatty acid β-oxidation (Latruffe et al., 2001)(Hamadeh et al., 2002)(Schoonjans et al.,
1996). Therefore, similar results were revealed in this study.
Genes known to be involved in the response to peroxisome proliferators were also up- regulated,
including genes responsible for liver fatty acid binding protein and acyl-CoA and growth regu-
latory genes (c-myc, c-Ha-ras, fos, jun, and egr-1) (Corton et al., 2000). 
Over-represented pathways among up- regulated genes from the transcriptome sequencing data
included those with relationships to DNA synthesis, cell cycle or PPAR signalling: The PPAR
signalling pathway, the fatty acid metabolic pathway and cell cycle regulatory genes. Other
smaller groups of genes (5-6 genes) were involved in sodium ion transport, oxidation reduction
and palmitoyl-CoA hydrolase activity. Other pathways were the metabolic process and bioacti-
vation pathway via cytochrome P450.
Others reported that in rodents treated acutely with Wy-14,643 a number of the significantly in-
duced genes were Il1β, Il1r1, Hnf4 and Stat3, and when they were treated chronically the genes
that had increased expression were Il1β, Il1r1, Il6 and Pparγ (Anderson et al., 2001). With nul-
lizygous mice for TNF-receptor I, II or both, they also demonstrated that the hepatic carcino-
genesis caused by peroxisome proliferators is not mediated through TNFα.
A number of the genes identified here were followed up with the quantitative real- time PCR.
Chosen pathways were tested in a time course for the ciprofibrate and CPA treatments. These
pathways were the DNA synthesis, the cell cycle pathway and PPAR signalling pathway genes
as they are related to the hepatic DNA synthesis and so to the liver growth mechanism. The
genes were G0/G1 switch 2 (G0s2), cyclin D1 (Ccnd1), stearoyl-coenzyme A desaturase 1
(Scd1), Cytochrome P450, family 4, subfamily a, polypeptide 1 member CYP4A1 and Cyto-
chrome P450, family 3, subfamily a, polypeptide 1 member CYP3A1.
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Section 4.3.5 Microarray analysis of rats dosed with CPA
CPA is an artificial progesterone analogue with progestogenic and antiandrogenic activities,
used in the treatment of prostate cancer to resolve androgenisation symptoms in females and to
reduce the male hormone testosterone to suppress the sexual drive in males (Neumann, 1994).
In rat liver, CPA has shown evidence of genotoxic activity, promoting specific DNA adducts
and mutagenesis (Krebs et al., 1998).
Microarray analysis of dosed rats with CPA after 24 hours resulted in 1597 significantly
changed genes (up and down- regulated), the 24 hour group was initially studied to specify
genes that are know to be induced at this time with PXR ligands, to act as a control for the anal-
ysis and processing of the data, and to be able to relate this to the experimental system. This was
done by finding specific genes that were used as markers, CYP3A1 (Slatter et al., 2006) or
Gstm3 (GstYb4) (Krebs et al., 1998).
Results from rats treated with 100 mg kg-1 CPA for 24 hours resulted in 21 up- regulated genes
and 10 down- regulated genes with Student’s t- test. Some of these up- regulated genes included
Gsta1, Hspa8, Gstm3 (GstYb4), Ugt1a5, Apoa1, Mup3, Ef1A1 and Rps6, and down- regulated
genes included are Mup2, Rnase4, Trf and CYP2d26 (a list of all the genes are found in a CD at
the end of the Thesis). 
Although CYP3A1 was not found in the initial 24 hour analysis, it is a well known marker for
PXR agonists in rats (Slatter et al., 2006), this could be related to the fact that the CYP3A1 is
highly induced at 24 hours and the microarray analysis (as reported earlier) can lose the ability
to detect the extremely high induced genes and the very low expressed genes (Tarca et al.,
2006)(Gerhold et al., 2001). On the other hand, Gstm3 (GstYb4) was found, and this gene was
also widely reported in the literature to be induced after 24 hours of dosing with CPA, and could
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also be used as a marker (Slatter et al, 2006)(Krebs et al., 1998). 
The microarray analysis of CPA dosed rats at the immediate early hours at 1, 3, and 5 hours,
with 1377 significantly up/ down- regulated genes. Some of the up- regulated genes at 1 hour
were Sstr4, Cd97, 4930477O03Rik, E2f3, Sirt2, Nrxn3, Trpc4ap and Rnf141. A number of the
3 hour up- regulated genes were Hpxn, Serpina3m, Cops4, E130101E03Rik, Cyp2c29 and
Al481316. While the genes up- regulated in the 5 hour group included mt, Mug1, Fabp1, Scd1,
Adamts1, Gc, Eef1a1 Fzd7 and Cyp2c29, other reported genes in rats and mice induced after 3
daily doses of PXRs are Gstm3, Abcd3, Abcc2, Amtl, CYP51, Foxa1, Fmo2, Gsta4, Gstt2,
Nr2f2, Slc16a6 (Slatter et al., 2006). Shah used qPCR to find that a number of genes were up-
regulated in guts of mice treated with PXR, Gsta1, Gstm1, Gstt1, and Mdr1a (Shah et al.,
2007b). From this it is noticeable that the Gst’s and Gstm’s are all up- regulated in this study
and in a number of previous studies. 
While the down- regulated genes in the 1 hour group included Pla2g2c, Card10, Apom, Sfrs16,
Rem1, Rac1 and Bmp7, the down- regulated genes in the 3 hour group were Axot, Alas1,
Ugt1a13, Edem1 and Sif1, and the down- regulated genes in the group treated for 5 hours in-
cluded Acadsb, Dbil5, Sfrs16, Inppl1, Centa1 and Gpx1. Also Shah found that PCN (a PXR)
inhibited TNFα activated NF kB luciferase reporter in the colon (Shah et al., 2007b) and in rat
liver (Menegazzi et al., 1997).
Section 4.3.6 CPA pathways of over-represented genes
The glutathione transferase activity pathway was over-represented among the functions of up-
regulated genes when the rat livers were treated with CPA. These results were similar to the
findings of Slatter (Slatter et al., 2006). The process interphase of mitotic cell cycle was also
over-represented among up-regulated genes along with the phospholipid metabolic process and
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the steroid metabolic process, as also found by (Slatter et al., 2006).
According to a heatmap from the 3 hour samples treated with CPA, immune responses, a re-
sponse to chemical stimulus, and a response to organic substance and other pathways were
over- represented. Unfortunately, there was not enough data from the analysis to perform a heat-
map analysis for the 1 and 5 hour time points. Previous studies have illustrated that citrate cycle,
pyruvate metabolism, fatty acid metabolism and bile acid biosynthesis were over- represented
among the data for PXR -treated cells suggesting that the PXRs regulate bile and lipid acid me-
tabolism (Slatter et al., 2006). 
Section 4.3.7 Quantifying genes with real- time PCR
To confirm and quantify genes of interest found by the microarray and the RNAseq analysis,
real- time PCR was applied. The choice of the genes analysed was based largely on the RNAseq
results: CYP4A1 was used as a positive control for ciprofibrate because it is known to be in-
duced by PPARα agonists (Bell et al., 1991)(Bars et al., 1993)(Morris and Davila, 1996).
CYP3A1 was used as a positive control for CPA as this is known to be highly induced by PXR
agonists (Lehmann et al., 1998)(Hosoe et al., 2005), and G0s2, Ccnd1, and Scd1 were also de-
tected as genes of interest, to check when their expression is increased and if the ciprofibrate
induces similar responses in these genes in comparision to the CPA samples. 
Validation of the normalization genes (AhR and β-actin genes) was essential to normalise the
measurements of mRNA to correct for loading differences, and was performed in each of the
experiments. This was done to exclude any sample differences attributable to RNA quality or
quantity. AhR and β-actin genes were found to have a minimal change according to the literature
and they are well known housekeeping genes regularly used for this purpose (Bazzi et al., 2009)
(Lee et al., 1995). The normalization / housekeeping gene expression is not always stable across
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the treatments (Pohjanvirta et al., 2006), and it is optimal practice to use more than one such
normalization/ reference genes (Vandesompele et al., 2002). Thus, two reference genes were
used in this study. 
Section 4.3.7.1 Effects of ciprofibrate and CPA on CYP4A1
The rat liver CYP4A1 is induced in rodent livers treated with peroxisome proliferators (Hard-
wick et al., 1987). This rapid induction is usually followed by liver hyperplasia and hypertrophy
(Bell et al., 1991), as liver enlargement of the treated rats was also found in this study.
The induction levels of CYP4A1 mRNA at different time points on ciprofibrate or CPA treated
samples in comparison with controls were measured. This generated a statistically significant
high induction of CYP4A1 after 3, 5 and 24 hours of ciprofibrate treatment with the 24 hour
treatment giving an induction of ~30- fold. The 3 hour ciprofibrate samples gave results with
real- time PCR consistent with the RNAseq analysis, ~2.4 fold induction and ~3.2 fold- induc-
tion, respectively. As for the microarray data it appears to be less sensitive and unreliable (in
particular at early hours), as the CYP4A1 did not correlate with the RT-PCR or the RNAseq, and
the genes were not consistent between the time points as expected, also no positive controls
were found in the early time points for the treatments. The literature reports CYP4A1 to be high-
ly induced with PPARα agonists in vivo and in vitro (Bell et al., 1991)(Bars et al., 1993)(Morris
and Davila, 1996). 
The high induction of CYP4A1 that has been seen here and the pathways that have been high-
lighted earlier in Section 4.3.4 correlate with results that state that induction of CYP4A1 happens
at the same time as other genes which are involved in the peroxisomal β oxidation pathway (Fu-
ruta et al., 1982). It has been reported that the CYP4A1 is involved in the metabolism of a range
of xenobiotics and in the hydroxylation of fatty acids (Aoyama et al., 1990)(Gonzalez and
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Nebert, 1990). The induction of CYP4A1 expression in the fisher rats treated with CPA was not
affected in the 1, 3 and 24 hour samples while it was significantly lower than the control at 5
hours.
Section 4.3.7.2 Effects of ciprofibrate and CPA on CYP3A1 
The quantitative real- time PCR results for the CPA treated samples showed a statistically sig-
nificant > 30- fold induction of CYP3A1 after 24 hours. These results were consistent with find-
ings in the literature that found that CYP3A1 was highly induced by PXR agonists (Lehmann et
al., 1998)(Hosoe et al., 2005). 
It has been reported that PXR mediates the genomic effects of a number of steroid hormones
and xenobiotics via the CYP3A gene family (Masuyama et al., 2001), and the difference in the
response to PXRs between the males and female rodents could not be overlooked, with the latter
having a higher induction of CYP3A1 (Eliasson et al., 1994)(Larsen and Jefcoate, 1995). PXRs
activate CYP3As specifically in hepatic cells because of the need for a hepatic nuclear factor-
4α (HNF4α) which apparently is involved in the transcriptional activation of the CYP3As (Ti-
rona et al., 2003). As for the induction of CYP3A1 in ciprofibrate treated fisher rats, there was
no difference from the control at any of the time points. 
Section 4.3.7.3 Effects of ciprofibrate and CPA on Ccnd1 
Cyclin D1 is involved in the cell cycle and was known to be induced after partial hepatectomy
(Boylan and Gruppuso, 2005)(Michalopoulos, 2007). Cyclin D1 is considered an important in-
tracellular mediator for the mitogenic signals that are responsible for hepatocyte proliferation in
the regenerating liver (Nelsen et al., 2001). It is also a delayed target of the c-Jun-N-terminal
kinase pathway during liver regeneration (Schwabe et al., 2003). Other studies demonstrate that
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the over expression of the cyclin D1 gene results in fast growth of a subset of hepatocellular
carcinomas (Nishida et al., 1994).
Real- time PCR analysis of Ccnd1 showed an up- regulation with ciprofibrate treated samples
at 3 hours (1.8 fold change) and this was similar to the corresponding RNAseq analysis (2.9 fold
change). These results were similar to previous studies that showed a high induction of cyclin
D1 mRNA in Wy14643 treated mice (Peters et al., 1998).
Ccnd1 was induced at 5 hours in CPA treated Fisher rats but not at 1, 3 or 24 hour samples. This
demonstrates that the Ccnd1 could be affected by both the ciprofibrate and the CPA at the im-
mediate early time points. 
These results demonstrate that Ccnd1 might be a common target for the hepatic DNA synthesis,
and is not specific for the peroxisome proliferators nor the PXRs. This was also suggested by
Pibiri, who found the Ccnd1 was highly induced at the early hours after a single dose with the
thyroid hormone (T3), and also suggested that Ccnd1 could be responsible for the mitogenic ac-
tivity of nuclear receptor ligands (Pibiri et al., 2001).
Therefore, conclusions could be drawn in relation to the effects of the Ccnd1 on the hepatic
DNA synthesis, as it is induced after 3 hours presumably stimulating the DNA to enter the cell
cycle and so cause the hepatic DNA synthesis that is observed after 24 hours. However, this
phenomenon is noticed additionally with the CPA signifying that the Ccnd1 is not specific to
the PPARa and that the PXRs have the same effects on the Ccnd1. 
Section 4.3.7.4  Effects of ciprofibrate and CPA on Scd1 
It has been shown previously that poly-unsaturated fatty-acids like linoleic acid repress the ex-
pression of Scd gene encoding (stearoyl-coenzyme A desaturase 1) in adipocytes (Sessler et al.,
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1996). When mice were fed a high-carbohydrate fat free diet, Scd1 was induced around 50-fold,
which could have been caused by carbohydrate or insulin (Waters and Ntambi, 1994)(Ntambi,
1995).
In the present study ciprofibrate significantly induced Scd1 at 1 hour (~9 fold change according
to real- timePCR, ~13- fold change according to RNAseq analysis) and at the other time points
Scd1 expression in ciprofibrate samples were slightly higher than the control samples, while
Scd1 expression in CPA treated rats was slightly lower than the control at all the time points,
though this difference was not significant. Research done by Miller showed that peroxisome
proliferators induced Scd1 in mouse liver (Miller and Ntambi, 1996).
This is interesting as it suggests that the signals from the Scd1, occurring as soon as 1 hour after
dosing with the ciprofibrate, stimulates the hepatocytes to divide. The hepatic DNA synthesis
could be seen after 24 hours with the immunohistochemical protocol. Apparently the induction
just stops within two hours, and this is reflected on the hepatic DNA synthesis as the cells slow
down their dividing within a couple of hours after the 24 hours peck. Furthermore, a noteworthy
reality is that the CPA is not involved in this pathway as it is specific for the PPARα, which is
as confirmed by the fact that Scd1 expression is not induced by CPA.
Section 4.3.7.5 Effects of ciprofibrate and CPA on G0s2 
The G0s2 gene was identified by chance during a screen to find differentially expressed genes
with links to lectin treatments of lymphocytes, and is involved with cell cycle development from
the G0 to the G1 stage (Cristillo et al., 1997). It was also considered that G0s2 is a target gene
of the all-trans-retinoic acid (this is an oxidized form of vitamin A used in the treatment of acute
leukemia) (Kitareewan et al., 2008). It has been reported that the PPARs agonist WY14,643 in-
duces G0s2 expression in vivo after 6 hours and in vitro after 5 days (Zandbergen et al., 2005).
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The results for the ciprofibrate samples show that the induction of G0s2 at 3 hours was signifi-
cantly higher than the control (5.4 fold induction). This result is similar to the findings from the
RNAseq analysis at 3 hours as the G0s2 gene expression was found to be 5.8 fold above control
samples (Section 3.4.6.2). The induction then subsided gradually at 5 hours, and then more so
at 24 hours. This is very interesting as the timing correlates with the hepatic DNA synthesis re-
sults (Section 3.1.2.1.1) which showed the hepatic DNA synthesis peaks at 24 hours before sub-
sequently declining. 
The data are consistent with a possible relationship between G0s2 expression and hepatic DNA
synthesis, as a G0s2 provoked G0 to G1 transition at ~ 3 hours, would be expected to give in-
duction of DNA synthesis during the following cell cycle at ~ 20 hours later, indicating a close
relation between the G0s2 and the hepatic DNA synthesis. 
The expression of G0s2 in fisher rats treated with CPA show no significant difference from the
control in all the samples treated at 1, 3, 5 and 24 hours, showing that the CPA promotes a dif-
ferent response from the ciprofibrate, and the G0s2 is specific to the PPARα. 
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Section 4.4Concluding remarks
In this thesis the effects of 50 mg/kg ciprofibrate treatment for 1, 3, 5 and 24 hours on immedi-
ate-early liver gene expression in rats was studied. This was done by using cDNA microarrays,
transcriptome sequencing and quantitative real- time PCR. 
The hepatic DNA synthesis induced by ciprofibrate was initially characterized. This was done
with BrdU immunohistochemical detection protocol, and was found to be significantly in-
creased at 24 hours in rat liver, while it was not significantly induced until after 4 days in mice.
For rats treated with ciprofibrate, the zonation of the hepatocytes found in S-phase were signif-
icantly different between centrilobular and periportal liver regions, being more dominant in the
periportal region by ~20 fold. The zonal distribution of S-phase hepatocytes in mice was not
different between the periportal and the perivenous zones, but had a random distribution across
the liver tissue. The difference in the period and localization of the hepatic DNA synthesis be-
tween mouse and rat liver suggests there is a species difference in the kinetics between the
mouse and rat's response to the ciprofibrate.
This study identifies many genes that appear to be up- regulated by ciprofibrate including pre-
viously known PPARα agonist-responsive genes involved in processes such as PPAR signal-
ling pathways, fatty acid metabolic pathway, cell cycle, palmitoyl-coa hydrolase activity, lipid
metabolism, inflammatory responses, and stress responses. In addition, the immediate- early
gene response shows novel candidate genes, consistent with a link between the genes expression
at 1- 3 hours and the hepatic DNA synthesis at 24 hours. The gene induction was up- regulated
at 1- 3 hours, then the induction came to control levels after 5 hours dosing, incorporating the
hepatic DNA synthesis that was significantly high at 24 hours and then gradually decreased to
control levels at 36 hours. This suggests that these genes were responsible for the hepatic DNA
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synthesis that occurred after 24 hours of dosing with ciprofibrate. This is similar to previous re-
sults obtained after partial hepatectomy with the gene expression for cell cycle regulated genes,
that peaks after 2-3 hours after partial hepatectomy (Taub, 2004). 
Five genes were followed up in ciprofibrate and CPA treated rats with quantitative real- time
PCR, these genes were CYP4A1, CYP3A1, Ccnd1, Scd1 and G0s2. CYP4A1 and CYP3A1 were
used as positive controls for ciprofibrate and CPA dosed animals, respectively. The Ccnd1 and
G0s2 genes both had a significantly high induction at 3 hours with ciprofibrate treated animals,
but only Ccnd1 expression was additionally significantly high at 5 hours with the CPA dosed
animals. Scd1 expression was induced significantly with the ciprofibrate at 1 hour and not with
the CPA. These results suggest that Scd1 and G0s2 are affected at the immediate-early hours by
ciprofibrate, while they are not affected by the CPA, so they would be expected to be in a dif-
ferent pathway than the CPA. Also, the Ccnd1 is a common gene that is expressed by both the
ciprofibrate and the CPA at the early time points after dosing and apparently it is induced by
other DNA inducers e.g. T3. 
Finally, this study was able to shed some light on the mechanism of action of hepatic growth
induced by ciprofibrate by studying the hepatic DNA synthesis in mouse and rat liver tissue, and
by characterizing the immediate early induced genes that are provoked by peroxisome prolifer-
ators, and can cause hepatic proliferation, which might be helpful in cancer studies. 
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Section 4.5Prospective work
A large number of the genes identified here could be interesting to follow up, as the microarray
and the transcriptome sequencing analysis both provide a large data base for the immediate ear-
ly time points and the acute response to ciprofibrate or CPA after a range of time points. 
Chosen pathways or particular genes could be tested with real- time PCR at different time
points, and in female rats treated with CPA as it is known that female rats give a hepatic DNA
synthesis higher than the males that were used in this study, so it would be expected to have
much more induction of the same genes, in particular, the DNA synthesis, the cell cycle path-
way or PPAR signalling pathway genes, such as G0/G1 switch 2 (G0s2), cyclin D1 (Ccnd1),
stearoyl-coenzyme A desaturase 1 (Scd1), carnitine palmitoyltransferase 1a (Cpt1a), cyclin
T1(Ccnt1), Myeloblastosis oncogene-like (Mybl1), Ets variant 3+6 (Etv3l + Etv6), Kelch repeat
and BTB (POZ) domain containing 11 (Kbtbd11), Myc myelocytomatosis viral oncogene ho-
molog 1 (Mycl1 v), Protein phosphatase 1K (Ppm1k) or T-box 3 (Tbx3). 
Additionally, the proteins induced by the PPAR could be studied by western blotting. These
genes could be tested in other species in particular human tissues for comparison and to predict
the level of danger, if any, from the peroxisome proliferators in concern with the hepatocarcino-
genesis. 
Also, immunohistochemical protocols could be used against specific antigens to indicate, where
in the liver zones do particular genes begin their induction (by following the pattern at the dif-
ferent time points) if periportal or perivenous, and this could help to tie groups of genes together
and introduce a small view of their mechanism of action in response to both the ciprofibrate and
the CPA.
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Furthermore, to prove that the genes identified in this study are actually involved in or required
for the hepatic DNA synthesis induction, it would be exciting to follow up with knock-out mice
or rats of these genes and test if the induction is affected. It might also be worth checking if the
rodents that do not react to peroxisome proliferators have these genes, and to examine if these
genes are induced after dosing. 
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Appendix I of RNA, cDNA and dye yields of the 
microarray samples
Sample ID RNA yield 
µg/µl
cDNA yield
 ng/µl 
for microarray
 
Alexa flour 555 dye 
attachment to cDNA 
pmol/ µl
CIPROFIBRATE 
Treated cipro 1h-1 10.08 79.6 4.7
Treated cipro 1h-2 15.66 92.7 2.5
Treated cipro 1h-3 9.4 112.9 10.5
Treated cipro 1h-4 8.38 159.4 12
Treated cipro 3h-1 13.6 350.6 13.6
Treated cipro 3h-2 11.7 144 11.7
Treated cipro 3h-3 13.36 43.97 6.3
Treated cipro 3h-4 11.06 35.2 5.2
Treated cipro 5h-1 9.14 218.1 50.1
Treated cipro 5h-2 10.26 152.2 33.5
Treated cipro 5h-3 12.82 71.32 19.7
Treated cipro 5h-4 13.8 129.6 15.9
Treated cipro 24h-2 4.88 19.8 3.6
Treated cipro 24h-3 3.59 13 1.3
Treated cipro 24h-5 3.06 17.3 1.7
Treated cipro 24h-6 5.33 51 8.8
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CYROTERONE 
ACETATE
Treated CPA 1h-1 3.95 99.6 11.3
Treated CPA 1h-2 5.2 60.3 5.7
Treated CPA 1h-3 7.8 77.1 16.8
Treated CPA 1h-4 9.75 69.1 7.5
Treated CPA 3h-1 8.43 12 4.9
Treated CPA 3h-2 2.93 7.9 2.3
Treated CPA 3h-3 4.67 39.9 3
Treated CPA 3h-4 7.32 19.3 6.7
Treated CPA 5h-1 7.01 19.9 10.8
Treated CPA 5h-2 7.3 57.5 13
Treated CPA 5h-3 4.75 34.1 11.5
Treated CPA 5h-4 3.69 5.9 4.4
Treated CPA 24h-1 8.34 84.4 11.4
Treated CPA 24h-2 8.24 140.5 10.8
Treated CPA 24h-3 12.34 62.8 9.6
Treated CPA 24h-4 4.02 140.6 44.9
CORN OIL 
(CONTROL)
control 1h-1 15.54 153.7 14.6
control 1h-2 8.08 114.4 7.6
control 1h-3 14.04 127.8 13
control 1h-4 7.46 136.5 16.7
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control 3h-1 8.14 36 4.4
control 3h-2 7.56 10.7 1.5
control 3h-3 5.31 16.8 3.8
control 3h-4 4.88 12.7 3.2
control 5h-1 11.2 9.8 2.3
control 5h-2 6.72 24 4.6
control 5h-3 8.14 8 2.4
control 5h-4 7.33 18 6.5
control 24h-1 3.65 142.5 26.9
control 24h-2 6.24 373 46.2
control 24h-3 3.86 45.4 6.7
control 24h-6 5.32 71.4 8.4
Abeer Amer   Section 4.3.7
Page 236
Record of Training Courses
 Mrs. Abeer H. A. Amer               student ID number 4047465
Record of Training courses  credits
Institute of genetics courses
Radiation training course
Safety training for postgraduate research student
Biological safety training
Training of Personnel under the Animals (Scientific Procedures) Act 1986 
Home office license course (model 1)
2
Home office license course (model 2) 2
Home office license course (model 3) 2
RT-PCR course 2
Seminars
Graduate School courses
Library induction and use of software 1
Exploiting the power of MS word a: for individual chapters and academic 
papers
1
Exploiting the power of MS word b: combining chapters into the thesis 1
MS Excel functionality a: entering, formatting and storing data 1
MS Power Point: developing a professional presentation 1
Computer and molecular biology 4
Further presentation skills 1
Getting started with research design and statistics 3
Planning research and time management 1
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Introduction to image and photo editing 2
Nature of the PhD and the supervision process 1
Guidelines for planning and formatting theses 1
Getting going on your thesis 2
Intensive learning and teaching program 8
Beginning writing 1
Academic writing/ synthesis sources
Introductory events to teaching for PG research students and researchers 
Training for reading to tape for disabled students
Training for note-taking
Training for invigilation
Training for information technology (IT) support
Presentations at the School Post-Graduate Symposia 2
First platform presentation
Second year poster presentation
Third year platform presentation
Demonstrating 2
Molecular and development neuroscience  (ligand binding practical class) 
The manipulating genes and genomes
The genes and cellular control
 
The C. Elegans practical
TOTAL CREDITS 41
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